Dissecting the Role of Cytosolic Nucleic Acid Sensors in the Type I Interferon Response to Herpes Simplex Virus-1 and other Ligands: A Dissertation by Thompson, Mikayla R.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2014-04-15 
Dissecting the Role of Cytosolic Nucleic Acid Sensors in the Type 
I Interferon Response to Herpes Simplex Virus-1 and other 
Ligands: A Dissertation 
Mikayla R. Thompson 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Immunity Commons, and the Immunology of Infectious Disease Commons 
Repository Citation 
Thompson MR. (2014). Dissecting the Role of Cytosolic Nucleic Acid Sensors in the Type I Interferon 
Response to Herpes Simplex Virus-1 and other Ligands: A Dissertation. GSBS Dissertations and Theses. 
https://doi.org/10.13028/M20W37. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/708 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
DISSECTING THE ROLE OF CYTOSOLIC NUCLEIC ACID SENSORS IN THE 
TYPE I INTERFERON RESPONSE TO HERPES SIMPLEX VIRUS-1 AND 
OTHER LIGANDS 
 
A Dissertation Presented 
By 
Mikayla Rae Thompson 
 
 
 
Submitted to the Faculty of the  
University of Massachusetts Graduate School of Biomedical Sciences, Worcester 
In partial fulfillment of the requirements for the degree of 
 
 
 
DOCTOR OF PHILOSOPHY 
April 15th, 2014 
Interdisciplinary Graduate Program
DISSECTING THE ROLE OF CYTOSOLIC NUCLEIC ACID SENSORS IN THE 
TYPE 1 INTERFERON RESPONSE TO HERPES SIMPLEX VIRUS-1 AND 
OTHER LIGANDS 
 
Dissertation Presented By 
Mikayla Rae Thompson 
The signatures of the Dissertation Committee signify completion and approval as 
to style and content of the Dissertation 
 
_____________________________________________ 
  Katherine Fitzgerald, Ph.D., Thesis Advisor 
 
_____________________________________________ 
  Evelyn Kurt-Jones, Ph.D., Thesis Advisor 
 
_____________________________________________ 
Egil Lien, Ph.D., Member of Committee 
 
_____________________________________________ 
Paula Pitha-Rowe, Ph.D., Member of Committee 
 
_____________________________________________ 
Eva Szomolanyi-Tsuda, M.D., Member of Committee 
 
_____________________________________________ 
Jennifer Wang, M.D., Member of Committee 
 
The signature of the Chair of the Committee signifies that the written dissertation 
meets the requirements of the Dissertation Committee 
 
_____________________________________________ 
Neal Silverman, Ph.D., Chair of Committee 
 
The signature of the Dean of the Graduate School of Biomedical Sciences 
signifies that the student has met all graduation requirements of the school.  
 
_______________________________________________ 
Anthony Carruthers, Ph.D., 
Dean of the Graduate School of Biomedical Sciences 
 
Interdisciplinary Graduate Program 
April 15, 2014 
 iii 
Acknowledgements 
Graduate school has been one of the most rewarding, yet most 
challenging experiences in my life. I would like to thank everyone who believed in 
me, encouraged me, and guided me over the past 6 years. Without your support, 
I would not have been successful throughout this process. 
I would like to thank my mentors, Dr. Katherine Fitzgerald and Dr. Evelyn 
Kurt-Jones for supporting my research throughout my time here at UMass. I am 
forever grateful for all that I have learned from you, for your advice along the 
way, and for the time you took to develop my skills as a researcher. I would like 
to thank Dr. Neal Silverman for his support and guidance over the years.  I would 
also like to thank Dr. Brain Lewis for his support outside of the lab as an 
advocate and mentor.  
I would like to thank the members and former members of the Fitzgerald 
Lab. Thank you Lisa, Vijay, Shruti, Zhao Zhao, Susan, Maninjay, Sandhya, John, 
Stefan, Jennie, Søren, Sreya, Numana, Joe, Priya, Pallavi, Kelly, and Annie for 
your help conducting experiments, scientific advice, and friendship over the 
years.  I would also like to thank the members of the Finberg/Kurt-Jones lab, for 
giving me useful advice and suggestions and supporting my project along the 
way. I would like to thank my Thesis Research Advisory Committee, Dr. Neal 
Silverman, Dr. Egil Lien, Dr. Eva Szomolanyi-Tsuda, and Dr. Jennifer Wang for 
guiding me towards the completion of my graduate studies.  
 iv 
 I would also like to thank my mother and father.  Your constant support, 
encouragement, love, and guidance continues to help me succeed in life.  
Without you both, I would not be where I am today.  Thank you.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
Table of Contents 
 
Title Page………………………………………………………………...………………i 
Signature Page……………………………………...………………………………….ii 
Acknowledgements ............................................................................................. ii
Table of Contents ................................................................................................ v
List of Publications ........................................................................................... vii
List of Figures ................................................................................................... viii
List of Tables ...................................................................................................... ix
List of Abbreviations ........................................................................................... x
Abstract ............................................................................................................. xiii
Preface to Chapter 1 ........................................................................................... 1
Chapter 1: Introduction ......................................................................................... 2
1.1 Introduction ........................................................................................................ 2
1.2 Pattern Recognition Receptors ............................................................................ 3
1.2.1 Toll Like Receptors ........................................................................................... 4
1.3 Intracellular Cytosolic Nucleic Acid Sensors ................................................... 21
1.3.1 RIG-I Like Receptors ...................................................................................... 21
1.3.2.Cytosolic DNA Sensors .................................................................................. 25
IFI16 ................................................................................................................................. 31
cGAS ................................................................................................................................ 33
1.3.3 The Inflammasome ......................................................................................... 35
1.4 Herpes Simplex Virus 1 ...................................................................................... 41
1.5 Type I IFN Induction ............................................................................................ 44
1.6 Dissertation Objectives ...................................................................................... 47
Preface to Chapter 2 ......................................................................................... 49
Chapter 2: Interferon Gamma Inducible protein (IFI)16 transcriptionally regulates 
IFN-α and other interferon stimulated genes and controls the Interferon response 
to both DNA and RNA viruses ............................................................................. 50
Abstract ...................................................................................................................... 50
Introduction ............................................................................................................... 51
Results ....................................................................................................................... 55
Discussion ................................................................................................................. 75
Materials and Methods .............................................................................................. 81
Preface to Chapter 3 ......................................................................................... 87
Chapter 3: IFI204 plays a partial role in the type I IFN response to DNA and 
RNA ligands in vivo ............................................................................................. 88
Abstract ...................................................................................................................... 88
Introduction ............................................................................................................... 90
Results ....................................................................................................................... 92
Discussion ............................................................................................................... 112
Materials and Methods ............................................................................................ 116
 vi 
Chapter 4: Discussion and Perspectives .......................................................... 119
Appendix A: CD200R1 Supports HSV-1 Viral Replication and Licenses Pro-
Inflammatory Signaling Functions of TLR2 ....................................................... 131
Preface to Appendix A ............................................................................................ 131
Introduction ............................................................................................................. 132
Results ..................................................................................................................... 134
Discussion ............................................................................................................... 138
Materials and Methods ............................................................................................ 139
Appendix B: Forward genetic analysis of type I IFN responses to DNA ligands 
reveals a novel polymorphism in the MOLF/Ei STING gene. ............................ 141
Preface to Appendix B ............................................................................................ 141
Introduction ............................................................................................................. 142
Results ..................................................................................................................... 143
Discussion ............................................................................................................... 150
Materials and Methods ............................................................................................ 151
References ....................................................................................................... 154
 
 
 
 
 
 
 
 
 
 
 
 vii 
List of Publications 
 
Thompson, Mikayla, R., Sharma, Shruti, Jensen, Søren, Atianand, Maninjay, 
Fitzgerald, Katherine, A., Kurt-Jones, Evelyn, A. (2014) “Interferon Gamma 
Inducible protein (IFI)16 transcriptionally regulates IFN-α and other interferon 
stimulated genes and controls the Interferon response to both DNA and RNA 
viruses.” J. Biological Chem. Submitted, under revision. 
 
Thompson, Mikayla R., Kaminski, John J., Kurt-Jones, Evelyn A., Fitzgerald, 
Katherine A. (2011) "Pattern Recognition Receptors and the Innate Immune 
Response to Viral Infection." Viruses 3, no. 6: 920-940. 
 
Soberman, Roy J., MacKay, Christopher R., Vaine, Christine A., Ryan, Glennice 
Bowen., Cerny, Anna M.,Thompson, Mikayla R,. Nikolic, Boris., Primo, Valeria., 
Christmas, Peter., Sheiffele, Paul., Aronov, Lisa., Knipe, David M., Kurt-Jones, 
Evelyn A. (2012) “CD200R1 Supports HSV-1 Viral Replication and Licenses Pro-
Inflammatory Signaling Functions of TLR2.” PLoS ONE 7(10). 
 
Conlon, Joseph, Burdette, Dara L., Sharma, Shruti, Bhat, Numana, 
Thompson, Mikayla, Jiang, Zhaozhao, Rathinam, Vijay A. K., Monks, Brian, 
Jin, Tengchuan, Xiao ,T. Sam, Vogel, Stefanie N., Vance, Russell E., Fitzgerald, 
Katherine A. (2013) “Mouse, but not Human STING, Binds and Signals in 
Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic 
Acid” The Journal of Immunology, (190). 
 
Horan, K A., Hansen K., Jakobsen, M R., Holm, C K., Søby, S., Unterholzner, L., 
Thompson, M R, West, J A., Iversen, M B., Rasmussen, S B., Ellermann-
Eriksen, S., Kurt-Jones E., Landolfo, S., Damania, B., Melchjorsen, J., Bowie, A 
G., Fitzgerald, K A., Paludan, S R. (2013) “Proteasomal degradation of herpes 
simplex virus capsids in macrophages releases DNA to the cytosol for 
recognition by DNA sensors.”The Journal of Immunology, Mar 1;190(5):2311-9. 
 
 
 
 
 
 
 
 
 
 viii 
List of Figures  
 
Chapter 1 
 
Figure 1.1. Cell surface and endosomal recognition of viruses by TLRs.   
 
Figure 1.2. Cytosolic and Nuclear PRRs 
 
Figure 1.3.  Type I IFN signaling 
 
Chapter 2 
 
Figure 2.1. Stable knockdown of IFI16 by lentiviral transduction 
 
Figure 2.2. IFI16 knockdown cells display an abrogated type I IFN response to 
various DNA stimuli 
 
Figure 2.3. IFI16 dependent IFN production occurs independently of NF-κB 
 
Figure 2.4. IFI16 Addback rescues the type I IFN phenotype 
 
Figure 2.5. IFI16 knockdown cells display an abrogated type I IFN response to 
various RNA stimuli. 
 
Figure 2.6. IFI16 has a global effect on ISG expression 
 
Figure 2.7. IFI16 transcriptionally regulates IFN-α expression independently of 
STAT-1 
 
Chapter 3 
 
Figure 3.1. Targeting strategy for the generation of the IFI204-/- mouse 
 
Figure 3.2. IFI204 plays a partial role in the type I IFN response to DNA ligands 
 
Figure 3.3 Nanostring Analysis of IFI204-/- BMDMs 
 
Figure 3.4 IFI204 does not play a role in the NF-κB response to DNA and RNA 
ligands, nor is it necessary for pyroptotic cell death  
 
Figure 3.5. IFI204 mediates the innate immune response to HSV-1 in vivo 
 
Figure 3.6. HSV-1 Survival Study 
 
Chapter 4 
 
Figure 4.1 IFI16 regulation of type I IFNs 
 ix 
 
 
Appendix A 
 
Figure 5.1 CD200R1 licenses pro-inflammatory signaling in peritoneal 
macrophages. 
 
Appendix B 
 
Figure 6.1. MOLF/Ei mice display a blunted IFN-β response to DNA ligands 
 
Figure 6.2 Decreased IFN-β production in MOLF/Ei mice can be mapped to 
Chromosome 18 and STING 
 
Figure 6.3.  MOLF/Ei mice have multiple polymorphisms in STING  
 
 
List of Tables 
 
Chapter 3  
 
Table 3.1 Nanostring Analysis of IFI204 -/- BMDMs, Fold Change  
 
 
 
 
 
 
 
 
 x 
List of Abbreviations  
 
AIM2   Absent in melanoma-2 
ALR   AIM2-like receptors 
ASC   Apopotosis-associated speck-like protein containing CARD 
BMDC              Bone marrow derived dendritic cell 
BMDM               Bone marrow derived macrophage 
CARD                 Caspase activation and recruitment domain 
c-di-AMP  Cyclic diadenosine monophosphate 
c-di-GMP  Cyclic diguanosine monophosphate 
CIA                          Collagen Induced Arthritis  
cGAS   Cyclic GMP-AMP Synthase 
cGAMP                    Cyclic guanosine monophosphate–adenosine  
                                 monophosphate 
CNS                         Central Nervous Sysytem 
DAI   DNA-dependent activator of IFN-regulatory factors 
DAMP                Danger-associated molecular pattern 
DC                      Dendritic cell 
DDX   DEAD (Asp-Glu-Ala-Asp) box polypeptide 
DHX   DEAH (Asp-Glu-Ala-His) box polypeptide 
DMXAA                    5,6-Dimethylxanthenone-4-acetic acid 
dsDNA               double-stranded deoxyribonucleic acid 
dsRNA  double-stranded ribonucleic acid 
EAE                         Experimental Autoimmune Encephalitis  
EBV   Epstein-Barr virus 
ECMV   Encephalomyocarditis virus 
ELISA                Enzyme-linked immunosorbent assay 
ER   Endoplasmic reticulum 
HCMV Human cytomegalovirus 
HEK Human embryonic kidney 
HHV Human herpes virus 
HIN-200 Hematopoietic interferon-inducible nuclear antigens with 200 
amino acid repeats 
HSE   Herpes simplex encephalitis 
HSV                   Herpes simplex virus          
ICP0   HHV infected cell polypeptide 0 
IFI   Gamma-interferon-inducible protein 
IFN                    Interferon 
IL   Interleukin 
IRF   Interferon regulatory factor 
ISD   Interferon stimulatory DNA 
ISG                    Interferon stimulated gene 
ISRE                        Interferon-sensitive response element  
JAK                         Janus Kinase 
JNK                          c-Jun N-terminal kinases 
KSHV   Kaposi sarcoma-associated herpesvirus 
 xi 
LCMV                      Lymphocytic choriomeningitis 
LGP2   laborator of genetics and physiology 2 
LPS                   Lipopolysaccharide 
LRR   Leucine-rich-repeat 
LRRFIP1  Leucine-rich repeat flightless-interacting protein 1 
Mal                   MyD88-adapter-like 
MAPK   Mitogen-activated protein kinase 
MAVS              Mitochondrial antiviral signaling protein 
MCMV  Murine cytomegalovirus 
MDA5              Melanoma differentiation-associated gene-5 
MHC                        Major Histocompatibility Complex  
MMTV                      Mouse mammary tumor virus  
MNDA            Myeloid nuclear differentiation antigen 
MyD88             Myeloid differentiation primary response gene 88 
NALP               NACTH, LRR and PYD domain-containing protein 
NDV   Newcastle disease virus 
NEMO                      NF-kB essential modulator 
NF-κB              Nuclear factor kappa-light-chain-enhancer of activated B   
                                cells 
NK                    Natural Killer 
NLRP               NOD like receptors   
NO   Nitric oxide 
PAMP                      Pathogen-associated molecular pattern 
PDC        Plasmacytoid dendritic cell 
PML   Promyelocytic leukemia protein 
Poly(dA:dT)  Polydeoxyadenylic acid : polythymidylic acid 
Poly(I:C)  Polyriboinosinic acid : polyribocytidylic acid 
PRD                         Positive Regulatory Domain  
PRR                 Pattern Recognition Receptor 
PS   Phosphorothioate 
PYD                Pyrin domain 
PYHIN  Pyrin and HIN domain-containing protein 
RD   Repressor domain 
RIG-I   Retinoic acid-inducible gene-I 
RIP                          Receptor-interacting serine/threonine-protein kinase 1 
RLR   Rig-I-like receptors 
ROS   Reactive oxygen species 
RSV   Respiratory syncytial virus 
SLE   Systemic Lupus Erythematosus 
ssDNA  single-stranded deoxyribonucleic acid 
ssRNA  single-stranded ribonucleic acid 
STAT   Signal transducer and activator of transcription 
STING  Stimulator of interferon genes 
SV   Sendai virus 
TBK1   TANK-binding kinase 1 
TGF                         Transforming growth factor  
 xii 
TIR   Toll/IL-1 receptor 
TLR   Toll-like receptor 
TMEV   Theiler’s murine encephalomyelitis virus 
TNF   Tumor necrosis factor 
TRAF   TNF receptor-associated factor 
TRAM   TRIF-related adapter molecule 
TRIF   TIR-domain-containing adapter-inducing interferon-β 
VSV   Vesicular stomatitis virus 
VACV   Vaccinia Virus 
VZV   Varicella-zoster virus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii 
Abstract 
 
The innate immune system provides the first line of defense against 
infection. Pathogens are detected though a variety of Pattern Recognition 
Receptors (PRRs), which activate downstream signaling cascades. Effector 
molecules such as cytokines and chemokines are released upon activation and 
aid in cell recruitment, control of pathogen replication, and coordination of the 
adaptive immune response. Nucleic acids that are released into the cytosol 
during viral and bacterial infection are recognized through a special class of 
PRRs, coined cytosolic nucleic acid sensors. Upon recognition, these receptors 
induce the production of type I interferons and other cytokines to aid in pathogen 
clearance. Although many cytosolic nucleic acid sensors have been discovered, 
it is unclear how they work in concert to mediate these responses.  
The Interferon Gamma Inducible protein (IFI)16 and its proposed mouse 
orthologue IFI204 are cytosolic DNA sensors that have been linked to the 
detection of cytosolic DNA during infection with Herpes Simplex Virus (HSV-1). 
IFI16 binds dsDNA that has been released into the cytosol during viral infection 
and engages the adaptor molecule Stimulator of Interferon Genes (STING) 
leading to TANK binding kinase-1 (TBK1) dependent phosphorylation of 
interferon regulatory factor 3 (IRF3) and transcription of type I interferons and 
interferon stimulated genes. In addition to its role as a sensor, in chapter two of 
this thesis we describe a broader role for IFI16 in the regulation of the type I IFN 
response to RNA and DNA viruses in anti-viral immunity. In an effort to better 
understand the role of IFI16 in coordinating type I IFN gene regulation, we 
 xiv 
generated cell lines with stable knockdown of IFI16 and examined responses to 
DNA and RNA viruses as well as other inducers of IFN such as cyclic-di-
nucleotides. As expected, stable knockdown of IFI16 led to a severely attenuated 
type I IFN response to cytosolic DNA ligands and DNA viruses. In contrast, 
expression of the NF-κB regulated cytokines such as IL-6 and IL-1β were 
unaffected in IFI16 knockdown cells, suggesting that the role of IFI16 in sensing 
these triggers was unique to the type I IFN pathway. Surprisingly, we also found 
that knockdown of IFI16 led to a severe attenuation of expression of IFN-α and 
IFN stimulated genes such as RIG-I in response to cyclic GMP-AMP (cGAMP), a 
second messenger produced in response to cGAS, as well as RNA ligands and 
viruses. Analysis of IFI16 knockdown cells revealed compromised occupancy of 
RNA polymerase II on the IFN-α promoter in IFI16 knockdown cells suggesting 
that transcription of ISGs is dependent on IFI16. Since IFI16 knockdown 
compromised not only DNA virus driven pathways, we propose additional 
regulatory roles outside of DNA sensing.  Collectively, these results indicate that 
IFI16 plays a role in the regulation of type I IFN gene transcription and production 
in response to both RNA and DNA viruses.  
The role of IFI16/IFI204 has been studied extensively in vitro, however the 
role of the receptors in vivo has yet to be determined. In chapter three of this 
thesis, we developed a mouse deficient in IFI204 to explore the role of IFI204 in 
in vivo immune responses to viruses.  We investigated the ability of IFI204 
deficient cells to induce type I interferons and other cytokines in response to a 
panel of DNA and RNA ligands in vitro. IFI204 deficient BMDMs displayed a 
 xv 
partial defect in type I interferon induction in response to both DNA and RNA 
ligands and viruses as compared to WT mice.  We also observed that this 
phenotype is time dependent, since there was no change in type I interferon 
induction after 12 hours post infection as compared to earlier time points. In 
contrast to these results, expression of the NF-κB regulated cytokines IL-6 and 
IL-1β were unaffected in IFI16 knockdown cells. These results suggest that 
IFI204 plays a partial role in the induction of type I interferons in response to both 
DNA and RNA ligands. Additionally, IFI204 may work in tandem with other 
receptors in a sequential manner to amplify the type I interferon response. We 
also studied the involvement of IFI204 in an in vivo model of HSV-1 infection. 
IFI204 knockout mice produce less brain and serum IFN-β, IL-6, and IL-1β 72 
hours post intraperitoneal infection with HSV-1. Furthermore, IFI204 -/- mice are 
more susceptible to HSV-1 infection as compared to WT mice. These data 
indicate that IFI204 mediates the response to HSV-1 in vivo by inducing the 
production of cytokines that are necessary for the control of viral infection.  
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Chapter 1: Introduction 
1.1 Introduction  
The innate immune system is crucial for regulation of early detection and 
clearance of invading pathogens. This response is governed by a specialized 
group of cells including macrophages, dendritic cells, mast cells, eosinophils, 
basophils, neutrophils, and natural killer cells(1). Activation of these leukocytes 
through Pattern Recognition Receptors (PRRs) leads to the production of 
effectors such as type I interferons and pro-inflammatory cytokines and 
chemokines, which aid in the clearance of infectious agents.  This innate 
detection acts as a primer for the long term, memory response governed by the 
adaptive immune system. In contrast to the innate immune system, the adaptive 
immune system is governed by a different set of cells including B cells, T cells, 
and γδ.T cells(1). Although the adaptive immune response is slower to form, it is 
essential for the long-term antigen specific memory response.  
Deficiencies in the innate immune system can lead to an onset of many 
diseases and reoccurring infections due to the inability of the host to initiate a 
proper immune response. Alternatively, hyper responses of the innate immune 
system can lead to uncontrollable inflammation, tissue damage, and autoimmune 
disease. Thus it is important that these responses are tightly regulated to ensure 
proper detection and clearance of invading pathogens without leading to 
collateral damage to the host. A greater understanding of how innate immunity 
defends against various microbes will further the development of safe and 
effective therapeutic strategies against infectious and inflammatory disease. 
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1.2 Pattern Recognition Receptors 
Cells of the innate immune system utilize pattern recognition receptors 
(PRRs) to identify viral pathogens by engaging pathogen-associated molecular 
patterns (PAMPs).  Once thought to be moieties found only on pathogens, our 
understanding of PAMPs (pathogen associated molecular patterns) has 
expanded to include not only classical PAMPS such as lipopolysaccharides 
found on bacteria but also nucleic acids.  Nucleic acid sensing has emerged as a 
major component of the immune systems anti-microbial arsenal. A diverse range 
of pathogens are sensed via recognition of their genomes or nucleic acids which 
accumulate during their replication. Nowhere is this more prevalent than in viral 
detection. PRRs respond to signatures present in viruses such as 5’ triphosphate 
RNA, which is not normally found in host RNA or to nucleic acids such as viral 
DNA which is exposed to sensors localized in the cytoplasm, a compartment 
normally void of DNA.    
Of the PRRs, the Toll-like receptors (TLRs) are perhaps the most 
extensively studied.  TLRs are type 1 transmembrane proteins that traffic 
between the plasma membrane and endosomal vesicles.  They are primarily 
responsible for detecting PAMPs in the extracellular environment.  Those located 
on the plasma membrane are usually specific for hydrophobic lipids and proteins 
while those found in endosomes detect nucleic acids.  This segregation appears 
intentional allowing innate cells to respond to components of the viral envelope 
such as fusion machinery at their surface.  In contrast, nucleic acids are detected 
in the endosome where many viruses uncoat their genomes and enter the 
 4 
cytoplasm.  Upon reaching the cytoplasm, viral components are subject to the 
scrutiny of the retinoic acid-inducble gene I-like receptors (RLRs), the nucleotide 
oligomerization domain-like receptors (NLRs), and cytosolic DNA sensors such 
as members of the AIM2 family or cGAS.  Similar to TLRs, RLRs and DNA 
sensors regulate transcription factors essential for the production of interferons 
and cytokines.  In contrast NLRs and AIM2 are mainly responsible for the 
maturation of IL-1β and IL-18 through the activation of caspase-1.  Interestingly 
AIM2 acts as a ‘check point,’ regulating the activation and release of these potent 
effectors.  In addition to the production of proinflammatory molecules, many 
classes of PRRs mobilize the adaptive immune response by increasing 
expression of MHC class II and inducing expression of the costimulatory 
molecules CD40, CD80 and CD86. 
1.2.1 Toll Like Receptors  
The Toll protein was first recognized for its role in dorsal-ventral patterning 
of drosophila embryos.  Later studies found it to be important for the adult fly’s 
immune response to bacterial and fungal infections fueling the search for 
mammalian homologs.  To date, 10 TLRs have been identified in humans, 13 in 
mice with TLRs 1-9 common to both.  TLR1, TLR2, TLR4, TLR5 and TLR6 are 
located on the plasma membrane while TLR3, TLR7, TLR8, and TLR9 are 
endosomal.  All TLRs share a common architecture consisting of extracellular 
leucine-rich repeats and a cytoplasmic Toll/Interleukin-1 Receptor (TIR) 
domain(2).  These receptors signal as dimers, differentially recruiting the adaptor 
proteins Mal (MyD88 adapter-like), also called TIRAP (TIR domain-containing 
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adaptor protein) and MyD88 (Myeloid differentiation primary response gene 88) 
and/or TRIF (TIR-domain-containing adaptor inducing IFNβ) and TRAM (Trif-
related adaptor molecule)(2).  Adaptors initiate signal cascades culminating in 
the activation of nuclear factor kappa b (NF-κB), mitogen-activated protein kinase 
(MAPK) and interferon regulatory factors 1, 3, 5 and 7 (IRF-3, -5 and -7)(3). 
Together these transcription factors not only drive expression of interferons, 
cytokines and chemokines but also influence cellular maturation and survival.  
 
TLR Signaling 
With the exception of TLR3, all TLRs recruit myeloid differentiation primary 
response gene 88 (MyD88) upon activation.  In the case of TLR2 and TLR4, the 
Mal/TIRAP protein acts as a bridging adapter to recruit MyD88 to the activated 
receptor(4).  MyD88’s death domain associates with and activates IL-1R-
associated kinase 1 (IRAK-1) and/or IRAK-2.  IRAK-4 also transiently interacts 
with this complex and is thought to phosphorylate IRAK-1.  IRAK-1 is 
subsequently released and engages TNFα receptor-associated factor 6 (TRAF6).  
Activated TRAF6 is capable of K63-linked polyubiquitination of itself and other 
proteins.  It interacts with NF-κB essential modulator (NEMO, also known as 
IKKγ), another of its ubiquitination targets, as well as TGF-β-activated kinase-1 
(TAK1) and the TAK1 binding proteins (TAB1, TAB2 and TAB3).  NEMO forms a 
complex with IKKα and IKKβ which are the catalytic kinases responsible for 
phosphorylating IκB.  IκB binds to and sequesters NF-κB in the cytoplasm.  
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Following phosphorylation, IκB is ubiquitinated and finally degraded by the 
proteasome releasing NF-κB to enter the nucleus and induce gene expression.  
Studies indicate that TAK1 plays an essential role in both the NF-κB and MAPK 
pathways by phosphorylating IKKβ and c-Jun N-terminal kinase (JNK) 
respectively(5,6). 
TLR3 is incapable of recruiting MyD88 and instead interacts with the 
adaptor protein TIR-domain-containing adapter-inducing interferon-β (TRIF).  
TRIF can directly bind TRAF6 and induce NF-κB in a manner similar to MyD88.  
In contrast to MyD88, TRIF is also able to recruit the protein receptor interacting 
protein-1 (RIP-1).  RIP-1 synergizes with TRAF6 resulting in more potent NF-κB 
activation.  A third protein recruited to TRIF is TRAF3.  TRAF3 associates with 
TANK binding kinase-1 (TBK1) and IKKi and is essential for the production of 
type I interferon.  TBK1 and IKKi mediate this production by phosphorylating 
interferon regulatory factor-3 (IRF3) and IRF7.  This allows them to dimerize and 
enter the nucleus where they cooperate with NF-κB and activator protein 1 (AP-
1) to bring about target gene transcription.  TLR4 can recruit TRIF through the 
adaptor TRIF-related adaptor molecule (TRAM) and can therefore signal through 
either pathway.   
A number of primary immunodeficiencies in humans are the result of 
defects in the innate signal pathways described above.  For instance, one study 
of children with nonfunctional MyD88 proteins found they were predisposed to 
recurrent life-threatening pyogenic bacterial infections(7).  A similar phenotype 
has been reported in patients with IRAK-4 deficiency(8).  A study of two 
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unrelated children with defects in UNC-93B1, a protein thought to be involved in 
trafficking TLR3, TLR7, TLR8 and TLR9 to the endosome, found an increased 
susceptibility to encephalitic herpes simplex virus-1 infection(9).  PBMCs and 
fibroblasts derived from these children demonstrated a reduced type I interferon 
response to HSV-1 challenge and a concomitant enhancement in viral 
replication(10). 
 
TLR Expression and Activity 
The inflammatory response evoked by viral PAMPs depends on a variety 
of factors.  Firstly cellular expression of TLRs differs between innate cell types.  
Human macrophages are known to express high levels of TLR2 and TLR4 while 
plasmacytoid dendritic cells (pDCs) mainly express TLR7 and TLR9(11).  
Expression patterns also vary between species, where TLR9 is restricted to a 
few cell types in humans it is widely distributed in mice.  Furthermore expression 
of certain downstream signaling molecules fluctuates between innate cell types.  
For example, pDCs are unique in that they constitutively express the transcription 
factor IRF7 allowing them to quickly produce high levels of type I IFNs in 
response to viral infection while other cell types such as macrophages may 
respond in a more delayed manner(12,13).  Thus the response to identical viral 
PAMPs may differ between cell types both in the nature of effector molecules 
produced and the kinetics of the response.  Virally encoded proteins that subvert 
or distort the TLR response often further complicate this picture.  In the 
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subsequent sections we discuss the TLRs individually, detailing the viruses they 
detect and wherever possible the specific viral products sensed.  
 
TLR4 
The TLR4-mediated response to LPS is well known for its critical role in 
innate immune control of Gram-negative bacterial infection.  It was also the first 
TLR shown to respond to a viral pathogen.  In 2000, Kurt-Jones et al. reported 
the interaction between the fusion (F) protein of respiratory syncytial virus (RSV) 
and TLR4(14).  The importance of TLR4 in human viral disease and RSV 
pathogenesis has been documented in genetic studies. In humans, inheritances 
of two different single nucleotide polymorphisms (SNPs) in the ectodomain of 
TLR4 are associated with reduced responses to both LPS and RSV F.  A highly 
significant association was found between RSV infection in high-risk infants and 
inheritance of hyporesponsive TLR4 SNPs(15).  This was confirmed in a 
separate study that likewise found a significant association between these same 
TLR4 SNPs and severity of RSV disease in infants(16).   
Initial studies linking TLR4 expression to RSV pathogenesis were done in 
the TLR4-deficient mouse strain C57BL6/ScNCr (which has a deletion of the 
gene region containing TLR4) as well as in C3H/HeJ mice (non-signaling point 
mutation of TLR4)(9,14).  These studies found that RSV activated NF-κB in a 
TLR4-dependent manner at early time points of infection(17). The original RSV 
infection studies with ScNCr mice were controversial as it was suggested that the 
failure to control RSV was due to a defect in IL-12R signaling(18).  However, this 
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discrepancy between the different studies was due in part to confusion about the 
mouse nomenclature since the ScNCr mice used in the initial studies (but 
misidentified as ScCR in the paper(14)) have normal IL-12R(19) while the SccR 
mice used in the second study were IL-12R-deficient(18).  More recent work 
using targeted TLR4 knockouts (with normal IL-12R) have confirmed the role of 
TLR4 in controlling RSV replication independent of IL-12R, but interestingly these 
studies have also revealed an even more important role for TLR2 in limiting RSV 
replication(20).  The purified F protein of RSV induced IL-6 production in a dose-
dependent manner in human peripheral blood mononuclear cells (PBMCs) and 
wild type mouse macrophages alike.  However, this response was lost in TLR4 
deficient and TLR4 knockout macrophages(14,20). Studies by Vogel and 
colleagues have shown that the ability of TLR4 to be triggered by RSV F is 
critical to prevent RSV-induced pathology.  Indeed, the formalin-inactivated RSV 
vaccine which caused exacerbated disease in clinical trials and was found to 
contain a denatured, non-stimulatory F protein.  The disease enhancing activity 
of the formalin-inactivated RSV vaccine could be reversed by the addition of 
MPL, a non-toxic lipid A TLR4 agonist(21).  Disease severity is also correlated 
with the absence of “alternatively activated” (AA) macrophages that play a crucial 
role in tissue repair(22).   Taken together with the human and mouse genetics, 
these studies suggest that TLR4-F protein interactions may protect the host from 
severe RSV disease by mitigating or reprogramming the host response to 
promote AA-macrophages and thus promote healing(23).   
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TLR4 is also important for infections by the retrovirus mouse mammary 
tumor virus (MMTV).  MMTV was shown to activate NF-κB and induce B220 and 
CD69 lymphocyte activation markers in B cells from wild type but not C3H/HeJ or 
congenic BALB/c (C.C3H Tlr4lps-d) lines(24).  TLR4 activation, attributed to the 
envelope (Env) protein, was found to stimulate production of IL-10(25).  
Surprisingly induction of TLR4 signaling appears to benefit MMTV.  First it 
activates quiescent B cells encouraging cell division, which is necessary for viral 
genome integration in the host chromosome.  Secondly it promotes secretion of 
IL-10, an immunosuppressive cytokine which helps the virus persist 
indefinitely(24).   
 
TLR2 
Functional TLR2 exists as a heterodimer with either TLR1 or TLR6 on the 
plasma membrane of both innate and adaptive immune cells.  It can be activated 
by lipoteichoic acid, a common component of gram-positive bacteria, as well as 
GPI anchors of parasitic protozoan such as Plasmodium falciparum.  The 
TLR2/TLR6 heterodimer has recently been shown to play a role in the innate 
immune response to RSV.  Macrophages from mice deficient in TLR2 or TLR6 
responded to RSV with lower levels of TNFα, IL-6, CCL2 (MCP-1) and CCL5 
(RANTES) than their wild type counterparts.  When TLR2 or TLR6 knockout mice 
were challenged intranasally with RSV they had elevated peak viral titers and 
lower numbers of neutrophils and activated DC in their lungs(20).  Thus 
TLR2/TLR6 signaling likely contributes to both innate immune cell recruitment 
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and viral clearance in vivo during RSV infection(20).  In human PBMCs, TLR2 
contributes to IL-8 and MCP-1 production in response to Epstein-Barr virus 
(EBV)(26).  A TLR2/TLR1-mediated proinflammatory response to the related 
human cytomegalovirus (HCMV) has also been reported.  One study found TLR2 
deficient mouse macrophages had significantly reduced IL-6 and IL-8 production 
in response to UV-inactivated HCMV(27).  Furthermore expression of TLR2 and 
CD14 was required for maximal NF-κB activation and IL-8 secretion in HEK293 
cells exposed to HCMV.  Envelope glycoproteins B and H were later shown to 
coimmunoprecipitate with TLR2 and TLR1 and are theorized to be the HCMV 
PAMPs stimulating TLR2(28).   
Lymphocytic Choriomeningitis (LCMV) is a non-cytolytic virus that can 
cause fatal encephalitis in mice.  Wild type glial cells infected with LCMV produce 
TNFα, CCL2 and CCL5, a response that is abolished in cells derived from TLR2 
deficient mice(29).  TLR2 also induces MHC class-I and class-II, CD40 and 
CD86 expression in microglia challenged with LCMV, implicating this pathway in 
the induction of adaptive immunity(29).  In LCMV infection, where much of the 
CNS damage is caused by the immune response itself, it remains to be 
determined if TLR2 signaling is protective or pathological. Interestingly TLR2 is 
important for type I IFN induction during LCMV infection but the mechanism is 
unclear(30).  Although TLR2 is normally not associated with type I IFN induction, 
a recent study from Barton and colleagues demonstrated that on inflammatory 
monocytes, TLR2 regulates induction of type I interferon in response to viral but 
not bacterial ligands(31).  
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Surprisingly, it appears TLR2 can play either a protective or detrimental 
role in disease caused by herpes simplex virus (HSV) depending on the context 
of the infection.  Studies using an intraperitoneal infection model found TLR2 
deficient neonates were protected from lethal HSV-1 encephalitis compared to 
wild type mice(32).  Despite having similar viral loads, the TLR2 knockouts 
demonstrated improved survival, attenuated symptoms and reduced CNS 
inflammatory lesions.  In contrast TLR2 was shown to work synergistically with 
TLR9 to promote survival in an intranasal HSV-1 infection model(33).  In addition, 
TLR2 has been shown to be beneficial in both intraperitoneal and intravaginal 
HSV-2 infection models(34).  TLR2’s role in murine HSV infection models may be 
influenced by factors such as the size of the viral inoculum, the route of 
administration and the age of the subject.  HSV induced two distinct responses; a 
TLR2-dependent inflammatory cytokine response and a TLR9 and/or non-TLR-
dependent type I IFN response.  A strong IFN response is necessary to control 
early virus replication (IFNAR-deficient mice quickly succumb to infection) and 
prevent spread from the genital tract to the brain (34).  Once in the brain, 
however, inflammation is linked to increased mortality(32).   
Measles virus (MV) is another infection in which TLR2 signaling may have 
both favorable and unfavorable effects.  Challenging mice with live or UV-
inactivated wild type MV induces IL-6 production and CD150 surface expression 
in mouse macrophages; a response that is impaired in TLR2-deficient cells(35).  
Intriguingly CD150 is required for entry of wild type MV into monocytes thus 
immune activation through TLR2 may in fact benefit the virus by conferring 
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susceptibility.  This study identified MV haemagglutinin (HA) protein as the viral 
PAMP triggering TLR2 activation(35).  MV vaccine strains carrying a single 
asparagine to tyrosine substitution in the HA protein lacked the ability to activate 
TLR2.   
 
TLR3 
With the exception of neutrophils and pDCs, TLR3 is widely expressed in 
innate immune cells where it is localized to the endosomal compartment(36,37).  
In 2001, Alexopoulou et al. demonstrated that activation of TLR3 signaling by the 
double stranded RNA analog poly(I:C) contributed to the production of type I IFN 
and cytokines in macrophages.  Moreover, genomic dsRNA isolated from 
reovirus was found to activate wild type but not TLR3 deficient splenocytes.  The 
idea that TLR3 could respond to dsRNA, a common viral PAMP, lead to intense 
speculation about its role in the host response to numerous infections.  
Counterintuitively, a later study found no difference in the survival, viral titers or 
pathology of TLR3 deficient mice following reovirus challenge(38).  The authors 
suggested that during in vivo infection, TLR3 may not encounter reovirus dsRNA 
or that levels may be too low to efficiently activate TLR3(38).  This study also 
reported indistinguishable immune responses to LCMV, VSV and MCMV 
infection in TLR3 deficient and wild type mice(38).  However, other evidence 
exists suggesting that TLR3 does in fact play a role in controlling MCMV as some 
studies observed blunted type I IFN and IL-12 production accompanied by higher 
viral loads in the spleens of mice lacking TLR3(39,40).  Despite this, only TLR9 
 14 
deficient mice had significantly decreased survival compared to wild type 
suggesting TLR9 is more crucial than TLR3 in MCMV infections(39).  A recent 
study also implicates TLR3 in immune suppression of the related herpes virus 
HSV-1.  Patients with TLR3 dominant negative mutations were found to be more 
susceptible to herpes simplex encephalitis, a rare but devastating manifestation 
of HSV-1 infection(41).  The presumed ligand for TLR3 in infections with DNA 
viruses is dsRNA generated during bidirectional transcription of opposing DNA 
strands.  TLR3 signaling also reduces lethality of encephalomyocarditis virus 
(EMCV), a ssRNA virus that directly damages heart tissue(42).  TLR3 deficient 
mice challenged with EMCV had decreased levels of TNFα, IL-6 and IL-1β 
mRNA in cardiac tissue and a corresponding reduction in inflammatory infiltrate 
at 3 days post infection(42).  Without TLR3 signaling, EMCV replicated to higher 
levels in the heart resulting in more rapid and extensive mortality in 
knockouts(42).   
Although this study indicates that the TLR3-mediated inflammatory 
response is beneficial in EMCV infections; TLR3 signaling appears to be 
detrimental in a number of other viral infections.  For instance, TLR3 deficient 
mice were protected compared to their wild type counterparts when challenged 
with a lethal dose of West Nile Virus (WNV)(43).  This study found that TLR3 
driven production of inflammatory cytokines compromised the blood-brain barrier 
facilitating WNV entry.  This resulted in higher viral loads in the CNS and 
worsened neuropathology.  Likewise, TLR3 was shown to play a pathologic role 
in infections with Punta Toro Virus (PTV)(44).  Wild type mice had drastically 
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reduced survival and increased hepatic injury compared to TLR3 deficient mice 
following PTV challenge.  Despite having similar serum and hepatic viral loads, 
wild type mice had elevated levels of IL-6, IFNγ, CCL2 and CCL5, suggesting 
these proinflammatory molecules may mediate much of the damage 
observed(44).  Interestingly, although TLR3 signaling increases inflammation and 
reduces Influenza A virus (IAV) lung titers, it causes a paradoxical decrease in 
survival.  Thus in IAV infections, lethality appears to be more dependent on TLR3 
signaling than direct virus-induced injury.  
 
TLR7 and TLR8 
TLR7 and TLR8 are two closely related receptors that, like TLR3, act in 
the endosome.  Human TLR7 and TLR8 were first shown to respond to the 
imidazoquinoline-like compound resiquimod (R-848) a synthetic drug recognized 
for its antiviral and antitumor activity(45,46).  We now know that nearly any long 
single-stranded RNA (ssRNA) is capable of activating TLR7 and TLR8(47). 
Despite this, differences do exist between these receptors.  For example, short 
dsRNAs containing certain motifs preferentially activate TLR7(48,49).  
Futhermore, synthetic agonists specific to TLR7 or TLR8 differentially activate 
innate immune cells leading to distinct cytokine profiles(50).  In 2004, Diebold et 
al. showed that TLR7 mediates IFNα production by pDCs in response to live or 
heat-inactivated influenza virus(51).  This TLR7 response could be elicited simply 
by exposure to purified genomic ssRNA and was completely abrogated by 
chloroquine, an inhibitor of endolysosomal acidification(51).  Thus the authors 
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proposed a model, now known as the exogenous pathway, whereby pDCs 
endocytose and degrade a portion of incoming influenza virions, allowing TLR7 
to engage exposed genomic RNA.  A similar TLR7-dependent type I interferon 
response was observed when pDCs were challenged with vesicular stomatitis 
virus (VSV)(52).  Under normal circumstances both influenza and VSV require 
endocytosis for viral entry.  However using a recombinant strain of VSV (VSV-
RSV-F), capable of fusing to the plasma membrane, Lund et al. demonstrated 
that VSV activated TLR7 regardless of the route of viral entry.  TLR7 is also 
responsible for pDC production of IFNα in response to Sendai virus (SV); another 
ssRNA virus which enters at the plasma membrane(53).  Interestingly studies of 
SV using human U937 and murine RAW 264.7 myeloid lines found only a partial 
role for TLR signaling in cytokine and chemokine production(54).  Recent 
evidence suggests the cytosolic RLR receptors are chiefly responsible for the 
cytokine and interferon response to SV in myeloid cell types other than 
pDCs(55). 
One important observation gleaned from studies using SV and VSV was 
that, in contrast to influenza, UV-inactivation of these virions abolished TLR7 
activation(53).  From this work a second model of TLR7 activation known as the 
endogenous pathway was proposed.  According to this theory ssRNA 
intermediates produced during SV and VSV infection are transferred from the 
cytoplasm to the endosome by means of autophagy(53).  Thus, to elicit a TLR7 
response by this route, cells must be exposed to live, replication competent virus.  
This model is supported by studies showing that selective inhibitors of autophagy 
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and mice deficient in autophagic pathways lack a TLR7 mediated response to SV 
and VSV(53).  Recent studies have implicated TLR7 and TLR8 in the response 
to human immunodeficiency virus (HIV).  ssRNA derived from the HIV genome 
caused murine pDCs and macrophages and human PBMCs to produce IFNα, IL-
6 and TNFα(56).  In mice this activity was TLR7-dependent while in humans it 
appears to rely on TLR8 suggesting that HIV receptors may be species-specific.  
A study by Wang et al. found IFNα production by human and mouse pDCs 
responding to Coxsackievirus B (CVB) was also dependent on TLR7(57).  
Interestingly this response required the presence of CVB-specific antibodies as 
well as functional Fc Receptor complexes on the pDC surface.  Thus they 
proposed a mechanism whereby opsonized CBV is delivered to the endosome 
via FcR and once internalized viral RNA is detected by TLR7(57).  This 
observation suggests previous exposure to CVB can influence subsequent innate 
responses furthering our understanding of the complex interplay between 
adaptive and innate immunity.  
 
 
TLR9   
In both humans and mice, TLR9 is highly expressed in pDCs, innate cells 
renowned for their ability to rapidly produce large amounts of type I 
interferon(11).  TLR9 responds to the unmethylated deoxycytidylate-phosphate-
deoxyguanylate (CpG) motifs in viral and bacterial DNA(58).  Not surprisingly 
TLR9 has been shown to play a crucial role in infections caused by a number of 
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DNA viruses.  For instance, TLR9 deficient mice infected with MCMV have a 
drastically increased mortality compared to their wild type counterparts.  This 
hypersensitivity is likely due to the blunted type I IFN and IL-12 response and 
reduced NK cell activation which results in an elevated MCMV load(39).  In EBV 
infection, production of type I IFN, IL-6 and IL-8 by pDCs is largely dependent on 
TLR9(26).  This is in contrast to monocytes where TLR2 synergizes with TLR9 to 
orchestrate the cytokine response to EBV(26).  TLR9 signaling also plays a role 
in the interferon response to HSV types I and II.  One study found IFNα 
production by mouse pDCs in response to HSV-2 was completely dependent on 
TLR9 and independent of viral replication(59).  Using cholorquine it was shown 
that this recognition required endosomal maturation and could be evoked simply 
by exposure to purified HSV-2 DNA(59).  Furthermore, following in vivo HSV-2 
challenge, IFNα was only detectable in the serum of mice with intact TLR9.  A 
similar role for TLR9 was described in the response to HSV-1 by splenic pDCs.  
However, this study also described a delayed IFNα response by conventional 
dendritic cells (cDCs) and macrophages that was both TLR9 and MyD88-
independent but required exposure to replication competent virus.  The TLR9-
independent IFN response is likely due to cytoplasmic RLRs and may explain 
why one study using TLR9 deficient mice identified no in vivo defects in HSV-1 
control(60).  Alternatively TLR9 signaling may be more important in certain 
manifestations of HSV-1 induced disease.  A recent study showed TLR9 deficient 
mice did have higher rates of mortality and viral replication when challenged 
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intranasally with HSV-1(33).  Thus TLR9’s precise role in HSV pathogenesis and 
the relative contributions of other PRRs requires further investigation.  
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Figure 1.1. Cell surface and endosomal recognition of viruses by TLRs.  TLR2 responds to a 
variety of viruses resulting in activation of a MyD88-dependent NF-κB and MAPK pathway.  TLR4, 
responding to viral proteins (eg. RSV F-protein) activates both a MyD88-dependent and MyD88-
independent response.  The MyD88-dependent response leads to transcriptional regulation of 
inflammatory cytokines, while the MyD88-independent response is regulated via TRAM/TRIF and 
the IKK-related kinases which drive IRF3 activation and type I Interferon production. In the 
endosome TLR3, TLR7, TLR8 and TLR9 sense viral nucleic acids and generate either IRF3 
activation (TLR3) or IRF7-driven type I IFNs (TLR7, 8 and 9).  
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1.3 Intracellular Cytosolic Nucleic Acid Sensors 
 
As discussed above, the TLRs play an important role in sensing viral 
PAMPS that are present within the extracellular compartment, as well as in 
endosomes. In certain contexts, TLRs can detect viral nucleic acids generated 
from viruses that replicate in the cytoplasm, via an autophagy mechanism. A role 
for intracellular sensors in the clearance of viruses that replicate and reside 
within the cytosol of cells has recently emerged. Following the generation of mice 
lacking TLRs and examination of their susceptibility to virus infections, it became 
clear that additional sensing mechanisms must also exist and contribute to anti-
viral defenses. The last decade or more has revealed numerous additional 
classes of innate sensors. Of particular relevance to anti-viral defenses was the 
discovery of specialized classes of cytosolic nucleic acid sensors, termed RIG-I 
like receptors (RLRs), which recognize intracellular RNA that is introduced to the 
cytosol during viral infection or that accumulates during replication. Additionally, a 
diverse selection of intracellular DNA sensors which recognize viral DNA within 
the cytosol have also emerged. 
 
1.3.1 RIG-I Like Receptors  
The RLR family is comprised of three DExD/H box RNA helicases: retinoic 
acid-inducible gene (RIG-I), melanoma differentiation-associated gene 5 (MDA-
5), and laboratory of genetics and physiology-2 (LGP-2)(61-65). Both RIG-I and 
MDA-5 are comprised of tandem N-terminal caspase activation and recruitment 
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domains (CARDs) followed by a DExD/H box RNA helicase domain which has 
ATPase activity and a C-terminal repressor domain (RD). Unlike RIG-I and MDA-
5, LGP-2 lacks the N-terminal CARD domains, containing only the RNA helicase 
domain. As such, LGP-2 was postulated to act as a negative regulator of the 
other RLRs (62,64). Under resting conditions, RIG-I resides in the cytoplasm in 
an inactive form that is auto inhibited by its regulatory domain. Upon viral 
infection, RIG-I undergoes a conformational change by which it dimerizes in an 
ATP dependent manner (64). The activated mulitmeric form of RIG-I or MDA5 
then interacts with the downstream adaptor protein mitochondrial antiviral 
signaling protein (MAVS), also known as VISA, IPS-1, and CARDIF, via CARD-
CARD interactions. MAVS is localized to the outerleaflet of the mitochondrial 
membrane which is an essential location to support downstream signaling. 
Recently, MAVS was also shown to be localized on peroxisomes, from where it 
induces an early antiviral response through the direct induction of a subset of 
anti-viral genes via the transcription factor IRF1.   Upon engagement of RIG-I or 
MDA5 with MAVS, MAVS activates the IKK-related kinase, TBK1/IKKi, which 
activates IRF3/IRF7, resulting in the transcription of type I interferons. MAVS also 
activates NF-κB through recruitment of TRADD, FADD, caspase-8, and caspase-
10 (66-70) 
 
RNA Recognition by RLRs 
The RLRs are critical components of the anti-viral defense pathway in 
many cell types including fibroblasts, epithelial cells, and conventional dendritic 
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cells(71). Initially, it was thought that both RIG-I and MDA-5 recognized the 
synthetic dsRNA, polyinosinic acid (polyI:C). However, studies from RIG-I and 
MDA-5 deficient mice determined that MDA-5 alone was responsible for 
interferon production by polyI:C stimulation (72). Instead, RIG-I recognizes 5’-
triphosphorylated (5’-ppp), uncapped ssRNA, which is a common feature in many 
viral genomes. However, it is unable to recognize the capped 5’-ppp ssRNA from 
the host cell (73-75). These finding suggest that RIG-I uses the 5’ end of a 
transcript to discriminate between viral and host RNA. MDA-5 distinguishes 
between viral and host RNA not by its 5’ end, but rather by the length of the RNA 
sequence; long dsRNA is not naturally present in host cells and acts as a ligand 
of MDA-5. In addition to recognizing 5’-ppp RNA, RIG-I is also capable of 
recognizing short dsRNA, which is produced as a byproduct of viral replication 
(76).  
RIG-I and MDA-5 appear to differentially recognize different classes of 
RNA viruses. Studies involving RIG-I deficient mice implicated RIG-I in the 
recognition of vesicular stomatitis virus (VSV), rabies virus, SV, Newcastle 
disease virus (NDV), RSV, measles virus, Influenza A and B, hepatitis C virus 
(HCV), Japanese encephalitis virus, and ebola virus (54,71,72,77-79). Studies 
from MDA-5 deficient mice show that MDA-5 is able to recognize EMCV, theiler’s 
virus, and mengo virus (72,78). All of these viruses do not contain a 5’-ppp RNA, 
but are able to produce long dsRNA, providing further evidence that MDA5 
discriminates between self and non-self RNA based on sequence length and not 
the 5’-ppp. More recently studies have shown that both Coxsackie B Virus (CVB) 
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and poliovirus are dependent on MDA-5 for type I IFN production (80,81). 
Moreover, some viruses, such as dengue, West Nile virus, and reovirus, signal 
through a combination of both RIG-I and MDA-5 (80,82,83).  
As discussed above, LGP-2 lacks N-terminal CARD domains, and was 
first thought to be a negative regulator of RLR function(62,64).  Initial studies 
found that overexpression of LGP-2 decreased the capacity of SV and NDV to 
induce interferon production.  Evidence that LGP-2 could associate with RIG-I 
through mutual RD domains lead to the proposal that LGP-2 directly prevented 
RIG-I association and activation.  Consistent with this idea, interferon signaling 
was found to be increased in LGP-2 deficient mice responding to polyI:C, 
providing evidence for negative regulation of MDA-5 as well (84). A second in 
vivo study using LGP-2 deficient mice as well as mice harboring an inactive 
ATPase in the DExD/H-box RNA helicase domain showed that LGP-2 acted as a 
positive regulator of RIG-I and MDA-5-mediated signaling after infection by RIG-I 
and MDA-5-specific RNA viruses. This phenotype is consistent with the 
possibility that LGP-2 might promote RNA accessibility, thus enabling RIG-I or 
MDA-5 dependent viral recognition. Further studies on these mice will no doubt 
clarify this upstream mechanism and the role of LGP-2 in this pathway.  
 
 DDX3 
 
Another member of the DExD/H box RNA helicase family, DDX3 has also 
recently been implicated in anti-viral defenses. Schroder et al. found that the 
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vaccinia virus protein K7 inhibited IFNβ induction by binding to DDX3, which led 
to the discovery that DDX3 had a positive role in the RLR signaling pathway(85). 
A more recent study reported that DDX3 binds to both polyI:C and viral RNA 
introduced into the cytosol and associates with MAVS/IPS-1 to upregulate IFNβ 
production. These results led the authors to speculate that DDX3 might enhance 
RNA recognition, forming a complex with RIG-I and MAVS to induce interferon 
production (86). Further studies are required to determine whether DDX3 is a 
bona fide RNA sensor or a component of the RLR signaling pathway in order to 
fully understand the function DDX3 plays in anti-viral surveillance and signaling.   
 
1.3.2.Cytosolic DNA Sensors  
Prior to the discovery of TLR9, it was known that DNA derived from 
pathogens could activate fibroblasts to produce type I IFNs (87). This 
phenomenon was ignored or underestimated for decades and was rediscovered 
following the observation that transfection of pathogen-derived dsDNA activated 
a TLR9 negative thyroid cell line to upregulate various immunological genes(88). 
Akira and colleagues subsequently demonstrated that TLR9-/- MEFs, which 
failed to respond to CpG DNA, produced large amounts of IFN in response to 
transfection with synthetic B-form dsDNA or genomic DNA isolated from bacteria, 
viruses, and mammalian cells (88). This was similar to findings presented by the 
Medzhitov lab using a 45bp dsDNA region from the Listeria monocytogenes 
genome, called Immunostimulatory DNA, or ISD. Cytosolic administration of 
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dsDNA did not appear to utilize any known TLRs to induce interferon since cells 
from mice lacking both MyD88 and TRIF responded normally.  
Like the cytosolic RNA recognition pathways, cytosolic DNA recognition 
also leads ultimately to activation of TBK1 and IRF-3 and production of type I 
IFNs. However, the signaling pathway linking upstream DNA sensors to TBK1 
are poorly characterized. TBK1 associates with DDX3, a DEAD box RNA 
helicase, which regulates IFNβ transcription via IRF-3 (85,86). In addition, TBK1 
interacts with the exocyst protein Sec5 in a complex that includes an 
endoplasmic reticulum (ER) adaptor stimulator of interferon genes (STING) (70) 
(89-91). STING plays a central role in the signaling pathway upstream of TBK1 
following HSV infection(70). STING also interacts with the ER translocon 
components Sec61β and TrapB in a manner essential for regulation of cytosolic 
DNA-induced type I IFN production, although the mechanistic understanding of 
this finding is not known (89). In unstimulated cells, STING localizes to the ER 
and perhaps ER-associated mitochondria (91). Following stimulation with 
cytosolic DNA and HSV-1, STING translocates to perinuclear foci, via the Golgi 
(89). STING localizes partially to endosomes, particularly Sec5 positive 
structures (89), whilst another report has demonstrated that STING localizes to 
vesicular structures, which are not peroxisomes, mitochondria, endosomes or 
autophagosomes (92). Further work is required to clarify the precise subcellular 
localization of STING. What is clear is the essential role of STING in cytosolic 
DNA sensing pathways. A growing number of DNA sensors have now been 
implicated and will be outlined below. 
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DAI 
DNA-dependent activator of IFN-regulatory factors (DAI) was among the 
first of the cytosolic DNA sensors to be discovered. It is composed of two binding 
domains for left-handed, Z form DNA, although the protein can recognize B form 
DNA as well. When DAI was exogenously expressed in L929 cells, it increased 
type I IFN production in a dose dependent manner following stimulation by both 
B and Z form DNA. Similarly, knockdown of DAI with siRNA impaired type I IFN 
production in response to DNA, the 45bp interferon stimulatory DNA (ISD) from 
Listeria and the herpesvirus, HSV-1 (93,94). The production of type I interferons 
by fibroblasts in response to HCMV was also found to be dependent on DAI 
(95,96). DAI-knockout mice were subsequently generated, and surprisingly, cells 
derived from DAI deficient mice respond normally to synthetic and viral dsDNA 
(93) (96). These results suggested that DAI might play a cell type specific, and 
redundant role in sensing cytoplasmic DNA, and that other sensors must also be 
necessary for inducing these responses. Lastly, studies have shown that DAI 
interacts with RIP-3 to mediate DNA virus induced necrosis. DAI knockdown or 
knockout cells are resistant to this pathway (97).  
 
RNAPolIII 
As discussed above, both synthetic and viral RNA trigger the production of 
type I IFNs via RIG-I. Although, the RLRs are sensors of RNA, some data has 
suggested a role for this system in detection of DNA. A somewhat surprising 
finding was that synthetic B-form dsDNA can also induce IFNβ production in 
 28 
human cells in manner that was dependent on the RIG-I adapter molecule 
MAVS(98-100). These findings suggested the existence of an unknown DNA 
sensor that would signal via MAVS. Recently, two independent studies have 
provided an explanation for these findings and shown that AT-rich DNA can be 
transcribed by RNA polymerase III into 5'-ppp RNA, which subsequently 
activates RIG-I(98,101). This pathway was reported to be involved in type I IFN 
induction during EBV infections where the EBERs are transcribed by RNA 
polymerase III(102). This indirect DNA-sensing system was also reported to be 
involved in induction of type I IFN following HSV-1 or Legionella 
infection(98,101,103), although its role in Legionella remains to be confirmed.  
 
DNA-PK/Ku70/Ku80 complex and Mre11 
DNA damage repair is an important component of host response to viral 
infection. Furthermore, DNA damage induces type I interferon production. 
Studies have implicated DNA-PKCs, Ku70 and Ku80 in the induction of IFN-β in 
response to DNA transfection and HSV-1 and MVA infection in MEFs. This 
response is mediated through IRF3, but was independent of NK-κB 
activation(104). Another DNA damage factor, Mre11, has also been shown to be 
required for IFN-β production in response to transfected dsDNA in BMDCs. 
However, Mre11 was dispensable for immune responses to HSV-1 and Listeria 
infection(105).   
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Universal Nucleic Acid Sensors LRRFIP1, HMGBs, LSm14A 
Several receptors have been identified that recognize both DNA and RNA 
ligands, acting as “universal nucleic acid sensors.” It has been proposed that 
these receptors are necessary for full immune activation (106). In addition to DAI 
and RNA Pol III, Leucine-rich repeat flightless-interacting protein 1 (LRRFIP1) 
has recently been implicated as a regulator of DNA-driven innate immune 
signaling. LRRFIP1 was found to bind to the drosophila homologue flightless I 
and play a role in actin organization during drosophila embrogenesis. In a study 
using Listeria monocytogenes to screen for potential cytosolic DNA sensing 
molecules, siRNA against LRRFIP1 was found to inhibit type I IFN production 
induced by the bacteria. The authors showed that the IFN response to VSV was 
dampened in these cells as well. Furthermore, knockdown of LRRFIP1 inhibited 
IFN production in response to polyI:C, and the synthetic DNA species, 
poly(dG:dC) and poly(dA:dT), implicating LRRFIP1 in the recognition of both 
dsRNA and both B and Z form dsDNA. Surprisingly, this function is independent 
of RNA Pol III. LRRFIP1 does not regulate IRF3 activation but instead appears to 
regulate a novel β-catenin-dependent coactivator pathway. LRRFIP1 binds RNA 
or DNA and leads to phosphorylation of β-Catenin, which subsequently 
translocates to the nucleus where it associates with the p300 acetyltransferase at 
the IFNβ1 promoter, leading to increased IFNβ production (103). Although 
LRRFIP1 has been implicated in the recognition of both Listeria monocytogenes 
and VSV, further studies are needed in order to determine its role in sensing 
other viruses, particularly DNA viruses.  
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The high mobility group box protein (HMGB1) acts as a danger signal 
when released from cells during necrosis. It interacts with RAGE, TLR2, and 
TLR4 to induce inflammation along with other cytokines.  HMGB1 has been 
shown to bind both DNA and RNA to license activation of RIG-I and other nucleic 
acid sensors. Further work is needed in order to determine where in the cell 
HMGB1 binds its ligands and how it interacts with other sensors(107).  
LSm14A has also been described as a universal nucleic acid sensor. 
LSm14A is a component of RNA processing bodies (P-bodies). It has been 
shown to bind both DNA and RNA and induce type I interferon production 
through IRF3 and requires STING, MAVS, and RIG I respectively. This suggests 
that viral recognition may take place within P-bodies and LSm14A plays a role in 
antiviral activation through nucleic acid sensors(108).   
 
DDX9 and 36 
Also in the family of DExD/H box RNA helicases, DHX9 and DHX36 have 
recently been shown to recognize and bind CpG-B and CpG-A DNA, respectively 
in plasmacytoid dendritic cells. Activation of DHX9 leads to IRF-7 activation and 
IFNα production, while activation of DHX36 leads to the activation of NF-κB and 
the production of IL-6 and TNFα. siRNA knockdown of DHX9 and DHX36 
inhibited cytokine production in response to the DNA virus HSV-1, while 
response to the RNA virus influenza A was unaffected (109).  
 
 
 31 
DDX41 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 41 (DDX41), another member 
of the DEAD/H helicases family, was recently identified as DNA sensor (110). 
siRNA knockdown of DDX41 in BMDCs and THP-1 cells led to a decrease in 
Type I IFN production in response to transfected DNA and HSV-1 infection (110). 
DDX41 was also shown to recognize the bacterial cyclic di-nucleotides cyclic di-
AMP and cyclic di-GMP. Binding to these ligands leads to STING dependent 
activation of type I IFNs (111). It remains to be seen if DDX41 interacts with other 
sensors in the type I IFN signaling pathway. 
 
IFI16 
 
IFI16 is a human member of the HIN200 proteins. It is expressed 
differentially in myeloid cells and is highly inducible in response to type I and type 
II interferons. IFI16 is alternatively spliced into three isoforms, 16a, 16b, and 16c, 
which have been shown to homo or heterodimerize.(112).  IFI16 and its mouse 
orthologue IFI204 contain two HIN200 DNA binding domains, HIN200A and 
HIN200B, and a pyrin domain(113). Each HIN200 domain contains two 
Oligonucleotide/Oligosaccharide Binding (OB) folds that bind to DNA. (114). 
Crystallography of the IFI16 HIN200 domains bound to dsDNA show that the 
DNA binding is due to electrostatic interactions between the negatively charged 
sugar phosphate backbone of the DNA and positively charged residues in the 
HIN200 domain. Thus, these interactions appear to be non-sequence 
specific(115).  
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Early experiments revealed that when IFI16 is fused to a GAL4 DNA 
binding domain it can act as a transcriptional repressor of CAT activity. 
Furthermore, in conjunction with SP1, IFI16 can repress transcription of a 
reporter gene containing the human cytomegalovirus promoter(116). IFI16 was 
also found to play a role in cell cycle regulation as it interacts with p53 and 
Rb(117). Due to its interaction with p53, IFI16 has also been described to play a 
role in a host of cancers such as breast and prostate cancer(118,119), 
apoptosis(120-125), and DNA damage responses(117,119,126). IFI16 has also 
been implicated in the pathology of SLE. Anti-IFI16 antibodies are secreted into 
the serum of SLE patients and serve as a biomarker for the disease(127-129).  
More recently, IFI16 was identified as a cytosolic DNA sensor that 
recognizes viral and bacterial DNA leading to the activation of STING and 
downstream type I IFN production(130). IFI16 has also been shown to play a role 
in the recognition of HSV-1. Although the expression of IFI16 is predominately 
nuclear, studies have shown that IFI16 is capable of shuttling to the cytosol to 
detect HSV-1 DNA. This is largely attributed to acetylation of the IFI16 bipartite 
nuclear localization signal upon infection(131).  Protesosomal degradation of the 
HSV-1 capsid allows for detection of the viral DNA by IFI16 in the 
cytoplasm(132). In contrast, other studies suggest that HSV-1 is detected by 
IFI16 in the nucleus, and an unknown factor is shuttled to the cytosol to activate 
STING and subsequent downstream pathways(133). IFI16 has also been shown 
to play a role in inflammasome activation in response to HSV-1(134) and to 
sense KSHV DNA in the nucleus and form a complex with the inflammasome 
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adapter molecule ASC(135,136) Most recently, IFI16 has been linked to 
inflammasome activation and pyroptotic death of bystander CD4 T cells during 
HIV infection(137-140).  
 Work from chapter two of this thesis indicates that IFI16 also plays a 
broader role in the regulation type I IFN gene transcription and production in 
response to both RNA and DNA viruses (Chapter 2). Our working hypothesis 
here is that IFI16 may act as both a sensor and in the nucleus as a regulator of 
gene transcription.  
 
cGAS 
 
 Recently the second messenger, cGAMP, was discovered to activate 
STING and downstream type I IFN signaling in response to transfected DNA. 
(141,142). The discovery of cGAMP led to a greater understanding of how cyclic-
di-nucleotides interact with STING. Crystallography of cGAMP with STING show 
that cGAMP binds at the interface of a STING dimer and then leads to a 
conformational change that activates STING and downstream signaling (143). 
Through protein purification and mass spectrometry, the enzyme responsible for 
synthesizing cGAMP was determined to be a nucleotidyltransferase the authors 
named cGMP-AMP synthase “cGAS”(144). cGAS synthesizes cGAMP from ATP 
and GTP upon stimulation with DNA(144). RNAi knockdown of cGAS in L929 
and THP-1 cells reveal that cGAS is necessary for the production of type I IFNs 
in response to DNA and HSV-1 (144). Later studies in cGAS knockout cells 
confirmed these findings.  
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 Multiple structrual studies found that cGAS undergoes a conformational 
change allowing its substrates access to its catalytic pocket in a DNA 
dependedant manner(141,145-148). This observation led to speculation that 
cGAS is the primary cytosolic DNA sensor. The cGAMP produced by cGAS 
contains a phosphor-di-ester linkage between 2′ -OH of GMP and 5′ -phosphate 
of AMP and another between 3′ -OH of AMP and 5′ phosphate of GMP. This form 
of cGAMP binds to STING with high affinity and leads to a more potent type I IFN 
response than that of bacterial cyclic-di-nucleotides (143,146,149).  
 cGAS has also been implicated in the recognition of HIV and other 
retroviruses(150). shRNA knockdown of cGAS in THP-1 cells inhibited the 
induction of IFN-β and phosphorylation of IRF3. This response was shown to be 
mediated by the reversed transcribed DNA of HIV. cGAS knockdown cells also 
produced less IFN-β in response to murine leukemia virus, and simian 
immunodeficiency virus.  
  Lastly, the generation of cGAS deficient mice provided further insight into 
the role cGAS plays in DNA sensing. BMDMs and BMDCs generated from 
cGAS-/- mice displayed a severely attenuated type I IFN response to DNA 
ligands as compared to WT mice. The type I Interferon response to Sendai Virus 
was unaffected in cGAS -/- cells (151). These mice were also more susceptible 
to HSV-1 infection than WT mice. cGAS-/- mice produce less IFNα/β in the 
serum up to 12 hours post infection. Thereafter, IFNα/β production returned back 
to WT levels. The cGAS -/- mice also display increased HSV-1 viral titer in the 
brain 72 hours post infection. Further studies are needed to determine if cGAS is 
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playing a redundant role or is working along with other cytosolic DNA sensors 
such as IFI16. 
 
1.3.3 The Inflammasome 
Although the sensing of cytoplasmic DNA is linked to the transcriptional 
induction of type I IFN and other pro-inflammatory cytokines, cytosolic DNA has 
also been shown to trigger the caspase-1-dependent maturation of the pro-
inflammatory cytokines IL-1β and IL-18 (152,153). IL-1β, a close biological 
relative of TNFα, has a variety of effects including innate cell recruitment, 
activation of T-lymphocytes and induction of fever (154). IL-18 increases the 
cytolytic activity and IFNγ production of natural killer (NK) cells and influences 
neutrophil recruitment and activation (154,155). Growing evidence supports the 
importance of these cytokines in anti-viral defenses (156,157). Mice lacking 
either one of these cytokines have demonstrated enhanced susceptibility to 
influenza A virus and HSV-1 infections (158).  Moreover, pretreating mice with IL-
18 protects them from subsequent HSV-1 and VV challenge (159,160).  
In contrast to type I IFNs and TNFα, the production of IL-1β is controlled at 
the level of transcription, translation, maturation and secretion (161,162). Many 
cell stimuli including TLR-ligands activate the transcription of the pro-forms of IL-
1β and IL-18. Unlike most other cytokines however, these pro-cytokines lack 
leader sequences and are retained in the cytoplasm rather than loaded into 
secretory vesicles. Maturation (i.e., the cleavage) of pro-IL-1β and pro-IL-18 is 
catalyzed by the cysteine protease caspase-1 (formerly known as IL-1 converting 
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enzyme). In resting cells, caspase-1 itself is present as an inactive zymogen pro-
caspase-1(163). A large ‘inflammasome protein complex‘ controls the activity of 
the inflammatory caspase-1 (163). Several protein complexes have been shown 
to form inflammasomes upon recognizing specific stimuli. NLRPs 2 to 14, which 
contain a C-terminal LRR-rich domain, a central nucleotide-binding NACHT 
oligomerization domain, and an N-terminal protein–protein interaction pyrin 
domain (PYD) associate with the PYD containing adaptor molecule apoptosis-
associated speck-like protein (ASC; also termed pycard or TMS1) (164). ASC 
links the NLRP’s via its C-terminal CARD domain to the CARD domain of pro-
caspase-1. This close association of pro-caspase-1 molecules is then believed to 
provoke self-cleavage into active caspase-1. Active caspase-1 then cleaves pro-
IL-1β and pro-IL18. ASC is critical for caspase-1 activation in response to many 
stimuli (154,165) (163) (166,167).   
 
AIM2 
 
Cytosolic dsDNA also triggers an ASC dependent activation of caspase-1 
resulting in the maturation and secretion of IL-1β and IL-18. These findings 
suggested the existence of an inflammsome complex that can be triggered by 
DNA. Analysis of this response in macrophages lacking members of the NLRs 
revealed normal caspase-1 activation in these cells. Subsequent studies from 
several groups revealed that this response was instead dependent on AIM2 
(Absent in melanoma-2), an interferon inducible protein that belongs to the same 
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PYHIN family as IFI16  (153) (168-170). AIM2 recognizes cytosolic dsDNA of self 
and nonself origin including viral DNA via its HIN200 domain in a sequence-
independent manner. Contrary to other cytosolic sensors of DNA, the recognition 
of DNA by AIM2 triggers the assembly of an inflammasome complex. Upon DNA 
binding, AIM2 likely undergoes oligomerization and associates with ASC via 
homotypic pyrin-pyrin domain interactions, which in turn recruits pro-caspase 1.  
Published data has shown that the AIM2 inflammasome is an integral component 
of innate sensing of DNA viruses (157). AIM2 is essential for the activation of 
caspase-1 and proteolytic processing of IL-1β and IL-18 in antigen presenting 
cells in response to infection with MCMV and VV. Furthermore, AIM2-ASC 
dependent IL-18 secretion and NK-cell activation is critical in the early control 
MCMV infection in vivo (153) (157).  In addition to viruses, AIM2 has also been 
shown to recognize Francisella tularensis and as observed for DNA viruses 
appears to be critical in early control of Francisella tularensis infection in vivo. 
Moreoever, AIM2 as well as NLRP3 and IPAF function in a redundant manner in 
the recognition of Listeria monocytogenes(157) (169). 
 
NLRP3 
 
In addition to the AIM2 inflammasome, a number of recent studies have 
shown that mice deficient in NLRP3 are more susceptible to virus infections, 
particularly RNA viruses (152) (171).  Loss of NLRP3 was found to attenuate the 
normal IL-1β and IL-18 responses to IAV and was associated with diminished 
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innate cell recruitment to the lung and increased pathology (171).  Further 
studies revealed that influenza’s M2 protein, a proton-specific ion channel was 
sufficient to trigger the NLRP3 inflammasome (172). Viral RNA has also been 
shown to trigger NLRP3 activation, although this is unlikely to be a direct RNA-
NLRP3-interaction. The precise relationship between M2 and RNA in NLRP3 
activation remains to be clarified. The NLRP3 inflammasome also plays a role in 
the response to adenovirus, a DNA virus (152).  Peritoneal macrophages isolated 
from NLRP3 or ASC deficient mice exposed to adenovirus are unable to secrete 
mature IL-1β (152).  When challenged in vivo, NLRP3 knockout mice had 
reduced levels of IL-1β, IL-6, CCL4 (MIP-1β) and CXCL10 (IP-10) in the liver. 
Recently, a viral NLR homologue was identified in the dsDNA virus, KSHV. The 
KSHV tegument protein ORF63 appears to be an NLR homolog that can inhibit 
inflammasome activation by binding to NLRP1 and NLRP3 (135). Inflammasome 
activation suppresses KSHV reactivation from latency, suggesting that 
inflammasome activation and IL-1β mediated signaling facilitates KSHV latency. 
These observations are consistent with a model whereby the KSHV tegument 
ORF63 protein might bind NLRP3 and/or NLRP1 to block the detrimental effects 
of inflammasome activation. More recently studies have shown that in response 
to gram-negative bacteria, caspase 11 can be directly activated by TRIF to 
license the NLRP3 inflammasome (173).   
Intriguingly, a recent study has revealed a role for IFI16 in the recognition 
of Kaposi sarcoma-associated herpesvirus (KSHV) in endothelial cells. IFI16 is 
known to recognize viral DNA in the cytosol and drive type I Interferon 
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production, as discussed above. In endothelial cells however, IFI16 in the 
nucleus can sense the KSHV DNA and form a complex with the inflammasome 
adapter molecule ASC. These findings suggest that IFI16 can form an 
inflammasome complex following recognition of nuclear DNA during infection 
with this virus (135). Figure 2 portrays the cytosolic and nuclear receptors known 
to respond to viral pathogens and their downstream signal pathways. 
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1.4 Herpes Simplex Virus 1 
Herpes Simplex Virus 1 (HSV-1) is a large, (152 kb), linear, double 
stranded DNA virus of the alpha herpresviridae subfamily that encodes for over 
80 proteins. The viral genome is encompassed by an icosahedral capsid that is 
surrounded by tegument proteins and a lipid envelope. The HSV-1 genome is 
transcribed by host RNA Pol II in three stages: Immediate early, early, and late, 
over the course of 8 hours. The immediate early genes are responsible for host 
transcription shut off and viral evasion mechanisms, the early genes regulate 
viral replication, and the late genes encode for the structural components of the 
virion. Viral entry to the host cell is mediated by a series of glycoproteins (gC, gD, 
gH, gL, gB) found on the viral envelope. The viral capsid then enters the 
cytoplasm, where it attaches to the host nucleus and injects the viral DNA 
through a nuclear pore. In the nucleus, the virus undergoes a lytic infection, 
where the genome is replicated and viral particles are formed and bud from the 
host cell. The virus can also enter a latent stage of infection in the trigeminal 
ganglia, where it expresses Latency Associated Transcripts (LAT), which silence 
lytic cycle genes(174). 
HSV-1 is typically associated with primary infections of the oropharynx, 
although it can infect the genitalia as well. The virus enters the host through skin 
lesions and contact through the mucosal membrane. HSV-1 primarily infects 
epithelial cells except for when it enters a state of latency whereby it resides 
dormant in the sensory neurons evading detection by the immune system.  
Reactivation of the virus from latency due to emotional or physical stress can 
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cause lesions commonly known as cold sores, which form as a result of cell lysis, 
apoptosis, and inflammation. The virus also has the ability to travel to the central 
nervous system (CNS), infecting neurons and astrocyte cell populations (175), 
resulting in Herpes Simplex Encephalitis (HSE), a disease that causes severe 
inflammation of the brain. These severe cases are rare in healthy adults but 
occur more frequently in immunocompromised individuals.  
The innate immune response is crucial for the early recognition and 
control of a HSV-1 infection. Recognition of the virus is largely dependent upon 
signaling through various pattern recognition receptors (PRRs) including the Toll-
Like Receptors (TLRs). TLR9, which recognizes dsDNA in the cytosol, has been 
shown to recognize HSV-1 in plasmacytoid dendritic cells (pDCs)(59,60) and 
splenic CD11c+ DCs(60). TLR2 has also been implicated in the recognition of 
HSV-1 via its glycoproteins in DCs, peritoneal macrophages, (32) and microglial 
cells(176) in the brain. Furthermore, it has been reported that bone marrow 
derived dendritic cells have the capacity to recognize HSV by both TLR2 and 
TLR9 simultaneously (177). Lastly, as HSV-1 has a dsRNA intermediate, it is 
able to signal through TLR3, and has been implicated as a vital receptor in 
immunity against HSE(41). HSV-1 can also be recognized by cytosolic RNA 
helicases such as retinoic acid inducible gene (RIG-I) and melanoma 
differentiation associated gene-5 (MDA-5), and cytosolic DNA sensors, IFI16 and 
cGAS, which leads to the production of Type-1 Interferons (178). HSV-1 
signaling induces type I interferon production in a MyD88 independent and 
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Interferon Regulating Factor (IRF7) dependent manner, which is known as the 
“classical pathway” (12).   
Signaling through these PRRs activate the common transcription factors, 
IRF3, IRF7, NF-κB and AP-1, thus triggering production of type-1 interferons, 
which play a major role in viral clearance, as well as inflammatory cytokines such 
as pro-IL-1, IL-6, pro-IL-18 and chemokines such as RANTES, and MCP-1. 
These effectors block viral replication and recruit additional immune cells 
necessary to activate the adaptive immune response. More recently, it has been 
suggested that the inflammasome complex provides a critical role in the 
clearance of HSV-1 as well. The role of IL-1β in HSV-1 clearance has been 
clearly elucidated(179), however the specific inflammasome that mediates this 
response are not well defined.  Preliminary data in our lab show that although 
NLRP3 does not respond to HSV in an HSE model in vivo, the NLRP3 
inflammasome mediates IL-1 responses to HSV in vitro in macrophages and 
DCs. Furthermore, the NLRP12 inflammasome also plays a role in driving IL-1 
maturation in HSV-1 infection in vitro, although how HSV-1 triggers NLRP12 
activation is unclear. Furthermore, loss of NALP12 leads to increased 
susceptibility to HSE in vivo. Other studies have suggested that IFI16 forms an 
inflammasome in response to HSV-1(135), however conflicting studies show that 
IFI16 expression suppresses caspase-1 activation by the NLRP3 and AIM2 
inflammasomes(134). Additional studies are necessary to determine the role the 
inflammasome plays in HSV-1 recognition.  
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1.5 Type I IFN Induction 
 
Upon viral infection and PRR activation, type I interferons are among the 
most important effectors that are secreted from cells and lead to an inflammatory 
antiviral response that is critical in the clearance of pathogens. The production of 
type I IFNs initiates the transcription of many interferon stimulated genes, which 
further aid in viral clearance, and triggers the production of other cytokines and 
chemokines that enhance the inflammatory response and viral clearance. These 
ISGs also potentiate the production of type I IFNs, thus leading to a positive 
feedback loop. The importance of type I IFNs in viral infection is highly evident 
from studies in IFNAR deficient mice, which are susceptible to many viral 
infections (180,181). In addition to their role in innate immunity, type I IFNs are 
also important for the development of adaptive immunity. Type I IFNs up regulate 
MHC-I to facilitate antigen presentation and long-term memory response(182). 
The  induction and regulation of type I IFNs are described below.  
The promoter of type I IFNs contains four positive regulatory domains, 
PRD I, PRD II, PRD III, and PRD IV. PRD I and PRD III are activated by binding 
of IRFs, while PRD II and PRD IV are activated by binding of NF-κB and ATF-
2/cJun respectively(183).  The IFN-β promoter contains all four response 
elements, PRDI-IV. Therefore, IFN-β activation requires binding of the IRFs, NF-
κB and ATF-2/cJun. Binding of these transcription factors to the IFN-β promoter 
leads to the formation of the enhancesome, which also contains the co-activator 
cAMP response element-binding (CREB)-binding protein (CBP) or p300, to 
initiate gene transcription (184).  In contrast, the IFN-α promoter contains only 
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PRD I and PRD III. Therefore, IFN-α is regulated solely via binding of the 
IRFs(185-188).  
To date IRF1, IRF3, IRF5, IRF7, and IRF9 have been implicated in type I 
IFN induction, with IRF3 and IRF7 being most crucial for IFNα/β gene induction. 
(188,189). As discussed above, upon viral infection, IRF3 is phosphorylated, and 
undergoes dimerization, and nuclear translocation. Binding of IRF3 to the IFN-β 
promoter induces the production of IFN-β and ISGs. IFN-β then activates the 
IFNAR receptor causing a positive feedback loop and amplifying the type I IFN 
response.  
Type I IFN feedback loop is mediated by binding of IFNα/β to the IFNAR 
receptor and subsequent activation of JAK/STAT pathway. IFNAR is comprised 
of two subunits, IFNAR1, which associates with tyrosine kinase 2 (TYK2), and 
IFNAR2, which associates with JAK1. Upon binding of IFNα/β, the receptor 
dimerization promotes phosphorylation of TYK2 and JAK1 and then 
phosphorylation of STAT1 and STAT2 and recruitment of IRF9. The 
heterotrimeric complex of STAT1, STAT2, and IRF9, termed ISGF3, translocates 
to the nucleus, and binds ISREs, leading to the production of IRF7, IFN-α, and 
many ISGs(190-192). Over 400 ISGs, including viperin and RIG-I have been 
identified, all of which are inducible by type I IFNs.  
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Figure 1.3 Type I IFN signaling. Binding of nucleic acids to cytosolic sensors leads to the 
phosphorylation of IRF3 and the production if IFN-β.  IFN-β then activates the IFNAR 
receptor, which then promotes IFNAR1/IFNAR2 dimerization, phosphorylation of TYK2 and 
JAK1, and phosphorylation of STAT1 and STAT2. After being activated, STAT1 and 
STAT2 heterodimers recruit IRF9 to form the transcriptional complex, ISGF3, which 
translocates into the nucleus to activate ISGs, including IRF7. IRF7 then turns on IFNα/β 
and other ISGs leading to the positive feedback loop and amplification of antiviral 
responses. Figure adapted from Mikayla R. Thompson, John J. Kaminski, Evelyn A. Kurt-
Jones, Katherine A. Fitzgerald. 2011. Pattern recognition receptors and the innate immune 
response to viral infection. Viruses. 6:920-40. 
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1.6 Dissertation Objectives 
This dissertation has two main objectives: (1) To Determine the role IFI16 plays 
in the innate immune response to cytosolic nucleic acids, not only by detection of 
dsDNA, but also in the nucleus by transcriptional regulation of ISGs that are 
critical in the type I IFN pathway. (2) Define the role of cGAS and IFI16 in anti-
viral immunity using mice deficient in cGAS and mice with a targeted deletion of 
the proposed mouse orthologue of IFI16, IFI204.  
 
1.1 Delineate the role of IFI16 in sensing RNA and DNA virus infection in vitro 
and determine the downstream signaling components necessary for this 
response. We tested the ability of RNA and DNA viruses and ligands to 
induce type I IFNs in IFI16 shRNA knockdown THP-1 cells and determined 
the downstream signaling components necessary for this response by 
western blot. We demonstrated that IFI16 is necessary for type I interferon 
production in response both DNA and RNA ligands in THP-1 and U2OS cells. 
1.2 Determine the impact of IFI16 knockdown on immune response gene 
expression. Using nanostring analysis, we demonstrate that IFI16 plays a role 
in the transcriptional regulation of type I IFNs and interferon stimulated genes.  
1.3 Assess the ability of IFI16 to bind to promoter regions of genes whose 
expression is dependent on IFI16. By ChIP analysis, we demonstrate that 
IFI16 knockdown THP-1 cells display less RNA Pol II recruitment to the IFN-α 
promoter.  
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2.1 Determine the role of IFI16 in anti-viral immunity using cells from mice with a 
targeted deletion of the proposed mouse orthologue of IFI16, IFI204. We 
determined that IFNα/β production in response to DNA and RNA ligands is 
partially dependent on IFI204 in primary mouse macrophages. However, this 
response is independent of NF-κB activation and cell death.   
2.2 Determine the role of cGAS in anti-viral immunity using cells from cGAS 
deficient mice. In contrast to IFI204 deficient cells, primary mouse cells 
deficient in cGAS were limited in their ability to produce type I IFNs in 
response to a broad range of DNA ligands. We also implicate cGAS in 
detection of Malarial DNA.  
2.3 Determine the role of IFI204 in HSV-1 infection in vivo. We demonstrate that 
IFI204 plays a role in mediating the host response to HSV-1 infection in vivo. 
IF204 deficient mice display decreased IL-6, IL-1β, and IFN-β levels in the 
serum and brains of infected mice as compared to WT infected mice.  
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Chapter 2: Interferon Gamma Inducible protein (IFI)16 transcriptionally regulates 
IFN-α and other interferon stimulated genes and controls the Interferon response 
to both DNA and RNA viruses 
 
Abstract  
The Interferon Gamma Inducible protein (IFI)16 has recently been linked to the 
detection of cytosolic DNA during infection with herpes simplex virus and HIV. 
IFI16 binds dsDNA via HIN200 domains and engages the adaptor molecule 
Stimulator of Interferon genes (STING) leading to TANK binding kinase-1 (TBK1) 
dependent phosphorylation of interferon regulatory factor 3 (IRF3) and 
transcription of type I interferons (IFN) and related genes. In an effort to better 
understand the role of IFI16 in coordinating type I IFN gene regulation, we 
generated cell lines with stable knockdown of IFI16 and examined responses to 
DNA and RNA viruses as well as other inducers of IFN such as cyclic-di-
nucleotides. As expected stable knockdown of IFI16 led to a severely attenuated 
type I IFN response to cytosolic DNA ligands and DNA viruses. In contrast, 
expression of the NF-κB regulated cytokines such as IL-6 and IL-1β were 
unaffected in IFI16 knockdown cells, suggesting that the role of IFI16 in sensing 
these triggers was unique to the type I IFN pathway. Surprisingly, we also found 
that knockdown of IFI16 led to a severe attenuation of IFN-α and IFN stimulated 
genes such as RIG-I in response to cyclic GMP-AMP (cGAMP), a second 
messenger produced in response to cGAS as well as RNA ligands and viruses. 
Analysis of IFI16 knockdown cells revealed compromised occupancy of RNA 
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polymerase II on the IFN-α promoter in IFI16-knockdown cells suggesting that 
transcription of ISGs is dependent on IFI16. These results indicate a broader role 
for IFI16 in the regulation of the type I IFN response to RNA and DNA viruses in 
anti-viral immunity. 
 
Introduction 
The innate immune system is crucial for regulation of early detection and 
clearance of invading pathogens. The innate detection of pathogens acts as a 
primer for the long term, memory response governed by the adaptive immune 
system. Innate immunity is triggered by a panel of germline encoded pattern 
recognition receptors that sense foreign pathogens and trigger downstream 
signaling. This leads to the production of effector proteins such as type I 
interferons (IFNs), pro-inflammatory cytokines, and chemokines, which are 
important mediators of this response.  
To date, several germline encoded pattern recognition receptors have 
been described. The Toll Like Receptors (TLRs), which are present on both the 
cell surface and within endosomal compartments, are perhaps the most widely 
known and extensively studied. The TLRs recognize conserved pathogen 
associated molecular patterns (PAMP) such as bacterial LPS as well as danger 
associated molecular patterns (DAMPS), such as host cell DNA released by 
damaged cells during cellular stress. During viral infection, members of the TLR 
family such as TLR3 and TLR7/8 recognize dsRNA and ssRNA respectively. 
Additionally, in plasmacytoid dendritic cells, TLR9 is responsible for the 
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recognition of CpG DNA, leading to the production of type I IFNs (58,193). The 
IFN response to nucleic acids is not exclusively mediated by TLRs, however. 
RNA and DNA that access or accumulate in the cytosol during viral and bacterial 
infection are also potent activators of the innate immune response (94,153,194). 
RNA and DNA elicits TLR-independent responses, particularly those leading to 
robust induction of type I IFNs. This observation led to the discovery of several 
cytosolic nucleic acid sensors that sense RNA and DNA in the absence of TLRs 
and couple pathogen recognition to immune activation.  
 In the case of RNA, the DExD/H box RNA helicases termed RIG-I like 
receptors (RLRs) respond to cytosolic RNA. This family is comprised of RIG-I, 
MDA5, and LGP2. RIG-I, recognizes 5’ppp ssRNA, a moiety commonly found on 
uncapped negative sense RNA viruses. MDA5, recognizes long dsRNA, a 
byproduct of positive sense RNA viral replication (72-74,195). A third member, 
LGP2 has been postulated to act as a negative regulator of RIG-I function but 
has also been shown to promote MDA5 signaling (61). Growing evidence also 
supports the existence of multiple cytosolic DNA sensing receptors, which 
engage STING, leading to TBK-1 dependent phosphorylation of IRF3 and 
transcription of type I IFN genes (70,89). Through less well-understood 
pathways, these sensors also elicit NF-κB activation and transcription of NF-κB-
dependent genes.  
Our lab has been involved in implicating two members of the PYHIN 
protein family in the recognition of DNA. The first of these AIM2, which is highly 
conserved in mice and humans, binds DNA via a HIN200 domain and forms a 
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mulitprotein inflammasome complex with ASC and caspase-1. Activation of 
caspase-1 results in the maturation and secretion of pro-IL-1β and pro-IL-18 as 
well as pyroptotic cell death (153,168,170,196,197). A second PYHIN protein 
IFI16 as well as a murine PYHIN family member IFI204 (also called p204), have 
also been shown to bind DNA via HIN200 domain(s). IFI16 was initially described 
as a transcriptional regulator. IFI16 contains a transcriptional regulatory domain 
and has been shown to bind and transcriptionally repress p53 (116,198,199). It 
has also been shown to interact with SP-1-like factors to block human 
cytomegalovirus replication (200,201). In a series of biochemical and loss of 
function studies, IFI16 was shown to associate with STING and coordinate IRF3 
and NF-κB signaling in response to Herpes Simplex Virus-1 and intracellular 
delivery of dsDNA. Although IFI16 is predominately nuclear, the recognition of 
DNA by IFI16 was proposed to occur in the cytosol and coordinate the 
transcription of type I IFNs and associated genes (130). Knockdown of IFI16 or 
IFI204 (in corresponding mouse cells) by RNAi lead to a decrease in IFN-β 
production in response to various synthetic DNA ligands and viruses. Orzalli et al 
have shown that nuclear localization of IFI16 is important in immunity to HSV-1 in 
human foreskin fibroblasts, permissive cells where HSV-1 undergoes productive 
infection. Nuclear localized IFI16 is capable of recognizing viral dsDNA and 
activating IRF3 in response to HSV-1 infection (133). Conrady et al have shown 
that knockdown of IFI204 in corneal epithelium leads to resistance of HSV-1 
infection (202). Other studies have shown that in endothelial cells, IFI16 forms an 
inflammasome with ASC to produce IL-1β in response to human Kaposi Sarcoma 
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Virus (KSHV) (135). Most recently, IFI16 has been linked to inflammasome 
activation and pyroptotic death of bystander CD4 T cells during HIV 
infection(138-140,203). 
Since the initial discovery of IFI16 and IFI204, compelling recent evidence 
from both human and mouse cells using both RNAi, TALEN knockdown 
approaches and gene knockouts has convincingly demonstrated the importance 
of a DNA sensing enzyme called cyclic GMP-AMP synthase (cGAS) in the 
cytosolic response to dsDNA. The Chen lab was the first to identify cGAS, which 
binds DNA in the presence of ATP and GTP leading to the generation of a 
second messenger cGAMP. cGAMP then binds to STING and leads to IRF3 
activation. This is true for responses to viruses such as HSV-1 and HIV 
(140,142,144,150). Given the compelling insight into DNA sensing obtained from 
the studies of the cGAS-cGAMP pathway, further work is needed in order to fully 
elucidate the mechanism by which IFI16 contributes to the immune response to 
cytosolic dsDNA and DNA viruses. 
 Here we elucidate the role that IFI16 plays in the induction of type I IFNs 
by examining responses to DNA as well as DNA viruses. Consistent with 
published studies, we find a critical role for IFI16 in coordinating the induction of 
type I IFNs and IFN stimulated genes in response to cytosolic DNA as well as 
DNA viruses. In contrast, we found that the induction of NF-κB dependent genes 
such as IL-1 and IL-6 however was unaffected in cells with reduced expression of 
IFI16.  Surprisingly, we also reveal that knockdown of IFI16 attenuates IFN/ISG 
responses to RNA viruses. The role of IFI16 in sensing RNA viruses was also 
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expanded to demonstrate compromised IFN-α and ISG expression in response 
to synthetic ligands, which engage the RIG-I pathway. Analysis of RNA 
polymerase II recruitment to the IFN promoter identifies compromised Pol II 
association, indicating that the effects on ISGs were at the level of gene 
transcription. Collectively, these studies describe a regulatory role for IFI16 in the 
induction of IFN stimulatory genes and subsequent IFN production in response to 
a broader array of IFN inducers than previously anticipated, expanding the 
function of IFI16 beyond strictly sensing of microbial DNA.   
 
Results  
DNA induced type I interferon production is dependent on IFI16.  
The type I IFN response induced by DNA in the human THP-1 monocytic 
cell line or mouse RAW 264.7 cells is dependent on IFI16 or its proposed mouse 
orthologue IFI204(130). siRNA studies have shown that transient knockdown of 
IFI16 in THP-1 cells leads to a decrease in IFN production and reduced IRF3 and 
NF-κB activation in response to the DNA virus HSV-1 as well as to DNA ligands. 
In order to provide a more in depth characterization of the DNA response through 
IFI16, we created a stable IFI16 knockdown in the human myeloid cell line THP-1 
via lentiviral transduction of shRNA in a pLKO.1 vector. We also created stable 
IFI16 knockdown in a second human cell line, U2OS.  Two different shRNA 
plasmids were used; one targeting the coding sequence of IFI16 (IFI16 shRNA 
CDS-KD), and one targeting the 3’UTR of IFI16 (IFI16 shRNA 3’UTR-KD). The 
empty pLKO.1 vector was used as a transduction control. In all IFI16 shRNA 
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transduced cell lines we achieved at least 50 percent reduction in IFI16 levels of 
both mRNA and protein (Figure 2.1).  
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Figure 2.1.  Stable knockdown of IFI16 by lentiviral transduction.  A. THP-1 or B and C. U2OS 
cells were targeted with shRNA against the coding sequence of IFI16 (IFI16 shRNA CDS-KD), 
the 3’UTR of IFI16 (IFI16 shRNA 3’UTR-KD), or empty vector control plasmid by lentiviral 
transduction.  Stable clones were selected and monitored for IFI16 expression by 
immunoblotting and q-RT-PCR. (* p<0.05 assessed by Two-Tailed t-Test compared to empty 
vector control, data are represented as mean + S.E. Data represents 3 biological replicates). 
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We next determined if the IFI16 knockdown cells were hindered in their 
ability to produce type I IFNs in response to DNA ligands. We challenged the 
THP-1 and U2OS IFI16-knockdown cells with poly(dA:dT), or HSV 60mer (a 
double stranded DNA sequences derived from the Herpes Simplex Virus-1 
genome), or infected with HSV-1 7134 (a mutant strain of the virus that lacks the 
immunosuppressive ICP0 gene), for 6 hours and then collected RNA from the 
samples. IFN-α and IFN-β levels were measured by q-RT-PCR and normalized 
to HPRT. Levels of IFN-β mRNA were decreased in IFI16 knockdown THP-1 
cells as compared to empty vector control cells in response to poly(dA:dT), HSV 
60mer and HSV-1 (Figures 2.2a, b, and c respectively). We also monitored these 
responses in U2OS cells as an independent control knockdown cell line. Similar 
to THP-1 cells, levels of IFN-β mRNA were decreased in IFI16-knockdown U2OS 
cells in response to poly(dA:dT) and HSV 60mer compared to empty vector 
controls (Figure 2.2d and e). More interestingly, levels of IFN-α were more 
drastically reduced in U2OS IFI16-knockdown cells as compared to the empty 
vector control cells in response to poly(dA:dT) (Figure 2.2f). This result is 
consistent with the production of IFN-α being downstream of IFN-β production 
and activation of IRF-7.  (In contrast to THP-1 cells, HSV-1 infection did not 
induce detectable IFN-β mRNA in either vector control or knockdown U2OS 
cells).   
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Figure 2.2. IFI16 knockdown cells display an abrogated type I IFN response to various 
DNA stimuli. IFI16 knockdown THP-1 cells were challenged with A. poly(dA:dT), B. HSV 
60mer, or C. HSV-1 virus for 6 hours.  Levels of IFN-β were measured by q-RT-PCR. 
IFI16 knockdown U2OS cells were challenged with D. poly(dA:dT) or E. HSV 60mer for 6 
hours and IFN-β levels were measured by q-RT-PCR. F. IFI16 knockdown U20S cells 
were challenged with poly(dA:dT) and IFN-α levels were measured by q-RT-PCR and 
normalized to HPRT.  (* p<0.05 assessed by Two-Tailed T-Test compared to empty 
vector control, data are represented as mean + S.E. Data represents 3 biological 
replicates). 
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IFI16 dependent interferon production occurs independently of NF-κB 
In addition to reduced IFN-α mRNA levels, we also noticed a marked 
decrease in IFN-α production by ELISA in response to poly(dA:dT) in both THP-1 
and U2OS IFI16 knockdown cells compared to empty vector controls (Figure 
2.3a and b). RANTES production, which is dependent on IFN signaling, was also 
decreased in U2OS IFI16 knockdown cells in response to poly(dA:dT), HSV 
60mer, and VACV 70mer (a double stranded DNA sequences derived from the 
Vaccinia Virus genome) (Figure 2.3c).  
In contrast to the lower levels of type I IFN production, NF-κB related 
cytokines, IL-6 and IL-1β were unchanged or increased in THP-1 IFI16 
knockdown cells that were treated with poly(dA:dT), HSV 60mer or HSV-1 for 12 
hours (Figure 2.3d and e). An increase in proinflammatory cytokines may 
suggest a compensation for the lack of IFN production in these cells. We did not 
detect differences in phospho-IκBα protein expression in response to 
poly(dA:dT), HSV 60mer or HSV-1 between IFI16 knockdown and control cells 
(data not shown). Further, we did not detect a significant difference in cell viability 
between the empty vector control and IFI16 knockdown cells under our 
experimental conditions (Figure 2.3f).  
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Figure 2.3. IFI16 dependent IFN production occurs independently of NF-κB. A, B.  IFI16 
knockdown THP-1 and U2OS cells were challenged with poly(dA:dT), VACV 70mer or 
HSV 60mer for 12 hours. Levels of IFN-α or C. RANTES were measured by ELISA . IFI16 
knockdown THP-1 cells were challenged with poly(dA:dT), HSV 60mer or infected with 
HSV-1 for 12 hours. Levels of D. IL-6 and E. IL-1β were measured by ELISA. F. IFI16 
knockdown cells were challenged with poly(dA:dT) or infected with HSV-1 for 6 hours. 
Cells were stained with calcein for 1 hour and viability was determined by uptake of 
calcein stain and FITC fluorescence.  (* p<0.05 assessed by Two-Tailed T-Test compared 
to empty vector control, data are represented as mean + S.E. Data represents 3 biological 
replicates). Bars without * are not significant.   
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To explore whether IFI16 is necessary and sufficient for the production of 
type I IFNs we performed an addback experiment in which IFI16 was ectopically 
expressed in the knockdown cell lines. We transduced both CDS and 3’UTR 
IFI16 knockdown cells with the pRGP-IFI16 retroviral vector to create a transient 
addback of IFI16. While we did achieve expression of the IFI16 transgene in the 
CDS knockdown cells, the expression levels were modest (Figure 2.4a). This is 
not surprising as the shRNA in this cell line could target the expression vector as 
well as the endogenous gene. We did however achieve much higher expression 
of IFI16 transgene in the 3’UTR knockdown cell line (Figure 2.4c.) The IFI16 
addback cells were challenged with poly(dA:dT), HSV 60mer, VACV 70mer or 
ISD (immunostimulatory DNA sequence (130)), or infected the cells with HSV-1 
or Sendai Virus (Figure 2.4b and data not shown). Despite the modest IFI16 
rescue in the CDS knockdown, we did see a partial restoration of IFN-α 
production in the addback cell line as compared to the knockdown cells without 
addback. The levels of IFN production were consistent with the amount of IFI16 
expression in the addback cell line. We also saw almost a complete restoration of 
IFN-β production in the 3’UTR addback cell line (Figure 2.4d), also consistent 
with the amount of IFI16 expression in the addback cell line. These results 
suggest that IFI16 is necessary for the production of type I IFNs, and the 
phenotype that we see is not due to off target effects of the shRNA used to 
knockdown IFI16. 
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Figure 2.4. IFI16 Addback rescues the type I IFN phenotype. A. IFI16 CDS or C. 3’UTR 
knockdown THP-1 cells were transduced with IFI16 plasmid to create a stable addback cell line. 
Levels of IFI16 were monitored by q-RT-PCR or by immunoblot. B, D. Cells were transfected with 
poly(dA:dT), HSV 60mer, ISD, VACV 70mer or infected with Sendai Virus for 6 or 12 hours for q-
RT-PCR or ELISA respectively. Levels of IFN-α and IFN-β were measured by ELISA and q-RT-
PCR. (* p<0.05 assessed by Two-Tailed T-Test compared to empty vector control or knockdown 
versus addback, data are represented as mean + S.E. Data represents 3 biological replicates). 
Bars without * are not significant.   
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IFI16 knockdown cells display an abrogated type I interferon response to 
various RNA stimuli and cGAMP. 
IFI16 is known to sense infection with DNA viruses such as HSV-1 but is 
not known to be involved in the detection of RNA viruses such as Sendai virus.  
Previous studies by Unterholzner et al. have shown that siRNA knockdown of 
p204 in RAW cells or IFI16 in THP-1 cells does not have an effect on Sendai 
Virus induced type I IFN production. In contrast to these studies of transient IFI16 
knockdown, we found that stable IFI16 knockdown cells display a decrease in 
type I IFN production in response to Sendai virus.  IFI16 knockdown reduced 
Sendai-induced IFN-β in THP-1 cells (Figure 2.5c) and both IFN-β and IFN-α in 
U2OS cells (Figure 2.5e and f). Furthermore, the inhibitory effect of IFI16 
knockdown on IFN responses was not limited to Sendai virus signaling. We also 
saw defects in responses to Listeria monocytogenes, cyclic di-AMP (a second 
messenger that is secreted by some bacteria, including Listeria, and binds to and 
activates STING), human metapneumovirus (HMPV) (a RNA virus that signals 
through RIG-I), and 5’pppRNA (a synthetic RNA that signals through RIG-I 
(Figure 2.5a, b, and d). We also detected a decrease in the response to EMCV, 
an RNA virus that signals through MDA5 (data not shown). In contrast to the IFN 
response, levels of IL-6 and IL-1β in response to Sendai Virus were not affected 
by IFI16 knockdown (data not shown). 
 We also monitored the ability of IFI16 knockdown cells to respond to 
cGAMP, since cGAMP is proposed to work at a level downstream of DNA 
sensing by engaging STING directly. Empty vector control and IFI16 KD THP-1 
 65 
cells were stimulated with 2’5’ linkage cGAMP overnight and supernatant was 
tested for IFN-α production by ELISA. Similar to the DNA and RNA ligands, IFI16 
knockdown cells produced less IFN-α than the empty vector control cells (Figure 
2.5g). We also looked at protein levels of cGAS by western blot and found that 
cGAS protein levels were normal in the IFI16 knockdown cells as compared to 
the control cells, even after stimulation with type I IFN and Sendai Virus (Figure 
2.5h).   
These results indicate that IFI16 not only plays a role in the detection of 
Sendai Virus and signaling through RIG-I but also has a global effect on type I 
IFN production in response to a diverse panel of innate triggers. Furthermore, 
since cGAS/cGAMP signaling should bypass the need for IFI16 as a DNA 
sensor, and directly activate STING, these results provide further evidence that 
although IFI16 can sense DNA leading to STING activation, IFI16 also regulates 
ISG expression independent of its role in DNA recognition.  
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Figure 2.5. IFI16 knockdown cells display an abrogated type I IFN response to 
various RNA stimuli. A. IFI16 Stable knockdown THP-1 cells were challenged with 
cyclic-di-AMP, Listeria monocytogenes, B. 5’pppRNA, C. Sendai Virus, D. HMPV, or 
G. 2’-3’ cGAMP for 12 hours. E., F. U2OS cells were stimulated with Sendai Virus for 
6 or 12 hours and IFN-β levels were determined by q-RT-PCR or IFN-α levels were 
measured by ELISA respectively. H. Empty vector (EV) and IFI16 knockdown (KD) 
cells were challenged with type-1 IFN of Sendai Virus for 2 hours and monitored for 
cGAS expression by western blot. (* p<0.05 assessed by Two-Tailed T-Test 
compared to empty vector control, data are represented as mean + S.E. Data 
represents 3 biological replicates). Bars without * are not significant.   
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IFI16 has a global effect on ISG expression 
 Since IFI16 knockdown cells display a dramatic decrease in IFN 
production to multiple triggers, and because we saw defects in response to both 
RNA and DNA stimulation, we next determined where IFI16 was acting in the 
type I IFN pathway. Western blot analysis demonstrated that expression levels of 
STING and TBK1 remained unchanged in IFI16 knockdown compared to control 
cells, however there was a decrease in activation of TBK1 by both RNA or DNA 
stimulants in IFI16 knockdown cells.  Levels of phosphorylated TBK1 were lower 
in IFI16 knockdown THP1 cells compared to empty vector control cells 
challenged with poly(dA:dT) or HSV 60mer (Figure 2.6a). Similarly, levels of 
phosphorylated IRF3 were also decreased. These results are consistent with 
IFI16 acting as a DNA sensor controlling TBK1 dependent IRF3 activation and 
type I IFN induction.  
 We next wanted to determine what effect IFI16 had on global expression 
of a panel of immune genes including IFN stimulated genes (ISGs). We treated 
empty vector control and IFI16 knockdown cells with poly(dA:dT) or Sendai Virus 
for 6 hours and collected RNA for multiplex gene expression analysis by 
nanostring technology.  Nanostring analysis use fluorescently labeled probes that 
hybridize directly to target mRNA, allowing each individual mRNA to be counted 
in a highly sensitive manner (204). We found a decrease in the expression of 
many ISGs and an increase in NF-κB related cytokine gene expression (Figure 
2.6b). Some immune genes such as NLRP3, MNDA, and MyD88 remained 
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unchanged (data not shown). More interestingly, we saw a decrease in RIG-I 
mRNA expression both basally (Figure 2.6c) and after treatment with LPS, 
poly(dA:dT), and Sendai Virus (Figure 2.6d). The reduced expression of RIG-I in 
knockdown cells may explain why there is a defect in Sendai virus signaling in 
IFI16 knockdown cells and further suggests a role for IFI16 in the transcriptional 
regulation of ISGs following challenge with RNA ligands or RNA virus infection in 
IFI16 knockdown cells.  
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Figure 2.6. IFI16 has a global effect on ISG expression. A. IFI16 knockdown THP-1 
cells were challenged with poly(dA:dT) or HSV 60mer for 6 hours and monitored for 
protein expression by immunoblot. B. IFI16 stable knockdown THP-1 cells were 
transfected with poly(dA:dT) or infected with Sendai Virus for 6 hours and RNA was 
collected. Graphs show selected genes from NanoString analysis. C. Basal and D 
stimulated levels of RIG-I as determined by NanoString analysis. Data represents one 
experiment.  
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IFI16 transcriptionally regulates IFN-α expression independently of STAT-1 
RIG-I is an IFN-inducible gene that is basally expressed and further 
upregulated in response to type I IFN production. To determine if a decrease in 
type I IFN production was responsible for the lower expression levels of RIG-I in 
IFI16 knockdown cells, we performed an IFN addback experiment. Cells were 
pretreated with pan-type I IFN for 2 hours and then infected with Sendai Virus for 
2, 8 or 24 hours. RNA was harvested from cells and IFN-α and RIG-I expression 
were monitored by q-RT-PCR. IFI16 knockdown cells were unaltered in their 
ability to produce IFN-α in response to exogenous pan-IFN (Figure 2.7a). 
Furthermore, IFI16 knockdown cells were able to produce levels of RIG-I 
comparable to that of empty vector control cells (Figure 2.7c). Type I IFNs signal 
through IFNAR and STAT-1 to induce expression of IFN-α and ISGs, such as 
RIG-I. Since production of IFN-α and RIG-I are normal in the IFI16 knockdown 
cells after pan-type I IFN stimulation, these results suggest that signaling through 
IFNAR and STAT-1 are unaffected in these cells.  
In contrast, IFI16 knockdown cells were limited in their ability to produce 
IFN-α mRNA when infected with Sendai Virus, even in the presence of 
exogenous IFN stimulation (Figure 2.7b). Furthermore, in response to Sendai 
Virus, IFI16 knockdown cells are only able to induce RIG-I expression to 50 
percent or less of that of control cells, even in the presence of exogenous IFN. 
Although the peak of RIG-I expression is at 2 hours post stimulation, even at 24 
hours post stimulation, RIG-I levels in the IFI16 knockdown cells do not return to 
normal (Figure 2.7c). We also saw a similar phenotype for other ISGs, including 
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viperin and levels of IRF3 and IRF7 (data not shown).  Both basal and IFN 
induced levels of IL-6 were unchanged or increased in response to exogenous 
IFN and Sendai Virus in the IFI16 knockdown cells which demonstrates that the 
phenotype is specific to the type-1 IFN pathway (Figure 2.7d). Taken together, 
these results suggest that IFI16 knockdown cells are capable of responding to 
exogenous IFN through the IFNAR/STAT-1 pathway to induce initial RIG-I 
expression. However, in response to Sendai Virus infection, IFI16 knockdown 
cells are incapable of amplifying the type I IFN response which controls long-term 
IFN-α production, and maintains levels of RIG-I expression. More importantly, 
levels of IFN-α in the IFI16 knockdown cells are dramatically reduced and never 
return to normal after Sendai Virus infection. These results led us to believe that 
IFI16 may impact the transcription of IFN-α, which subsequently results in 
reduced expression of ISGs.  
We next monitored STAT-1 expression and activation in these cells. We 
stimulated cells with type I IFN or infected with Sendai Virus for 2, 8, and 24 
hours and collected total cell lysate for immunoblot analysis. Basal levels of 
STAT-1 were decreased in the IFI16 knockdown cells, which is consistent with 
IFI16 playing a role in the tonic singling of IFN-α. In response to exogenous IFN 
and Sendai Virus, the levels of STAT-1 are similar in both the knockdown and 
control cell lines at 2 hours, suggesting that the initial addition of IFN is enough to 
induce a response through IFNAR and STAT-1. However, consistent with the 
inability of the knockdown cells to continuously produce type I IFNs, STAT-1 
levels in the IFI16 knockdown cells decrease over time (Figure 2.7e). These 
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results further support the claim that the defect in IFI16 knockdown cells is not 
due to their inability to respond to IFN but due to the fact the IFI16 has a plays a 
role in the regulation of IFN-α expression and IFN stimulatory gene expression.   
In order to determine if IFI16 is playing a role in the transcription of IFN-α 
we next performed a chromatin immunoprecipitation assay in which we 
monitored RNA Pol II recruitment to the IFN-α, IL-6, and TNF-α promoters. 
Empty Vector control and IFI16 knockdown cells were stimulated with Sendai 
Virus for 4 hours and cells were crosslinked with formaldehyde. Chromatin was 
immunoprecipitated with antibodies directed against RNA Pol II or IgG1 control. 
Primers for the region immediately upstream of the transcription start site of IFN-
α, IL-6, or TNF-α were used to detect Pol II recruitment to these regions via q-
RT-PCR. We found that IFI16 knockdown cells have less basal RNA Pol II 
recruited to the IFN-α promoter than the empty vector control cells. Consistent 
with our work mentioned above, RNA Pol II recruitment to both IL-6 and TNF-α 
promoter was higher in the IFI16 knockdown cells (Figure 2.7f). These results 
suggest that IFI16 plays a role in controlling RNA Pol II recruitment to the 
promoter of IFN-α.  
Based on our results and previous IFI16 siRNA knockdown studies, we 
suggest that there are multiple mechanisms by which IFI16 can induce type I 
IFN. IFI16 can act as an intracellular sensor, whereby in response to DNA, IRF3 
is activated and type I IFNs and ISGs are produced. Here we show that in the 
absence of IFI16, DNA activation through TLRs can compensate to induce a pro-
inflammatory response. RNA viruses signal through RIG-I to also induce IRF3 
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activation leading to the production of type I IFNs and ISGs. However, IFI16 also 
acts at the transcriptional level, whereby it regulates the transcription of IFN-α 
and ISGs, by facilitating Pol II placement at the promoter of the target gene, thus 
allowing for the production of genes that regulate type I IFN production. Lastly, 
type I IFNs can signal through the IFNAR receptor leading to the activation of 
STAT-1 and type I IFN production. IFI16 operates independently of this pathway 
(Figure 2.7g).  
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Figure 2.7. IFI16 transcriptionally regulates IFN-α expression independently of STAT-1. Pan Type I IFN was added to cells for 
2 hours. A. IFN-α expression was measured by q-RT-PCR. Pan Type I IFN was added to cells 2 hours before stimulation with 
Sendai Virus (SeV) for 2, 8, or 24 hours. B. IFN-α, C. RIG-I, and D. IL-6 expression were measured by q-RT-PCR. E. Empty 
vector (EV) and IFI16 knockdown (KD) cells were stimulated with Type I IFN or Sendai Virus for 2, 8, and 24 hours and 
monitored for total STAT-1 expression by immunoblot. F. Cells were stimulated with Sendai Virus for 4 hours and ChIP Assay 
was performed. RNA Pol II recruitment to IFN-α, IL-6, and TNF-α was determined by q-RT-PCR. Data is represented as 
%input minus IgG background. Data is representative of 3 experiments. G. Proposed signaling pathway for IFI16.  (* p<0.05 
assessed by Two-Tailed T-Test compared to empty vector control, data are represented as mean + S.E. Data 
represents 3 biological replicates). Bars without * are not significant.   
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Discussion  
Here we expand our understanding of IFI16’s role. We demonstrate a 
broader role for IFI16 in the transcriptional regulation of ISGs in response to 
multiple stimuli. In keeping with previous work by Unterholzner et al, IFI16 
knockdown leads to an abrogated type I IFN production when cells were 
stimulated with either synthetic DNA or viral DNA. However, in contrast to 
previous work, we also see a defect in type I IFN production in response to RNA 
ligands, including a defective IFN response to Sendai Virus which was not seen 
in the original studies. The observed impact of IFI16 deficiency on the IFN 
response  may be attributed to the fact that we used a stable knockdown of IFI16 
whereas previous studies used only transient siRNA knockdown. Complete or 
chronic abrogation of IFI16 protein expression may be necessary to see the full 
effects of IFI16 deficiency on both DNA and RNA viral ligands. Consistent with 
these results, when IFI16 is added back to the knockdown cell lines, we see 
levels of IFN-β restored towards normal production (comparable to empty vector 
contol cells) when stimulated with various DNA and RNA ligands, suggesting that 
IFI16 is necessary for these responses.  
In addition to a type I IFN response, viral nucleic acids trigger the 
production of NF-kB-dependent inflammatory cytokines.  In contrast to a defect in 
type I IFN production, the NF-κB response is unchanged or elevated in IFI16 
knockdown cells. We see an increase in both IL-6 and IL-1β production in 
response to both DNA and RNA ligands. We did not see any changes in levels of 
phospho-IκBα (data not shown) post-challenge indicating that there is no defect 
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in NF-κB signaling and the impact of IFI16 deficiency on the antiviral response is 
specific to the type I IFN pathway. However, the increase in inflammatory 
cytokine production suggests that there may be a shift to a pro-inflammatory 
phenotype in IFI16 knockdown cells to compensate for a lack of a type I IFN 
response that is the primary defense when exposed to cytosolic nucleic acids.  
In addition to a cytosolic nucleic acid sensing role for IFI16, we also see a 
role for IFI16 in the transcriptional regulation of IFN-α gene expression as well. 
Both basal and stimulated levels of RIG-I, a major driver of the IFN response to 
RNA ligands, are decreased in IFI16 knockdown cells. We also saw a similar 
defect in other ISGs, including IRF7 and Viperin (data not shown). We postulate 
that the lower levels of RIG-I in IFI16 knockdown cells are due to the fact that 
RIG-I is itself an ISG, meaning that type I IFN production leads to the 
upregulation of the RIG-I gene. When type I IFN is added to cells, expression 
levels of RIG-I return to normal. In contrast, stimulation with Sendai Virus did not 
restore expression of RIG-I in IFI16 knockdown cells but did enhance RIG-I 
levels in control cells. These results suggest that the low level of RIG-I 
expression is not due to an inability of IFI16 knockdown cells to respond to IFN, 
but due to the fact that IFI16 plays a role in regulating the production of IFN-α. 
We also see a decrease in type I IFN production when IFI16 knockdown cells are 
stimulated with 2’-3’ cGAMP. This result provides further evidence that IFI16 has 
plays a role in the regulation of IFN-α as cGAMP bypasses DNA sensing by IFI16 
and activates STING.    
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 To date there has been confilicting studies in determining the role for IFI16 
in innate immunity. Part of the perceived conflicts may be due to the dual cellular 
location of IFI16.  IFI16 is both nuclear and cytosolic and the function of this 
protein may differ by location. The cytosolic location of IFI16 is important for the 
DNA sensing function of the protein. Studies have shown that acetylation of IFI16 
which inhibits the nuclear localization of the protein, allows IFI16 to be exposed 
to cytosolic viral DNA during HSV infection for interaction with STING and 
subsequent downstream activation of the type I IFN pathway (131). Furthermore, 
it was shown that the HSV-1 capsid can be ubiquitinated and degraded by the 
proteosome, leading to leaked DNA that is then recognized by IFI16 in the 
cytosol (132). However, several studies have shown a nuclear role for IFI16 
during virus infection as well. Thus IFI16 is capable of forming an inflammasome 
with ASC in the nucleus of epithelial cells in response to KSHV (135) or in CD4 T 
cells in the case of bystander cells to HIV infected T cells (138,140). Other work 
shows that IFI16-dependent recognition of HSV-1 occurs in the nucleus of 
infected human foreskin fibroblasts (133). In our current studies using THP-1 and 
U2OS cells, we noted that IFI16 is predominantly nuclear and knockdown of 
IFI16 occurred in the nucleus (data not shown). The nuclear location of IFI16 
along with the effect of IFI16 knockdown on IFN and ISG gene expression 
provide evidence for a regulatory role for the gene in addition to its role as a 
cytosolic sensor. 
 We propose that IFI16 acts to position RNA Pol II in a complex with other 
transcription factors at the IFN-α promoter in order to regulate activation of 
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transcription of type I IFN production. Previous studies have shown that IFI16 is 
capable of acting as a transcriptional repressor.  Before IFI16 was implicated in 
innate sensing of DNA, much of the work focused on IFI16 as a transcriptional 
regulator in cancer cells. It is well known that IFI16 is capable of binding double 
stranded DNA through its HIN200 domains (130,205). Studies show that when 
IFI16 is fused to the GAL4 DNA binding domain and transfected into HeLa cells 
with GAL4-tk-CAT, there was a dose-dependent decrease in CAT activity, 
suggesting transcriptional repression. This activity is dependent on the HIN200 
domain of IFI16 (116). Negative transcriptional regulation is also seen when 
IFI16 is transfected into HeLa cells with a reporter fused with the promoter of 
HCMV(116). IFI16 was also shown to repress transcription of CMV DNA 
polymerase when bound in a complex with SP1 and IR-1 promoter element 
(200,201). A possible cross talk between transcription regulation and viral nucleic 
acid sensing with IFI16 may prove to be an important addition to antiviral innate 
immunity whereby IFI16 not only recognizes an infection to trigger the production 
of type I IFNs but also promotes the transcription of important antiviral effectors.  
There is also evidence that IFI16 plays a role in the cell cycle by negative 
regulation of p53. IFI16 was found to be bound directly to p53 (199). This 
interaction inhibits binding of p53 to the p21 promoter, leading to cell cycle arrest 
(198). Although we do not see an effect on cell death in the IFI16 knockdown 
cells, these studies provide further evidence that IFI16 is capable of acting in a 
regulatory manner.  In our studies, we reveal a positive regulatory role for IFI16 
on ISGs.  
 79 
 Further work needs to be done in order to determine the mechanism by 
which IFI16 mediates the expression of IFN-α. ChIP analysis of IFI16 would be 
ideal, however a suitable antibody for these studies is not yet available. We 
predict that IFI16 may bind directly to the promoter region of IFN-α, possibly in 
complex with other transcription factors or co-regulators, thus regulating its 
expression. In addition, ChIP assays coupled to deep-sequencing would provide 
further information on what promoter regions IFI16 binds and some insight as to 
what other factors IFI16 may interact with that bind in that region. In the present 
study, we have performed a ChIP assay  in which RNA Polymerase II (Pol II) 
recruitment to the IFN-α promoter in both empty vector and IFI16 knockdown 
cells was assessed. Interestingly we found that there was less Pol II recruitment 
to the IFN-α regulatory region in the IFI16 knockdown cells basally, consistent 
with the defect in IFN-α transcription. Previous studies have shown that serine 5 
phosphorylated Pol II is bound and inactive on some promoters at a basal state. 
Upon stimulation, Pol II is phosphorylated on serine 2 leading to active 
transcription (206-209). IFI16 knockdown cells may recruit less Pol II to the IFN-α 
promoter basally, leading to a defect in IFN-α production and, therefore, a defect 
in basal levels of ISGs. Stimulation is not enough to overcome the absence of 
Pol II basally in these cells, thus leading to a continued defect in type I IFN 
production.  
 There are many conflicting results in the literature surrounding the 
cytosolic sensing of nucleic acids. Many sensors, including IFI16, DDX41, and 
cGAS, and even direct binding to STING have been implicated in the sensing of 
 80 
cytosolic DNA. More work needs to be done in order to clearly elucidate the 
contribution of IFI16 to these events and to determine if these proteins are 
working together, playing redundant roles or functioning in cell type specific 
manners. This work offers a broader understanding of the role IFI16 plays in tight 
regulation of the IFN/ISG pathway.  
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Materials and Methods 
 
Reagents and Antibodies  
LPS and poly(dA:dT) were obtained from Sigma-Aldrich (St. Louis, MO). 5’ppp-
RNA was from Invivogen (San Diego, CA). HSV 60mer, VACV 70mer, and ISD 
oligonucleotides were synthesized as described in (130), Cyclic-di-GMP was 
from Biolog (Hayward, CA). cGAMP 2’-3’ was from Veit Hornung (U. Bonn, 
Germany). L. monocytogenes (clinical isolate 10403s) was from V. Boyartchuk 
(NTNY, Trondheim, Norway).  HSV-1 (7134) was a gift from D. Knipe (Harvard 
Medical School, MA).  Sendai virus (SeV, Cantrell strain) was purchased from 
Charles River Laboratories (Wilmington, MA). The trypsin-independent HMPV 
isolate A1 (NL\1\001) was from MedImmune (Gaithersburg, MD) and was 
propagated in Vero cells cultured in IMDM containing 4% BSA and trypsin 
(210,211). Lipofectamine 2000 was from Invitrogen (Carlsbad, CA).  Genejuice 
was from Novagen (Madison, WI). Universal Type I IFN was from PBL IFN 
Source (Piscataway, NJ).  
 
ShRNA-Mediated Silencing 
Lentiviral shRNA sequences targeting IFI16 in the pLKO.1 TRC cloning vector 
were purchased from Sigma-Aldrich (St. Louis, MO). The IFI16 silencing 
sequences were from the MISSION TRC-Hs 1.0 (Human) as follows: 
TRCN0000019079 (CDS), and TRCN0000364735 (3’UTR). The production of 
viral particles and transduction of target cells were conducted according to the 
following protocols:  
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(http://www.broad.mit.edu/genome_bio/trc/publicProtocols.html). Lentiviral 
particles were produced in 293T HEK cells transfected with 3 µg shRNA along 
with 4 µg pSPAX and pMD2 for 48 hours. Viral supernatant was collected, 
filtered, and then added to target THP-1 cells. THP-1 cells with shRNA 
knockdown were selected by puromycin 48 hours later. Knockdown efficiency in 
stable knockdown cell lines was assessed q-RT-PCR with the following primers: 
IFI16-F 5′-CCGTTCATGACCAGCATAGG -3′; IFI16-R 5′-
TCAGTCTTGGTTTCAACGTGGT -3’ 
 
IFI16 Addback 
IFI16 coding sequence was cloned into the pRGP retroviral vector and the 
production of viral particles and transduction of target cells were conducted 
according to the protocols referenced above. Addback cells were selected by 
puromycin.  
 
Cell Culture, Stimulation and ELISA 
THP-1 cells were differentiated with 0.5 µM PMA overnight prior to stimulation.  
For stimulations, poly(dA:dT) (1 µg/ml), ISD (3 µM) HSV 60mer (3 µM) VAVC 
70mer (3 µM) ci-di-AMP (3 µM),  5’ppp RNA (600ng/mL), cGAMP 2’-5’ (3 µM) 
were transfected into the cells with lipofectamine in accordance with the 
manufacturer's instructions. Cells were infected with HMPV or HSV-1 viruses at 
multiplicities of infection (MOI) of 10.  Cells were infected with Sendai virus at 
200 IU/ml.  Cells were stimulated with Pan Type-1 IFN at 1000 U/mL for 2, 8, or 
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24 hours. For bacterial infection, cells were challenged with L. monocytogenes at 
an MOI of 5 for 1 hr.  Infected cells were then washed twice and medium 
containing gentamicin (100 µg/ml) was added to kill extracellular bacteria. 
Knockdown and control cells were challenged with stimulants or microbes for 6 
hrs (for RNA analysis and immunoblot analysis) or 12 hours (for protein analysis 
by ELISA). Cytokine and IFN levels in culture supernatants were assayed for IL-
1β and IL-6 (BD Biosciences, Franklin Lakes, NJ) and IFN-α (Mabtech, 
Mariemont, OH) by sandwich ELISA. 
 
Nanostring and RT-QPCR experiments 
Cells were treated for 6 hours and RNA was purified with a quick RNA mini prep 
kit (Zymo Research, Irvine, CA). RNA transcript counting was performed on total 
RNA hybridized to a custom gene expression CodeSet and analyzed on an 
nCounter Digital Analyzer.  Counts were normalized to internal spike-in and 
endogenous controls per Nanostring Technologies’ specifications.  A pseudo 
count was added to all values such that the smallest value in the dataset was 
equal to 1. 
cDNA was synthesized, and quantitative RT-PCR analysis was performed as 
described (212,213).  Primers used include: HPRT-F 5’-
ATCAGACTGAAGAGCTATTGTAATGA-3’, HPRT-R 5’-
TGGCTTATATCCAACACTTCGTG-3’, IFN-α-F 5’-
CACACAGGCTTCCAGGCATTC-3’ 
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IFN-α-R 5’-TCTTCAGCACAAAGGACTCATCTG-3’, RIG-I-F 5’-
CTGGACCCTACCTACATCCTG-3’, RIG-I-R 5’-GGCATCCAAAAAGCCACGG-3’ 
IFN-β-F 5’-GTCTCCTCCAAATTGCTCTC-3’, IFN-β-R 5’-
ACAGGAGCTTCTGACACTGA-3’ 
Gene expression is shown as a ratio of gene copy number per 100 copies of 
HPRT ± SD.  
 
Immunoblotting 
Cells were washed twice with PBS and lysed using a 1% NP-40 buffer.  
Immunoblotting was performed as described (157). Anti-murine IFI16 was from 
Abcam, anti-rabbit STAT-1 was from Santa Cruz, anti-rabbit phospho-STAT-1, 
anti-rabbit phospho-IRF3, anti-rabbit TBK1, and anti-rabbit phospho-TBK1 are 
from Cell Signaling, anti-murine IRF3 is from BD Biosciences, anti-murine STING 
was a gift from Glen Barber (University of Miami Health System), anti cGAS is 
from Sigma.  
 
Cell Viability Assay  
Calcein AM stain was obtained from R&D Systems. Cells were stimulated as 
described above and cell viability was assayed according to the following 
protocol http://www.funakoshi.co.jp/data/datasheet/RSD/4892-010-K.pdf Cells 
were washed in PBS and incubated in calcein AM stain for 30 min at 37°C. 
Calcein AM stain was then washed off with PBS and cells were monitored for 
FITC fluorescence.  
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Chromatin Immunoprecipitation  
8.0×106 empty vector control and IFI16 Knockdown THP-1 cells were stimulated 
with 200 HAU Sendai Virus for 4 hours, washed with PBS and fixed with 1% 
formaldehyde for 5 min at RT. Formaldehyde fixation was stopped with the 
addition of 1.25 M glycine for 5min at RT. The nuclear pellet was sonicated using 
Bioruptor UCD-200 (Diagenode Inc., Sparta, NJ) to shear the DNA to obtain 
fragments ranging from 200-500 bp in size. 5µg/IP of sheared chromatin was 
immunoprecipitated with 2µg anti-RNA pol II (Active Motif; Clone 4H8) or IgG1 
isotype control (Imgenex) antibody overnight and 10µl magnetic beads for 1 hr. 
Following reversal of the cross-linking and protein digestion with proteinase K, 
immunoprecipitated DNA was purified with the PCR purification kit (Qiagen). Q-
RT-PCR analysis was performed on the input DNA (diluted 1:10) and the ChIP 
as described above. The primer sequences used for detecting the RNA polII 
recruitment are as follows:  
IFN-α-F 5’AAAGCCTTTGAGTGCAGGTG3’ IFN-α-R 
5’TCGGCCTCTAGGTTTTCTGA3’; IL-6-F 5’ATTGGGAGACCAGCTCATTG3’ 
IL-6-R 5’TTCCTGGCGCATAGTAATCC3’; TNFAIP3-F 
5’GACCAGGACTTGGGACTTTG3’ TNFAIP3-R 
5’AAAACCAACGCCAGGTAGAC3’. 
All oligo sequences were designed using Primer3web (http://primer3.wi.mit.edu/), 
and were targeted within the 500 nucleotides region downstream of the 
transcription start site of each gene. 
ChIP data is represented as %input minus IgG1 background.  
 86 
 
Statistical Analysis  
Two Tailed T-test was performed using Prism 4 Software (GraphPad, San Diego, 
CA).  P values of <0.05 were considered significant.  
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Preface to Chapter 3 
 
The work for this chapter was done in collaboration Søren Beck Jensen, who did 
the initial work with the generation of the IFI204 knockout mouse and Zhao Zhao 
Jiang who helped with the breeding and characterization of the IFI204 and cGAS 
knockout mice.  
• Soren Jensen generated the IFI204 knockout mouse 
• Zhao Zhao Jiang bred the IFI204 knockout mouse 
• Mikayla Thompson and Zhao Zhao Jiang performed the experiments in 
chapter 3 collectively 
• Mikayla Thompson wrote chapter 3 
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Chapter 3: IFI204 plays a partial role in the type I IFN response to DNA and 
RNA ligands in vivo 
 
Abstract  
The Interferon Gamma Inducible protein (IFI)204 has recently been linked to the 
detection of cytosolic DNA during infection with Herpes Simplex Virus. IFI204 
binds dsDNA via HIN200 domains and engages the adaptor molecule Stimulator 
of Interferon genes (STING) leading to TANK binding kinase-1 (TBK1) dependent 
phosphorylation of interferon regulatory factor 3 (IRF3) and transcription of type I 
interferons (IFN) and related genes(130). The role of IFI204 has been studied in 
vitro, however the role of the receptor in vivo has yet to be determined. Here we 
developed a mouse deficient in IFI204 to explore the role of IFI204 in in vivo 
immune responses.  We investigated the ability of IFI204 deficient cells to induce 
type I interferons and other cytokines in response to a panel of DNA and RNA 
ligands in vitro. IFI204 deficient BMDMs display a partial decrease in type I 
interferon induction in response to both DNA and RNA ligands and viruses.  We 
also observed that this reduction in IFN was transient, type I interferon induction 
returns to wild type levels at 12 hours post infection. In contrast to these results, 
expression of the NF-κB regulated cytokines such as IL-6 and IL-1β were 
unaffected in IFI204 knockdown cells. These results suggest that IFI204 plays a 
partial role in the induction of type I interferons in response to both DNA and 
RNA ligands. Additionally, IFI204 may work in tandem with other receptors to 
amplify the type I interferon response. We also studied the involvement of IFI204 
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in an in vivo model of HSV-1 infection. IFI204 knockout mice produce less IFN-β, 
IL-6, and IL-1β in the brain and serum, 72 hours post intraperitoneal infection 
with HSV-1. Furthermore, IFI204 -/- mice are more susceptible to HSV-1 infection 
as compared to WT mice. These preliminary findings indicate that IFI204 
participates in the response to HSV-1 in vivo by inducing the production of 
cytokines that are necessary for the control of viral infection. Further studies are 
needed to define the in vivo cell type(s) responsible.  
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Introduction  
Herpes Simplex Virus -1 is a highly prevalent and contagious pathogen 
that can range in symptoms from recurrent infections of the oropharynx and 
genitalia to lethal encephalitis of the brain. The innate immune response is 
crucial for early detection and clearance of the pathogen. This response is largely 
governed by PRRs including TLR2, TLR 3, TLR 7, TLR9, and 
NLRP3(32,59,60,176,177). Activation of these PRRs leads to a cascade of 
cytokines and chemokines, such as IL-6 and IL-1β, that recruits leukocytes to the 
site of infection. IL-1β deficient mice have increased susceptibility to HSV-1 due 
to high viral load and rapid spread of disease(179).  
The type I interferons are arguably the most important of these effectors, 
activating an antiviral state in the host that is essential for viral clearance. 
Perhaps the most striking evidence for this is the increased susceptibility to HSV-
1 infection in mice deficient in key players of type I IFN production or response 
pathway. Mice deficient in IFNAR, STING, and TBK1 are unable to mount the 
appropriate immune response, which leads to lethality upon HSV-1 infection 
(12,89,180,181,214,215). On the other hand, HSV-1 has evolved its own 
mechanisms to evade the host immune response. The immediate early protein 
ICP0 ubiquitinates IRF3 and IRF7, and targets them for degradation, thus blocks 
the production of type I interferons (216-218). The mutant HSV-1 7134 strain, 
which is deficient in ICP0, induces a more robust immune response. For this 
reason, in our in vitro studies we use HSV-1 7134 strain to investigate the 
receptors recognizing the viral ligands as well as the critical factors upstream of 
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IRF3 and IRF7 for type I IFN signaling. We use the WT KOS strain or WT 
equivalent HSV-1 7134R revertant strain in our in vivo studies, as ICP0 is 
necessary for viral replication.  
Many cytosolic nucleic acid sensors have been implicated in the response 
to HSV-1 including RIG-I and MDA5, which detect viral RNA intermediates, and 
DAI, DHX9, DHX36, DDX41, IFI16, and cGAS, which detect viral DNA in the 
cytoplasm (178). Recent studies have defined IFI16 as an important mediator of 
HSV-1 responses. Knockdown of IFI16 by siRNA or shRNA in THP-1 cells leads 
to decreased IFN-β production in response to HSV-1 in vitro. Furthermore, IFI16 
mediates a type I IFN response through STING and TBK-1 dependent 
phosphorylation of IRF3(130). The role of IFI16 has been extensively studied 
with knockdown techniques in vitro, however its role in vivo has yet to be defined.  
IFI204 is the only member of the PYHIN family in murine cells that has the 
same domain structure as IFI16 and is proposed as the mouse orhtologue to the 
gene. IFI204 contains two HIN200 domains and a pyrin domain and is capable of 
binding DNA. Similar to IFI16, when IFI204 is knocked down by siRNA in murine 
RAW 264.7 macrophages, bone marrow derived macrophages, or MEFs, type I 
interferon production is inhibited in response to dsVACV 70mer, HSV60mer, and 
HSV-1 virus. Contrastingly, in response to Sendai Virus, an RNA virus that 
produces a robust type I IFN response through the RNA sensor RIG-I, IFN-β 
production was unaltered in IFI204 knockdown cells(130). Furthermore, 
knockdown of IFI204 in corneal epithelium leads to resistance of HSV-1 infection 
in vitro (202). 
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In the present study, we generated a mouse deficient in IFI204 to explore 
the role of IFI204 in in vivo immune responses.  We investigated the ability of 
IFI204 deficient cells to induce type I interferons and other cytokines in response 
to a panel of DNA and RNA ligands in vitro. Additionally, we studied the 
involvement of IFI204 in an in vivo model of HSV-1 infection. These responses 
were compared to those of cGAS deficient mice, which were also generated. Like 
IFI16, cGAS has been shown to play a role in the immune response to HSV-1 in 
vitro. Analysis revealed that IFI204 plays a partial role in type I interferon 
induction in response to both DNA and RNA ligands in BMDMs as compared to 
cGAS deficient cells which display a complete abrogation of type I IFN production 
in response to DNA ligands in all cell types. We also show that IFI204 deficient 
mice produce less IFN-β, IL-1β, and IL-6 during HSV-1 infection in vivo as 
compared to WT and cGAS deficient mice.  
 
 
Results  
 
IFI204 plays a partial role in the type I IFN response to DNA ligands. 
Recently, IFI16 and its proposed mouse orthologue IFI204 has been 
identified as a novel cytosolic nucleic acid sensor(219). Much work has been 
done to study the role of IFI16/IFI204 in vitro with knockdown or overexpression 
of IFI16/IFI204 in cell lines, however to date the role of IFI16/IFI204 in vivo is 
unknown.  We have successfully generated an IFI204 gene targeted mouse. A 
targeting plasmid designed to delete the Pyrin domain (exons 2, 3, 4, and 5) of 
IFI204 was generated and verified by EcoRI- and HindIII digestions and 
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sequencing (Figure 3.1). BL6 Embryonic stem cells (ES) were electroporated and 
500 ES colonies were expanded and screened for the targeted IFI204 allele by 
Southern blot analysis. The screening procedure outlined in Figure 3.1 was used. 
Successfully targeted clones were identified and expanded for verification by 
southern blot analysis. Correctly targeted ES cells were injected into the 
blastocyst of albino BL6 mice and chimeric mice were generated. After crossing 
chimeric mice to albino C57BL6 mice, agouti mice were generated, suggesting 
that the targeted gene was transmitted to the germline. The mice heterozygous 
for the IFI204 targeted allele were selected by PCR analysis, which were then 
bred to ZCRE mice. ZCRE is expressed in the germline and will delete the 
targeted cassette in order to generate a complete IFI204 knockout allele (Figure 
3.1b). The IFI204 knockout mice were born in appropriate Mendelian ratios and 
appear to be developmentally normal.  
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Figure 3.1. Targeting strategy for the generation of the IFI204-/- mouse. A. (a) domain structure for IFI204 (also 
called p204). (b). Southern blot screening strategy outline. (c). IFI204 IFI204. (d,e,). Targeted IFI204 allele and 
screening strategy. B. PCR analysis of IFI204 knockout mice. Lanes 1,3,4,6 are WT, lane 2 is IFI204 +/-, and 
lane 5 is a complete IFI204 -/- mouse.  
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In order to determine if IFI204 plays a role in type I IFN production, we 
generated primary cells from IFI204 deficient mice and ZCRE mice as a control. 
As a control we used cGAS deficient mice, which are known to be limited in their 
ability to produce type I IFNs in response to HSV-1 and other DNA ligands, 
Thioglycolate elicited peritoneal macrophages were collected from IFI204 -/-, 
ZCRE, WT, and cGAS-/- mice and stimulated with a panel of synthetic RNA and 
DNA ligands as well as RNA viruses and DNA viruses as indicated. After 18 
hours of stimulation, supernatants were collected and cytokines were measured 
by ELISA. We did not notice any significant decrease in IFN-β production in 
response to poly(dA:dT) or ISD in the IFI204 deficient peritoneal macrophages as 
compared to ZCRE cells (Figure 3.2a), in contrast to siRNA studies, which 
implicated IFI204 as a cytosolic DNA sensor marked by decreased type I 
interferon induction.  However, consistent with published reports, IFN-β 
production in cGAS deficient mice was completely abrogated in response to 
these ligands as well as to HSV-1 and mCMV, a second DNA virus. Interestingly, 
HSV-1 and mCMV driven IFN-β production was partially dependent on IFI204 in 
peritoneal macrophages. We did not notice any significant decrease in IFN-β 
production in response to cGAMP for either IFI204 or cGAS deficient mice. This 
result was expected, as cGAMP bypasses the need for a sensor and directly 
binds STING to induce type I interferons (Figure 3.2a).   
 We also derived bone marrow derived macrophages (Figure 3.2 c and d) 
and dendritic cells (Figure 3.2 b) from IFI204 -/-, ZCRE, WT, and cGAS-/- mice. 
We stimulated BMDCs with a panel of stimuli as indicated for 18 hours and 
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monitored IFN-β production by ELISA. Consistent with results from peritoneal 
macrophages, BMDCs from IFI204 -/- mice were not altered in their ability to 
produce IFN-β in response to DNA ligands, poly(dA:dT) and ISD, whereas 
responses from cells derived from cGAS -/- mice were severely attenuated as 
compared to WT mice(Figure 3.2 b). Unlike peritoneal macrophages, IFN-β 
production was not governed by IFI204 in BMDCs in response to HSV-1 or 
mCMV. Furthermore, we saw no dependency on IFI204 or cGAS in response to 
Sendai Virus or cGAMP, which is consistent with pervious studies.  
We next stimulated BMDMs from IFI204 and cGAS deficient mice with a 
panel of RNA and DNA stimuli, including poly(dA:dT), ISD, SV, HSV-1, and 
cGAMP for 6 hours and monitored their ability to induce IFN-β mRNA production 
by q-RT-PCR (Figure 3.1c and d). When we monitored fold change induction of 
IFN-β in the IFI204 -/- cells, we noted a 50 percent decrease in IFN-β induction in 
response to cGAMP, poly(dA:dT), ISD, and Sendai Virus (Figure 3.2d). These 
results suggest that IFN-β response to both DNA and RNA ligands is partially 
dependent on IFI204. This is consistent with results from IFI16 knockdown cells 
shown in chapter 2 of this thesis. Thus, IFI204 may play a broad role in 
regulating the response to both DNA and RNA ligands both as a sensor and 
transcriptional regulator. It also suggests that IFI204 may play a role in early 
responses to infection, since we saw no decrease in IFN-β production in BMDCs 
after 12 hours. Consistent with previous results, cGAS deficient BMDMs display 
a decrease in IFN-β production to HSV-1, poly(dA:dT), and mCMV (Figure 3.2c) 
Interestingly, cGAS deficient cells were also unable to produce IFN-β in response 
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to Plasmodium falciparum genomic DNA and AT5 Plasmodium DNA, a 20mer 
derived from the Plasmodium falciparum genome, as well as CpGA. This 
observation has not been previously described and may suggest a role for cGAS 
in the detection of Plasmodium infection. Furthermore, CpG DNA may be 
detected by not only TLR9, but also detected by cGAS and driving the synthesis 
of cGAMP to further induce type I interferon responses. This suggests that cGAS 
has the ability to detect a broader range of DNA ligands than previously 
described. Together these results show that while cGAS plays a clear role in the 
recognition of DNA ligands and the induction of type I interferons, IFI204 may 
play only a partial or redundant, yet broader role in sensing DNA and RNA 
ligands.  
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Figure 3.2. IFI204 plays a partial role in the type I IFN response to DNA ligands. A. Peritoneal Macrophages, B. 
BMDCs or C,D. BMDMs were stimulated with poly(dA:dT), 3-5 cGAMP, ISD, HSV-1, mCMV, Malarial DNA, or 
SV for 6 hours and monitored for IFNβ expression by q-RT-PCR or ELISA. Results are represented as fold 
change over media. C. Data is representative of one experiment. (* p<0.05 assessed by Two-Tailed T-Test 
compared to WT or ZCRE mice, data are represented as mean + S.E. Data represents 3 biological replicates). 
Bars without * are not significant.   
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In order to further study the role of IFI204 in type I interferon responses, 
we monitored the induction of a panel of Type I IFNs, cytokines, chemokines, 
and PRRs before and after DNA stimulation by multiplex gene expression 
analysis using nCounter (Nanostring) technology in primary BMDMs. We 
stimulated BMDMs derived from ZCRE and IFI204 deficient mice with 
poly(dA:dT), ISD, cGAMP, and Sendai Virus for 6 hours and isolated RNA for 
nanostring analysis. We did not detect any differences in many of the genes that 
were upregulated in response to these ligands when we compared IFI204 
deficient BMDMs to control cells (Figure 3.3 and Table 3.1). We did, however, 
notice a specific decrease in IFN-β and IFN-α levels in response to both DNA 
and RNA ligands in IFI204 KO cells. Furthermore, IFI204 deficient cells also 
displayed lower levels of IRF7 and Viperin after stimulation.  This result is 
consistent with suggesting a partial role for IFI204 in Type I interferon induction. 
It is also consistent with our results from IFI16 knockdown cells discussed in 
chapter two of this thesis, in that IFI204 plays a broader role in the induction of 
type I interferons and ISGs in response to both DNA and RNA ligands. 
Specifically, there is a more prominent decrease in IFN-α levels supported by the 
fact that IRF7 is decreased as well.  
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Figure 3.3. Nanostring Analysis of IFI204-/- cells. ZCRE and IFI204 deficient BMDM’s were 
stimulated with poly (dA:dT), Sendai Virus,, ISD, and cGAMP for 6 hours. RNA was collected 
for nanostring analysis. Results displayed as fold change over medium.   
ASC
GAPDH
Irf5
stat3(Isoform 1)
?????
?????
?????
????
?????
nfkb1
?????????
Irf3
?????
?????
stat1
AP1
??????????
?????
??????
Socs3
??????
MNDA
Pydc3
CXCL1
????????
Irf1
?????????????
Irf7
MNDAL
?????
??????????form 1)
?????
???? ?????
????
??????
Rantes
SOCS1
?????????
CCL3
??????
????r??
????
????
????????
????????? ? 1 ? 3
Value
ZCRE ????????? ZCRE ????????? ZCRE ????????? ZCRE ?????????
cGAMP ?????? ????? poly(dA:dT) ISD
 101 
Table 3.1. Nanostring Analysis of IFI204 -/- BMDMs, Fold Change  
 cGAMP Sendai Virus poly(dA:dT) ISD 
 ZCRE IFI204-/- ZCRE IFI204-/- ZCRE IFI204-/- ZCRE IFI204-/- 
AIM-2 1.8 1.6 3.4 4.0 0.9 0.9 1.1 1.2 
AP1 1.4 1.2 4.4 3.4 1.4 1.4 1.4 1.6 
ASC 1.2 1.9 0.7 2.7 0.7 1.7 1.1 2.0 
CCL2 10.4 7.1 33.0 18.5 4.7 3.9 6.7 5.5 
CCL3 7.9 6.4 50.9 27.7 4.9 4.3 5.4 5.2 
CXCL1 1.1 1.2 12.3 8.0 1.5 2.0 1.0 1.3 
Caspase-1 1.8 1.4 2.4 2.5 1.2 0.9 1.4 1.2 
Caspase-11 1.7 1.5 4.5 3.4 1.1 1.0 1.3 1.2 
GAPDH 0.9 1.1 0.9 1.0 1.0 1.0 0.9 1.0 
IFI202 5.4 0.8 10.7 2.6 2.4 0.8 3.5 1.3 
IFI203 8.5 5.1 26.1 21.3 2.1 1.7 4.3 2.8 
IFI205 17.9 24.9 81.7 143.5 2.3 3.2 7.1 8.1 
IFI206 13.0 8.9 34.2 34.4 1.5 1.7 6.7 4.2 
IFN-Alpha 110.2 34.7 3318.0 884.3 73.3 13.4 55.8 13.7 
IFN-beta 220.8 133.7 2865.0 1378.0 81.5 45.3 111.7 78.6 
IL-1 alpha 2.3 3.7 31.6 30.8 1.8 2.9 1.7 3.0 
IL-10 0.4 3.5 5.2 6.5 1.0 1.4 0.9 1.0 
IL-18 0.9 1.1 1.5 1.3 1.1 0.9 1.0 1.2 
IL-1beta 2.8 3.9 14.7 18.3 2.8 4.6 2.1 3.3 
IL-6 32.9 43.9 301.9 417.9 7.5 11.4 12.6 16.6 
IP10 90.0 69.9 232.4 238.6 6.6 4.0 32.2 27.0 
Il12a 0.8 1.2 3.7 2.8 0.9 0.9 1.1 0.8 
Il12b 4.1 13.1 31.4 111.6 1.0 1.1 6.0 15.1 
Irf1 10.0 9.5 15.0 16.0 2.1 1.5 5.2 5.1 
Irf2 1.5 1.3 1.9 2.4 1.1 1.0 1.2 1.2 
Irf3 1.2 2.7 2.5 3.6 0.6 2.1 0.5 2.9 
Irf5 0.9 0.9 0.9 1.0 0.8 0.9 0.8 0.9 
Irf7 14.9 9.1 22.2 19.5 3.1 2.0 7.6 4.5 
MNDA 5.5 6.9 11.4 18.9 1.8 1.8 3.2 4.8 
MNDAL 6.3 3.7 22.5 22.0 1.5 1.6 2.9 2.3 
PYHIN-1 9.4 8.0 20.7 23.2 1.9 1.7 4.9 3.7 
Pydc3 6.8 0.9 12.0 1.7 1.5 0.6 2.5 0.9 
Pydc4 17.4 6.9 24.7 20.9 3.3 1.8 9.0 5.2 
Rantes 5.2 5.1 35.5 50.1 2.1 1.8 3.3 3.0 
SOCS1 33.0 15.9 46.4 26.4 5.5 2.6 17.2 8.3 
Socs3 3.3 2.6 10.3 6.0 1.7 1.8 2.2 2.4 
TNF-alpha 6.9 10.7 50.8 68.3 4.4 6.7 4.6 8.4 
nfkb1 1.2 1.0 2.4 2.5 0.9 1.0 1.0 1.1 
nfkb2 1.2 1.2 2.2 2.3 0.9 0.9 1.0 1.2 
p53-1 1.2 1.2 1.4 1.8 1.0 0.9 1.1 1.2 
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p53-2 1.2 0.8 1.6 1.5 0.8 0.5 1.3 0.8 
stat1 4.0 3.6 4.3 5.3 1.5 1.3 2.8 2.4 
stat3 0.9 1.1 1.2 1.5 0.8 0.9 0.8 1.1 
viperin 46.6 27.5 178.2 131.1 4.6 2.7 18.2 10.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1 Nanostring Analysis of IFI204-/- cells, Fold Change. ZCRE and IFI204 deficient 
BMDM’s were stimulated with poly (dA:dT), Sendai Virus,, ISD, and cGAMP for 6 hours. RNA 
was collected for nanostring analysis. Results displayed as fold change over medium.   
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IFI204 does not play a role in the NF-κB response to DNA and RNA ligands, 
nor is it necessary for pyroptotic cell death.  
 
 Previous in vitro studies did not detect a role for IFI204 in upregulating NF-
κB associated genes. Furthermore, work in chapter 2 of this thesis discusses that 
in IFI16 knockdown cells, levels of NF-κB driven cytokines, IL-6 and IL-1 β are 
unchanged or often slightly increased in response to DNA ligands as compared 
to EV control cells. To determine if IFI204 plays a role in the NF-κB responses 
driven by RNA and DNA ligands, we stimulated peritoneal macrophages and 
BMDCs from IFI204 -/-, ZCRE, WT, and cGAS-/- mice with a panel of ligands 
and monitored IL-6 production by ELISA. We found that IL-6 production was 
unchanged or slightly elevated in IFI204 deficient cells after stimulation. We also 
stimulated ZCRE and IFI204-/- BMDMs with poly(dA:dT), ISD, Sendai Virus, and 
cGAMP for 6 hours and collected RNA for nanostring analysis. Consistent with 
the above results, we found that levels of IL-6, TNF-α, and IL-1β were 
unchanged or slightly increased in response to all ligands. Furthermore, in the 
IFI204-/- cells, we noticed a slight decrease in expression of SOCS-1, which has 
been shown to negatively regulate NF-κB driven cytokine production (Figure 3.3 
and Table 3.1).  
We also noticed a partial defect in IL-6 production in cGAS deficient cells 
in response to poly(dA:dT), ISD, and malarial DNA. This response was even 
more dramatic in the cGAS deficient BMDCs (Figure 3.4 a and b). These results 
suggests that cGAS has a broader impact in immune activation to DNA infection 
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than the IFI204. It also provides further evidence that cGAS may be an important 
player in the immune response to malarial DNA. Furthermore, we saw severe 
attenuation of IL-6 in response to DNA virus mCMV in the cGAS -/- cells as 
compared to WT cells. This is surprising, as the response to the other DNA virus, 
HSV-1, is unaltered in cGAS knockouts compared to WT cells. For these studies, 
we used the ICP0 mutant HSV-1 7134 virus. ICP0 is a viral produced 
immunosuppressive gene that has been deleted in order to induce a greater 
immune response in cells. Alteration in this strain as compared to the WT mCMV 
may be responsible for the differences in the way the viruses are detected by 
cGAS. Further study is needed in order to determine the role of cGAS in mCMV 
and plasmodium responses.  
 Previous work has shown that IFI16 participates in the formation of an 
inflammasome in the nucleus in response to KSHV. We next wanted to explore 
the ability of IFI204 to induce inflammasome responses to various ligands. 
Peritoneal macrophages from IFI204 -/-, ZCRE, WT, and cGAS-/- mice were 
primed with LPS for 2 hours and then stimulated with DNA and inflammasome 
dependent ligands, ATP and Nigericin. We did not notice any significant changes 
in IL-1β production for either the IFI204 or cGAS deficient cells (Figure 3.4 c and 
d), suggesting that neither gene plays a role in inflammasome activation by the 
poly(dA:dT), HSV-1, ATP, or Nigericin.  
Studies have also defined a role for IFI16 in pyroptotic cells death during 
HIV infection. We next monitored IFI204 BMDMs and BMDCs for their ability to 
undergo pyroptotic cell death using the cell glo assay. Cells were primed with 
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LPS for 2 hours and then stimulated with DNA ligands. We did not detect any 
difference in cell death in the IFI204 deficient cells as compared to control ZCRE 
cells. (Figure 3.4e and f). These results suggest that IFI204 does not play a role 
in NF-κB activation, inflammasome induced IL-1β production, or cell death in 
response to DNA ligands.  
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Figure 3.4 IFI204 does not play a role in the NF-κB response to DNA and RNA ligands, nor is it necessary for 
pyroptotic cells death. A. Pertitoneal Macrophages and B. BMDCs were stimulated with poly(dA:dT), 3-5 cGAMP, 
ISD, HSV-1, mCMV, Malarial DNA, or SV for 6 hours and monitored for IF-6 production by ELISA. C. cGAS or D. 
IFI204 deficient cells were primed with LPS for 2 hours and stimulated with poly(dA:dT), 3-5 cGAMP, ISD, HSV-1, 
mCMV, Malarial DNA, or SV for 12 hours and monitored for IL-1β production ELISA. E. BMDMs or F. BMDCs from 
IFI204 deficient mice were primed with LPS for 2 hours and stimulated with poly(dA:dT), 3-5 cGAMP, ISD, HSV-1, 
mCMV, Malarial DNA, or SV for 12 hours and monitored for cell death by Cell Glo Assay. (* p<0.05 assessed by Two-
Tailed T-Test compared to WT or ZCRE mice, data are represented as mean + S.E. Data represents 3 biological 
replicates). Bars without * are not significant.   
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IFI204 mediates the innate immune response to HSV-1 in vivo 
To date, the role of IFI204 in vivo has not been investigated. Thus, with 
the generation of the IFI204 knockout mouse, we explored the role IFI204 in the 
response to HSV-1 infection in vivo. We infected IFI204 -/-, WT, cGAS-/-, and 
TBK1-/- mice with 5.0X108 pfu HSV 7134R per mouse via intraperitoneal 
injection. None of the mice showed obvious sign of susceptibility upon virus 
infection during 72 hours. We collected serum at 24 hour and 72 hour time 
points, and harvested brain, liver and spleen. We extracted RNA from half of the 
brain tissue, liver and spleen, and collected brain homogenates from the other 
half of the brain tissue. We did not detect a difference in IFN-β mRNA expression 
in the brains of the mice by q-RT-PCR, however TBK-1 mice displayed higher IL-
6 and IP-10 levels suggesting that an active infection was taking place (Figure 
3.5a-c). We did detect a higher HSV genome copy number in the brain of cGAS -
/- mice, which was consistent with previous studies (Figure 3.5h). Furthermore, 
the viral load was below the limit of detection of the plaque assay performed. 
Studies have shown that cGAS -/- mice are more susceptible to HSV-1 infection, 
marked by decreased survival, decreased IFNα/β serum cytokine production, 
and increased viral load(151). We also saw higher HSV genome copy number in 
the liver and spleen of cGAS-/- mice (data not shown). While IFN-β and IL-6 
mRNA levels were not changed, we were able to detect differences in cytokine 
production from brain homogenates by ELISA. WT and cGAS-/- mice induced 
higher levels of IL-β, IFN-β, and IL-6 than the IFI204 -/- mice (Figure 3.5d, e, and 
f). IFN-β levels were significantly lower in the IFI204 -/- mice as compared to WT 
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mice, while levels of IL-1β and IL-6 were approaching significance. In subsequent 
studies, a higher dose of virus and younger mice may be necessary in order for 
the virus to travel to the brain in high amounts. 
We also wanted to determine if IFI204 mediates the immune response to 
HSV-1 systemically. We analyzed blood serum collected at 24 and 72 hours post 
infection for production of IFN-β, IL-6, and IL-1β by ELISA. Consistent with 
results from brain homogenates, IFI204 -/- mice produced lower amounts of IL-6, 
IL-1β, and IFN-β in the serum 72 hours post infection as compared to WT mice 
(Figure 3.5i, j, and k). IL-1β levels were significantly lower in the IFI204 -/- mice 
as compared to WT mice, while levels of IFN-β and IL-6 were approaching 
significance. These results provide further evidence that IF204 mediates that 
innate immune response to HSV-1 in vivo.  
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Figure 3.5. IFI204 mediates the innate immune response to HSV-1 in vivo. Brain Homogenates were 
collected 72 hours post infection and monitored for A. IFNβ, B. IL-6, C. IP-10, or G. HSV-1 copy number by 
q-RTPCR. Brain homogenates were monitored for D. IL-1β, E. IFNβ, or F. IL-6 production by ELISA. H. 
Serum was collected at 24 hours post infection and monitored for IFNβ by ELISA and at 72 hours post 
infection and monitored for I. IFNβ, J. IL-6 and K. IL-1β production by ELISA. (* p<0.05 assessed by Two-
Tailed T-Test compared WT infected mice, data are represented as mean + S.E.) Data without p values are 
not significant.  
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 Lastly, we wanted to determine if the IFI204 -/- mice are more susceptible 
to HSV-1 infection in vivo. We infected 15 day old WT, STING -/-, and IFI204 -/- 
mice via intraperitoneal injection with 1.0X10^7 pfu HSV-1 7134R. 100% of 
STING -/- mice, which have been shown to be more susceptible to HSV-1 
infection(89), died at day 4 post infection. >65% of IFI204-/- mice died at day 5 
post infection as compared to WT mice, which did not succumb to infection at all 
(Figure 3.6). 3 of the 9 WT mice developed hind leg paralysis on day 5 and 
recovered from the paralysis on day 7 post infection, which is an indication that 
an active infection was taking place in these mice. Of the remaining IFI204-/- 
mice, 2 developed hind leg paralysis on day 5 post infection and the paralysis 
remained until the mice were sacrificed on day 14 post infection. Further study is 
necessary to determine which cells types are responsible for lower cytokine 
production observed in the in vivo experiments.  
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Figure 3.6. HSV-1 Survival Study. 15 day old STING -/-, IFI204-/- and WT -/- mice were infected with 
1.0X10^7 pfu HSV-1 7134R via intraperitoneal injection and monitored for survival. (* p<0.05 assessed by 
Mantel-Cox test compared WT infected mice). 
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Discussion 
 
The type I interferons play a critical role in HSV-1 infection by activating an 
antiviral state that leads to clearance of the virus.  Mice deficient in key players of 
type I IFN production, such as IFNAR, STING, TBK1, as well as IRF3 and display 
increased susceptibility to HSV-1 infection (12,89,180,181,214,215). IFI16 and its 
mouse orthologue IFI204 have been extensively studied for their role in HSV-1 
recognition in vitro, however to date the role of IFI16 or IFI204 in vivo has yet to 
be determined. In this study, we developed an IFI204 knockout mouse and 
studied its role in immune responses to a panel of ligands in vitro and its role in 
HSV-1 infection in vivo.  
We began by stimulating peritoneal macrophages, BMDMs, and BMDCs 
with a panel of DNA and RNA stimuli and viruses and monitoring the cells for 
cytokine production. IFI204 deficient cells were unaltered in their ability to 
produce type I interferons to many of the stimuli, including poly(dA:dT) and ISD in 
peritoneal macrophages, in contrast to cGAS deficient cells. We did, however, 
observe a partial phenotype in response to both HSV-1 and mCMV in the IFI204 
deficient peritoneal macrophages. Furthermore, in BMDCs, IFI204 was not 
required for IFN-β production by ELISA.  These results are in contrast to previous 
siRNA studies that show that IFN-β production is strongly dependent on IFI204 in 
response to these ligands in RAW cells. It is unclear if siRNA targeting of IFI204 
was specific and it is possible that siRNA yielded some off target effects that 
enhanced the observed phenotype. Many of the PYHIN proteins are closely 
related to one another and siRNA may have some overlapping effects. IFI204 
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may work in tandem with other PYHIN proteins or other cytosolic sensors to 
induce these responses and a double knockout mouse may be necessary in 
order to see full effects.  
In contrast to these results, when IFI204 deficient BMDMs were stimulated 
with both DNA and RNA ligands for 6 hours and RNA was analyzed for IFN-β 
production by q-RT-PCR, we noticed a 50 percent decrease in IFN-β induction in 
response to all ligands. The results are consistent with IFI16 knockdown studies 
found in chapter two of this thesis, suggesting that IFI204 plays a broader role in 
the production of type I interferons to both DNA and RNA ligands. Furthermore, 
nanostring analysis confirms that levels of viperin and IRF7 are also decreased. 
The lower levels of viperin and IRF7 may provide an explanation for why IFN-α 
levels are more greatly attenuated.  Further work is necessary in order to 
determine whether IFI204 also plays a role in the regulation of transcription of 
type I interferons. It would be interesting to determine if levels of RIG-I are 
decreased in the IFI204 knockdown cells, since there is a partial defect in SV 
induced production of IFN-β in BMDMs. In contrast to IFI16 studies, basal levels 
of ISGs are not attenuated. It is important to note that the PYHIN proteins are 
closely related genes and other PYHIN proteins may contribute to type I 
interferon production at a basal level, although IFI204 is important for type I 
interferon induction after stimulation. Furthermore, IFI204 may be playing both a 
redundant and time dependent role along with other cytosolic sensors. This may 
explain why we saw no dependence on IFI204 after 12 hours, but a partial 
decreased in IFN-β production after 6 hours was observed.  
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We also monitored levels of NF-κB driven cytokines in IFI204 and cGAS 
deficient cells. In all cell types, IL-6, IL-1β, and TNF-α were unchanged or slightly 
increased in the IFI204 deficient cells after stimulation. This suggests that 
although IFI204 plays a role in type I interferon production, the NF-κB axis of 
activation is unaffected. Slight increases in cytokine production may be due to 
compensation mechanisms of the cell to ensure pathogen clearance. 
Interestingly, we found that IFN-β production in response to CpG and malarial 
DNA is dependent on cGAS. These results suggest a role for cGAS in malaria 
infection and a broader role for cGAS in the recognition of DNA ligands.   
Previous studies indicate that IFI16 is capable of assembling into an 
inflammasome complex with ASC in response to KSHV. We investigated the 
ability of IFI204 to induce IL-1β after LPS priming in response to a panel of 
stimuli. We did not see a defect in IL-1β production in either cGAS or IFI204 
deficient cells. There is much debate as to whether or not IFI16 forms an actual 
inflammasome since studies show only indirect evidence of inflammasome 
assembly via ASC colocalization with IFI16. Contradictory studies find that IFI16 
expression suppresses caspase-1 activation by the NLRP3 and AIM2 
inflammasomes. The role of IFI16 and type I interferon production is well defined, 
thus the production of IL-1β may be due to type I interferon induction and not 
bona fide inflammasome assembly. Furthermore, studies have shown that type I 
interferons inhibit IL-1β production by STAT-1 inhibition of NLRP3 (220). With 
less type I interferon production in the IF204 deficient cells, you would expect 
that this pathway would not be engaged, and IL-1β production would be normal.  
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Recent studies have linked IFI16 as the receptor responsible for 
inflammasome activation and pyroptotic death of bystander CD4 T cells during 
HIV infection. Thus, we also monitored IFI204 deficient cells their ability to induce 
pyroptosis in response to various stimuli after LPS priming.  We did not detect 
any differences in cell death in the IFI204 deficient BMDMs or BMDCs. Although 
this is in contrast to HIV studies mentioned above, IFI16 dependent pyroptosis 
may be ligand and cell type specific and dispensable for HSV-1 responses in 
macrophages and dendritic cells.  
We next wanted to determine if IFI204 plays a role in HSV-1 infection in 
vivo.  Previous studies have shown that type I interferon induction is important for 
HSV-1 viral clearance. Mice deficient in cGAS and TBK1 display increased 
susceptibility to HSV-1. Although we did not detect higher viral load in IFI204 
deficient mice, we did detect lower levels of IFN-β, IL-6, and IL-1β in the brain 
and serum post infection. These results suggest that HSV-1 is recognized by 
IFI204 to induce these responses. Furthermore, IFI204-/- mice display increased 
susceptibility to HSV-1 as compared to WT mice. Further study is necessary to 
determine how IFI204 mediates the response to HSV-1 in vivo.  
 To date, there has been much discussion as to whether or not IFI16 is a 
bona fide nucleic acid sensor for DNA viruses. This study is the first to describe a 
role for IFI204 in vivo during a viral infection. Further work is necessary in order 
to determine how IFI204 interacts with other cytosolic sensors and the role it 
plays during HSV-1 infection.  
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Materials and Methods 
 
Reagents and Antibodies  
LPS, 3-5 cGAMP, and poly(dA:dT) were obtained from Sigma-Aldrich (St. Louis, 
MO). HSV 60mer, and ISD oligonucleotides were synthesized as described in 
(130), Cyclic-di-GMP was from Biolog (Hayward, CA). HSV-1 (7134) and HSV-1 
7134R was a gift from D. Knipe (Harvard Medical School, MA).  Sendai virus 
(SeV, Cantrell strain) was purchased from Charles River Laboratories 
(Wilmington, MA). mCMV (Smith strain) was a gift from R. Welsh (UMASS 
Medical School, MA)Lipofectamine 2000 was from Invitrogen (Carlsbad, CA).  
Genejuice was from Novagen (Madison, WI).  
 
Cell Culture, Stimulation and ELISA 
Peritoneal Macrophages were harvested 3 days after i.p. injection of 1 ml of 
thioglycolate. As described in (32). Bone marrow from the femur of mice was 
harvested and BMDMs and BMDCs were derived as described in (157). For 
stimulations, poly(dA:dT) (1 µg/ml), ISD (3 µM) HSV 60mer (3 µM) ci-di-AMP (3 
µM),  5’ppp RNA (600ng/mL), cGAMP 3’-5’ (3 µM) were transfected into the cells 
with lipofectamine in accordance with the manufacturer's instructions. Cells were 
infected with mCMV or HSV-1 7134 viruses at multiplicities of infection (MOI) of 
10 for in vitro. Cells were infected with Sendai virus at 200 IU/ml. Cells were 
challenged with stimulants or microbes for 6 hrs (for RNA analysis) or 12 hours 
(for protein analysis by ELISA). Cytokine and IFN levels in culture supernatants 
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were assayed for IL-1β and IL-6 (BD Biosciences, Franklin Lakes, NJ) and IFN-β 
by sandwich ELISA. 
 
In Vivo Studies 
6 week old mice were infected with 5.0X10^8 pfu via intrapertioneal injection  
with HSV-1 7134R and brain, liver, spleen, and serum were collected from the 
mice 72 hours post infection. 15 day old mice were infected with 1.0X10^7 pfu 
HSV-1 7134R via intraperitoneal injection and monitored for survival over 14 
days.  
 
Mice 
ZCRE mice were from Jackson Laboratories (Bar Harbor, ME). cGAS 
embryos were obtained from International Mouse strain resource. All 
experiments were conducted with mice maintained under specific pathogen-free 
conditions in the animal facilities at the UMASS Medical School and were carried 
out in accordance with the guidelines set forth by the Institutional Animal Care 
and Use Committee. 
 
Nanostring and RT-QPCR experiments 
Cells were treated for 6 hours and RNA was purified with a quick RNA mini prep 
kit (Zymo Research, Irvine, CA). RNA transcript counting was performed on total 
RNA hybridized to a custom gene expression CodeSet and analyzed on an 
nCounter Digital Analyzer.  Counts were normalized to internal spike-in and 
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endogenous controls per Nanostring Technologies’ specifications.  A pseudo 
count was added to all values such that the smallest value in the dataset was 
equal to 1. 
cDNA was synthesized, and quantitative RT-PCR analysis was performed as 
described (212,213). Gene expression is shown as a ratio of gene copy number 
per 100 copies of HPRT ± SD.  
 
Cell Viability Assay  
Cell Glo stain was obtained from Promega. Cells were stimulated as described 
above and cell viability was assayed according to the manufacture’s protocol. 
Cells were washed in PBS and incubated in cell glo stain for 30 min at room 
temperature. Cells were monitored for FITC fluorescence.  
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Chapter 4: Discussion and Perspectives 
 
  
The innate immune system is the body’s first line of defense against 
pathogens. This response is governed by a variety of PRRs that recognize 
PAMPS and DAMPS and activate downstream signaling molecules. Effectors 
such as type I interferons (IFNs) and pro-inflammatory cytokines and chemokines 
aid in mediating this response. Nucleic acids that are released into the cytosol 
during bacterial and viral infection are recognized by a range of intracellular RNA 
and DNA sensors that activate the type I interferon response.  
It is well known that type I interferons play a critical role in the clearance of 
viruses. The production of IFNαβ activates an antiviral state which initiates the 
transcription of many interferon stimulated genes and production of other 
cytokines and chemokines that enhance the inflammatory response and viral 
clearance. To date over 400 ISGs have been identified and found to play a role in 
viral pathogenesis. Among these ISGs are the well known PKR, Mx Proteins, and 
OAS. PKR is a serine-threonine kinase that binds to dsRNA intermediates that 
are formed during viral replication. Once bound, PKR phosphorylates the 
eukaryotic initiation factor 2a (eIF2a), which in turn inhibits viral gene translation. 
PKR has been shown to play a role in HSV-1, Vaccinia Virus, and 
EMCV(190,221). The Mx Proteins are GTPases that are expressed in the cytosol 
after type I interferon induction. Here, they bind to viral capsid proteins and 
prevent import to the nucleus, thus inhibiting vial replication. Mx Proteins have 
been implicated in Influenza virus and VSV infection(190,221,222). Lastly OAS 
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has been shown to bind dsRNA and convert ATP into 2’-5’ linked AMP-oligomers 
(2-5A), which in turn activates RNAseL. RNAseL then cleaves viral which inhibits 
viral replication. This cleaved RNA also activates RIG-I which amplifies the type I 
interferon response. OAS has been shown to play a role in SV and EMCV 
infection(190,221,223).  
The importance of the type I interferon pathway is evident as viruses have 
evolved ways to evade the type I interferon response. Herpes Simplex Virus 
encodes an immediate early protein ICP0 which inhibits IRF3 and IRF7 and 
subsequent type I interferon responses(218). The crucial role type I interferons 
play in innate immunity has made them a target of many therapeutic approaches. 
Type I interferons are well known to inhibit tumor growth(224) and have been 
used in the clinic to treat leukemia, melanoma, and Kaposi’s sarcoma(225). 
Furthermore, Type I interferons have also been implicated in a variety of 
diseases such as inflammatory bowel disease, psoriasis, and Systemic lupus 
erythematous (SLE). 
Since type I interferons have such effects on immunomodulation, it is 
important to understand how they are regulated. Studies have shown that 
SOCS1 can negatively regulate type I interferon production by inhibition of the 
JAK/STAT pathway. Patients with SLE have defects in SOCS1 regulation, thus 
exhibiting a hyper production of type I Interferons(226). The key to understanding 
other ways in which type I interferons are regulated is first determining how they 
are induced.  
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 To date, many cytosolic DNA sensors have been described, however it is 
unclear how these receptors work in concert to mediate pathogen clearance. In 
chapter two of this thesis, we describe a broader role for the intracellular DNA 
sensor, IFI16, in regulating these responses. IFI16 is the human member of the 
PYHIN family of proteins. Initial reports of IFI16 described it to be a negative 
regulator of cell cycle regulation. However recent siRNA studies have shown that 
IFI16 binds cytosolic DNA via its HIN200 domains and activates type I interferon 
response through STING, TBK1, and IRF3. In contrast to these findings, we 
determined that when IFI16 is knocked down in human THP1 cells by shRNA, 
type I IFN production is abrogated in response to both DNA and RNA ligands. 
We have now shown that IFI16 plays a role in regulating transcription of IFNα. 
Given the critical function of type I interferons in disease, our studies have 
unveiled an important additional way for type I interferons to be activated. By 
regulating IFNα gene expression, IFI16 bypasses the viral evasions mechanisms 
that shut down type I IFN responses through IRF3.  
Our work also provides insight as to how IFI16 may be targeted as a 
potential therapeutic for disease. SLE is an autoimmune disease that is 
characterized by overproduction of type I Interferons. In fact, the hallmark of 
disease is elevated levels of IFNα in the serum of patients(227-230). Clinical 
trials in which neutralizing antibodies to IFNα were administered to patients 
greatly reduced symptoms of disease(231). IFI16 has also been linked to SLE. 
Several groups have shown the production of anti-IFI16 antibodies in patients 
with SLE(127,129,232). Furthermore, patients with the IFI16 SNP rs866484, 
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which causes an amino acid change in the protein, have higher incidences of 
SLE(233). Although the production of type I interferons is beneficial for viral 
clearance, the over production of type I interferons in autoimmune diseases 
demonstrates the need for a tight balance of these responses. Taken together 
with our studies, the presence of IFI16 autoantibodies in SLE and the fact that 
IFI16 plays a role in the regulation of IFNα expression suggest that IFI16 may be 
a potential therapeutic target for autoimmunity. Furthermore, the onset of 
autoimmune diseases has been linked to persistent viral infection. This 
observation provides a correlation between the induction of IFI16 after viral 
infection and its importance in SLE immunopathology.  
These results also provide insight into how IFI16 may work with other 
cytosolic sensors. Recent studies have suggested that although many cytosolic 
DNA sensors have been discovered, cGAS is the only bona fide DNA sensor. 
Since much of the work has been limited to siRNA studies, more stable 
knockdown or complete knockout models of these receptors may prove that the 
proposed molecules are not actual receptors at all. Our results suggest that IFI16 
is not only an innate sensor for DNA, but works also in tandem with other 
receptors to amplify the type I interferon response to viruses. IFI16 is interferon 
inducible, as such its levels are increased after viral infection and initial induction 
of type I interferons. cGAS levels remain constant in cells. In fact, cGAS is 
expressed broadly across all tissue types, whereas IFI16 has a very specific and 
limited pattern of expression. We have shown that cGAS levels are normal in 
IFI16 knockdown cells. It is possible that cGAS directly recognizes DNA to initiate 
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the type I interferon response and upregulate IFI16, which then itself regulates 
IFN production to further the antiviral state. This idea would lead us to believe 
that viral evasion mechanisms would exist to directly target IFI16. In fact, it has 
been shown that HSV-1 ICP0 protein targets IFI16 for degradation in the nucleus 
of HFF cells(133).  Perhaps this persistent and long term antiviral state 
contributes to the activation of LAT transcripts, pushing HSV-1 into latency.  
In addition to the fact that DNA sensors may act in a timing dependent 
manner, a cell type dependence may explain the redundancy of receptors as 
well. As mentioned above, it is necessary for complete knockout of proposed 
DNA sensors in order to fully elucidate their roles in type I interferon response. In 
chapter 3 of this thesis we generated an IFI204 knockout mouse to determine the 
role of the proposed DNA sensor in vivo. In contrast to siRNA studies, we 
demonstrate that IFI204 plays only a partial role in the response to viral DNA 
ligands in BMDMs. This is in contrast to cGAS, which responds to a broader 
range of DNA ligands in multiple cell types. These results are consistent with the 
idea that cGAS is a bona fide DNA sensor for all intracellular DNA signaling, 
whereas the IFI204 response is only ligand and cell type specific. Further work is 
needed in order to determine if timing is necessary for IFI204 signaling and 
whether it works with cGAS in a sequential manner. We also demonstrated that 
IFNαβ levels in IFI204 knockout mice were decreased in BMDMs in response to 
both DNA and RNA ligands, which is consistent with IFI16 data presented in 
Chapter two. More work is needed in order to determine if IFI204 is in fact the 
mouse orthologue to IFI16 and functions to regulate type I interferon production.  
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There has been much question as to whether or not IFI204 is the true 
orthologue of IFI16. IFI204 and IFI16 were hypothesized to be orthologues 
mainly due to their similarities in domain structure, as each contains two HIN200 
domains and one Pyrin domain. In addition, studies by Unterholzner et al., found 
that the two function similarly, producing less IFN-β in response to DNA ligands 
when IFI204 or IFI16 are knocked down with siRNA (124). However, 
phylogenetic analysis of both the Pyrin domain and HIN200 domains revealed 
that IFI16 and IFI204 are not evolutionary orthologues (234). Both IFI16 and 
IFI204 are more closely related to other members of the ALR family with respect 
to their HIN200 and Pyrin domains than they are to one another. Furthermore, 
conflicting results show that when IFI204 is knocked down in BMDMs and MEFs 
with a siRNA that was designed to target IFI204 specifically and not any of the 
other PYHIN family members, IFN-β production is not impaired in response to a 
panel of DNA ligands (234). Despite the similarity in domain structure, IFI204 and 
IFI16 are not evolutionary orthologues. It remains to be determined whether or 
not the two are functional orthologues, however. Data from this thesis suggests 
that the two function similarly by playing a broader role in the detection of both 
DNA and RNA ligands. However, IFN-β production is only partially dependent on 
IFI204, suggesting that IFI204 is a redundant DNA sensor and may require other 
PYHIN proteins for its full function.  
The role of type I interferons in HSV-1 infection is well known. Mice 
deficient in IFNAR, IRF3, and TBK1 are more susceptible to HSV-1 viral 
infection. However the role of DNA sensors that activate this pathway is unclear. 
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Here we show that, IFI204 plays a role in pathogenesis to HSV-1 infection in 
vivo. Mice deficient in IFI204 are limited in their ability to produce IFNβ, IL-6 and 
IL-1β after HSV-1 infection as compared to WT infected mice. Our work also 
provides evidence that IFI204 works in conjunction with cGAS to mediate HSV-1 
clearance. Previous studies have shown that cGAS-/- mice produce less IFNβ up 
to 12 hours post HSV-1 infection as compared to WT mice. However, after 12 
hours, levels of IFNβ return to normal. In our work, we found that levels of IFNβ 
in the brain and serum of cGAS -/- mice are normal as compared to WT mice 72 
hours post infection, which is consistent with previous studies. However, IFI204-/- 
mice produce less IFNβ in both the brain and serum 72 hours post infection. 
These results suggest that cGAS is important for the initial early responses to 
HSV-1 and IFI204 plays a role later during infection.  Furthermore, IFI204 -/- 
mice display increased susceptibility to HSV-1 as compared to WT mice.  This 
result, coupled with the lower levels of IFN-β production seen in the IFI204 -/- 
mice after HSV-1 infection, suggest the mice deficient in IFI204 would be 
hindered in their ability to modulate viral load. Further work is needed to 
determine if HSV-1 replication is affected in the IFI204 -/- mice after infection, 
and what cell types are responsible for the decreased cytokine production.   
These results provide a better understanding of how type I interferons are 
regulated in response to viral infection in vivo.  
In Appendix B we highlight the importance of STING in type I interferon 
responses. MOLF mice are limited in their ability to produce type I interferons in 
response to DNA ligands. Using forward genetics we show that this defect is due 
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to the fact that MOLF mice have a mutation in STING. This emphasizes the 
importance of STING as it has evolved to play a central role in the antiviral 
response.  Studies have shown that the C terminal domain of STING is important 
for binding of ligands and its activity. DMXAA has been shown to bind to mouse 
STING, but not human STING due to a SNP mutation in the C terminus. This 
provides an explanation for why DMXAA failed to target tumors in clinical trials. 
However in our studies, we found the mutation in the N terminus of STING to be 
responsible for lack of activity. It is possible that the N terminus of STING 
interacts with DNA sensors to regulate type I interferon responses. These results 
contribute to the knowledge of how STING is activated and can provide insight 
into how therapeutics such as DMXAA can be altered to bind STING more 
effectively in humans.  
Lastly, this thesis highlights the importance of equilibrium of innate 
immune responses. The production of type I interferons is important for the 
clearance of viruses and activation of the antiviral state. However, it is clear that 
over production of type I interferons can be detrimental to the host as is seen 
with autoimmune diseases such as SLE. In chapter two of this thesis, we show 
that although IFI16 knockdown cells produce decreased amounts of type I 
interferons, these cells produce similar or higher amounts of NF-κB driven 
cytokines, IL-6 and IL-1β. It is possible that the host releases these cytokines in 
excess to act as compensation for the lack of type I interferons necessary to 
clear infection. Type I interferon and ISG induction play a crucial role in 
containing pathogen load. When this line of defense is disrupted, pathogen 
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replication can then induce the production of NF-κB driven cytokines, shifting to a 
pro-inflammatory driven response. Furthermore, it has been shown that these 
cytokines regulate one another to maintain tight balance of immune responses. 
Type I interferons have been shown to inhibit pro-IL-1β production in a STAT-1 
dependent manner(220).  Furthermore, patients receiving IFN-β treatment have 
weakened immune responses due to a decrease in IL-1β production(220). 
Knowledge of how these cytokines work together to control the immune response 
will aid in creating therapeutics that are better targeted. Perhaps IFI16 can be 
targeted for inflammatory diseases as well.  
During HSV infection, the production of cytokines and chemokines is 
important for viral clearance, however cytokine storm can lead to severe 
inflammation and death if the response is not tightly regulated. In Appendix A we 
discuss the role of the CD200R1 in HSV-1 infection.  While it is well known that 
TLR2 plays a role in the HSV-1 survival in vivo, how TLR2 is regulated was 
unknown. CD200R -/- mice are more susceptible to HSV-1 infection. They also 
lack the ability to upregulate TLR2 and produce cytokines in response to TLR2 
ligands. These results suggest a role for CD200R in ensuring a tight balance of 
TLR2 activation in response to HSV-1. We also found a role for CD200R in 
regulating IL-1β production. IL-1β has been used as a therapeutic for multiple 
inflammatory diseases such as rheumatoid arthritis. Blocking IL-1β production 
has been used in treatment of the disease, however side effects due to inability 
to mount immune responses have been noted.   A greater understanding of how 
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IL-1β is regulated introduces the possibility that receptors such as CD200R may 
be targeted to produce more specific and effective therapeutics.  
In conclusion, this thesis provides a model for the activation of cytosolic 
nucleic acid sensors by HSV-1 and other ligands, and the regulation of type I 
interferons by IFI16. IFI16 transcriptionally regulates the basal expression of IFN-
α and ISGs, including RIG-I. Type I interferons then signal through the IFNAR 
and STAT pathway to further induce type I Interferons in a feedback loop. This 
tonic type I interferon signaling exists to maintain ISGs at appropriate basal 
levels.  Disruption of this balance can lead to increased susceptibility to disease 
or cancer in the case of too little type I IFN being produced, or the development 
of autoimmune disease if too much type I IFN is produced.  
Upon infection with DNA ligands, such as HSV-1, cGAS induces the 
production of type I Interferons and ISGs, such as IFI16, through activation of 
STING and phosphorylation of IRF3. IFI16, which is predominantly nuclear, plays 
a role in regulating the transcription of type I interferons and other ISGs, further 
amplifying the antiviral response. Viral evasion mechanisms, such as the HSV-1 
ICP0 gene, block this response by inhibiting IRF3, or IFI16. 
Lastly, there are long term effects of type I interferon signaling. After viral 
infection, IFI16 regulates IFN-α and subsequent ISG expression. Receptors such 
as RIG-I, which recognize Sendai Virus are upregulated as a result of IFI16 
activation. Thus in the absence of IFI16, type I interferon signaling in response to 
Sendai Virus is abrogated. However, HSV-1 can also be recognized by TLR2 to 
induce NF-κB dependent cytokines, IL-6 and IL-1β. In the absence of IFI16, the 
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host shifts to a pro-inflammatory response to compensate for lack of type I 
interferon antiviral activity. Figure 4.1 shows a model for IFI16 regulation of type I 
interferons.  
Collectively, this thesis defines a broader role for IFI16 in the regulation of 
type I interferons. Furthermore, we provide insight into how cytosolic nucleic acid 
sensors work together to regulate the type I interferon response to HSV-1 and 
other ligands. We highlight the importance of the balance of the immune 
response as is relates to the development of disease. Thus, this knowledge can 
be used to create safe and effective therapeutics. 
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Appendix A: CD200R1 Supports HSV-1 Viral Replication and Licenses Pro-
Inflammatory Signaling Functions of TLR2 
Preface to Appendix A 
 
This Appendix has appeared in the following publications/manuscripts:  
 
Soberman, Roy J., MacKay, Christopher R., Vaine, Christine A., Ryan, Glennice 
Bowen., Cerny, Anna M.,Thompson, Mikayla R,. Nikolic, Boris., Primo, Valeria., 
Christmas, Peter., Sheiffele, Paul., Aronov, Lisa., Knipe, David M., Kurt-Jones, 
Evelyn A. (2012) “CD200R1 Supports HSV-1 Viral Replication and Licenses Pro-
Inflammatory Signaling Functions of TLR2.” PLoS ONE 7(10). 
 
• Mikayla Thompson performed the experiments in 5.1b and c 
• Mikayla Thompson wrote the introduction and added to and adapted the 
results and discussion from the paper listed above.  
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Introduction  
 
 The innate response to pathogens activates cells of the immune system, 
which aids in viral clearance; however prolonged activation or severe 
inflammation can be harmful to the host.  In order to maintain this delicate 
balance, negative regulators, such as suppressor of cytokines (SOCS) (235,236), 
and apoptosis mechanisms (236) exist to restore the system back to its basal 
state. In fact, defects in negative regulation can lead to the onset of autoimmune 
disorders (236-239). In the case of herpes simplex virus 1 (HSV-1), the 
interaction of the virus with Toll-like receptor (TLR) 2 is critical. 
 Studies have shown that HSV-1 signals through TLR-2 to trigger the 
production of NF-κB driven cytokines. (32,240-242) This activation leads to the 
recruitment of leukocytes to the site of infection to aid in viral clearance. While 
these responses can be beneficial, excessive TLR2 activation can cause a 
cytokine storm, which causes harmful inflammation, tissue damage, and potential 
lethality (240,242,243). TLR2-/- mice are less susceptible to HSV-1 infection, 
marked by decreased production of CCL5 (Rantes), CCL2 (MCP-1) and IL-6 in 
the brain. Levels of these cytokines have been correlated to the severity of HSV-
1 infection and the development of disease (242,244-247). Therefore, survival 
from HSV-1 encephalitis is determined not only by viral replication but also by the 
balance between pro-inflammatory and down-regulatory responses. To date, the 
mechanisms by which TLR2 signaling is down regulated are poorly described.  
 The CD200 receptor (CD200R1), which is expressed on all myeloid cells 
(248) as well as some T and B cell subsets (249), has been shown to down 
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regulate the immune response when it interacts with its ligand, CD200, which can 
be released by a wide range of cell subtypes (250-253). Myeloid cells that display 
the receptor receive an “off” signal from a cell that produces the CD200 ligand. 
This has been observed in models of experimental autoimmune encephalitis 
(EAE) (254), collagen induced arthritis (CIA) (255), and renal allografts (256). 
The CD200R signals by recruiting the adaptor molecules Dok1 and Dok2, which 
recruit RasGAP and mediate inhibition of the MAP kinase pathway (257). 
However, the specific pro-inflammatory signal transduction pathways in 
macrophages, dendritic cells, and mast cells that are down regulated by 
CD200R1 (251-253) have yet to be elucidated. How CD200R1 impacts TLR2 
signaling, particularly in macrophages, is not known. 
 To understand how CD200R1 signaling impacts TLR2 function, we 
generated CD200R1-/- mice. We determined the ability of macrophages 
generated from CD200R1-/- mice to produce cytokines and chemokines in 
response to the TLR2 agonist Pam2CSK4 and to HSV-1. CD200R1-/- 
macrophages were limited in their ability to produce both IL-6 and CCL5 (Rantes) 
in response to stimulation by both Pam2CSK4 and HSV-1. However, we did not 
notice a decrease in cytokine production in response to LPS.  CD200R1-/-
macrophages also lacked the ability to up-regulate TLR2 expression in response 
to HSV-1 infection. Furthermore, CD200R1-/- embryonic fibroblasts and 
macrophages exhibited a defect in HSV-1 replication. 
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Results  
 
CD200R1 Licenses Pro-inflammatory Signaling by TLR2 in Macrophages 
 In order to determine how CD200R interacts with TLR2 in response to HSV-
1 infection, we generated peritoneal macrophages from CD200R1+/+ and 
CD200R1-/- mice. Cells were infected with HSV-1 (multiplicity of infection; MOI = 
10), or challenged with Pam2CSK4 (100 ng/ml), or LPS (100 ng/ml), and levels 
of IL-6, CCL5 (Rantes), or CCL2 (MCP-1) were measured at 24, 48, and 72 
hours post infection by ELISA. HSV-1 infected CD200R1+/+ macrophages 
produced 35,000 pg/ml IL-6 24 hours after stimulation, which rose to 60,000 
pg/ml by 48 and 72 hours (Figure 4A). In contrast, CD200R1-/- macrophages 
only generated between 20,000 to 30,000 pg/ml IL-6 in response to HSV-1 
stimulation. Pam2CSK4 stimulated IL-6 levels averaged 70,000 to 80,000 pg/ml 
over the 3 day experiment in CD200R1+/+ cells, CD200R1-/- macrophages 
generated only 10,000 to 20,000 pg/ ml. Similar to the IL-6 response, the 
generation of CCL5 (Rantes) by CD200R1-/- macrophages stimulated with HSV-
1 was decreased when compared to CD200R1+/+ macrophages. To address 
whether the decrease in CCL5 (Rantes) was a property of signaling by TLR2, or 
secondary to low levels of IFN, we determined whether CD200R1-/- peritoneal 
macrophages exhibit a blunted CCL5 (Rantes) response to stimulation with the 
TLR4 ligand, LPS. In contrast to the attenuated response to TLR2 stimulation, 
there was only a slight decrease in the levels of IL-6 at 24 and 48 hours and no 
difference in the levels of CCL5 (Rantes) generated in response to TLR4 
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stimulation via LPS in CD200R1+/+ or CD200R1-/- cells at any time point (Figure 
5A). In the case of CCL2 (MCP-1) generation, no difference was found between 
CD200R1-/- and CD200R1+/+ with any stimulant; though LPS induced a marked 
increase in CCL2 (MCP-1) expression in CD200R1-/- cells. 
 The formation of mature IL-1β requires two distinct steps (258,259). The 
first signal induces the transcription and translation of pro-IL-1β. Expression of 
pro-IL-1β is regulated at the transcriptional level by NF-κB, which, for HSV-1, is 
activated downstream of TLR2 signaling. The second signal activates assembly 
of the inflammasome complex and cleavage of pro-IL-1β into its mature secreted 
form, IL-1β. This can be triggered by a variety of mechanisms, including 
extracellular ATP acting on the P2X receptor, reactive oxygen species, or 
potassium efflux triggered by the antibiotic Nigericin (260). The interaction of 
double stranded DNA and viral replication intermediates with intracellular DNA 
sensors can also induce inflammasome assembly. 
(152,153,157,168,169,261)The assembly and function of the inflammasome is 
therefore dependent on the quantity of viral replication intermediates within cells. 
We therefore hypothesized that if CD200R1 was required for efficient viral 
replication, then CD200R1-/- macrophages should show lower levels of 
inflammasome formation and impaired conversion of pro-IL-1β to mature IL-1β. 
 Stimulation of CD200R1-/- peritoneal or bone marrow- derived 
macrophages with HSV-1 led to the production of approximately 20% of the 
mature IL-1β levels seen in CD200R1+/+ cells (Figure 5B). In contrast, no 
difference was found in mature IL-1β levels between CD200R1+/+ or CD200R1-
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/- macrophages stimulated with LPS (100 ng/ml) for 3 hours followed by the 
addition of ATP (1 mM) for 1 hour. These results suggested that that there was 
no intrinsic defect in inflammasome formation or in the capacity of CD200R1-/- 
macrophages to generate pro-IL-1β mRNA, while virus-induced inflammasome 
formation was significantly attenuated in CD200R1-/- macrophages. The 
difference in the production of mature IL-1β between CD200R1+/+ and 
CD200R1-/- macrophages following HSV-1 infection were confirmed by Western 
blot (Figure 5C). 
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Figure 5.1 CD200R1 licenses pro-inflammatory signaling in peritoneal macrophages. 
(A) CD200R1+/+ (WT) or CD200R1−/− (KO) elicited peritoneal macrophages were stimulated with either HSV-1 (MOI 10 1, 
left column), Pam2CSK4 (100 ng/ml, center column), LPS (100 ng/ml, right column), or medium for 24, 48, or 72 h. IL-6 
(upper row, pg/ml), CCL5/Rantes (middle row, pg/ml), and CCL2/MCP1 (lower row, pg/ml) levels were measured by ELISA. 
Data shown are mean and SD of representative experiment (total of 3 experiments, n = 4, WT and KO). An unpaired, two 
tailed Student’s t-test was used to determine statistical significance of independent experiments, p values; * p<0.05, † p<0.01. 
(B) Supernatant IL-1β levels from WT and KO elicited peritoneal macrophages (left panels) or bone marrow macrophages 
(right panels) 16 h after addition of HSV-1 (MOI 10 1) or after a 3 h stimulation with LPS (100 ng/ml) followed by ATP (1 mM) 
for 1 h. ELISA results are representative of 3 experiments. (C) WT and KO elicited peritoneal macrophages were cultured for 
20 h with HSV-1 (MOI 10 1). Media (left lanes) and cells (right lanes) were analyzed by SDS-PAGE followed by Western blot 
for cleavage of pro-IL-1β to IL-1β. Data representative of 3 experiments (n = 4, WT; n = 5, KO). 
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Discussion  
 
 A delicate balance between immune activation and suppression is crucial 
for the proper detection and clearance of viruses. Improper regulation of these 
responses can lead to severe inflammation and tissue damage and lethality. In 
the case of HSV-1, signaling through TLR2 is important for this balance. The 
CD200R1 has been shown to play a role in down regulating immune responses 
when it interacts with its ligand CD200, however its role in TLR2 responses are 
unknown. Here we defined a unique role for CD200R1 in supporting (licensing) 
pro-inflammatory signaling by TLR2. This role was revealed by studies with 
peritoneal macrophages in which the generation of IL-6 and CCL5 (Rantes) in 
CD200R1-/- macrophages was blunted by 80% in response to TLR2 ligands and 
HSV-1; this was not observed in response to LPS suggesting a specific defect in 
TLR2-driven responses. Furthermore, CD200R1-/- macrophages lacked the 
ability to assemble a functional inflammasome. Both the NLRP3 and AIM2 
Inflammasomes have been implicated in HSV-1 signaling, however further 
studies are needed to determine which inflammasome complex is being activated 
by CD200R1.  
 It is unclear why IL-6 and CCL5 (Rantes) but not MCP-1 levels were 
reduced in CD200R1-/-. It may be that there is differential regulation of IL-6 and 
CCL2 (MCP-1) generation via TLR2 signaling. Although these cytokines are both 
NF-κB driven, there are distinct transcription factors that drive expression of IL-6 
or MCP-1. In previous studies we have noted that HSV-induced IL-6 is strictly 
dependent on TLR2 expression while some MCP-1 secretion still occurs in 
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TLR2-/- cells, albeit at reduced levels compared to TLR2+/+ macrophages (262). 
Currently, the mechanism(s) are not known. It is also possible that CD200R1 
regulates IL-6 and CCL2 (MCP-1) differently. It is also unclear why the 
expression of CCL5 (Rantes) but not CCL2 (MCP-1) is decreased in CD200R1-/- 
mice. It is possible that CCL5 (Rantes) secretion is secondary to decreased IFN, 
though ultimately this also is a consequence of the control of TLR2 signaling by 
CD200R1. An additional defect in TLR2 function, the inability to up-regulate the 
expression of TLR2 in response to HSV-1 infection, may contribute to the inability 
to perpetuate and amplify HSV-1 infection, though this may be secondary to the 
role of CD200R1 in regulating viral replication. These studies provide evidence 
for a new checkpoint and balance during HSV-1 infection.  
 
Materials and Methods  
 
Ethics Statement 
This study was approved and performed in strict accordance with the guidelines 
set forth by both the University of Massachusetts Medical School Department of 
Animal Medicine Institutional Animal Care and Use Committee (IACUC) (assur- 
ance number A3306-01) and by the Massachusetts General Hospital (MGH) 
Center for Comparative Medicine, Subcommittee on Research Animal Care 
(SRAC), which serves as the Institutional Animal Care and Use Committee 
(IACUC) at MGH (assurance number A3596-01). Mice were bred and maintained 
under specific-pathogen-free conditions at the animal facilities at both the 
University of Massachusetts Medical School and the Massachusetts General 
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Hospital Charlestown Facility, and all efforts were made to minimize suffering. 
 
Antibodies 
Anti-IL-1β was goat polyclonal anti–mouse IL-1β (AF-401-NA; R&D Systems). 
The secondary anti-rabbit antibody used in blotting studies was rabbit anti-goat 
(H+L) IgG HRP conjugate (172–1034; Bio-Rad) 
 
Preparation of Viruses 
HSV-1 strains were generated in the laboratory of Dr. David Knipe. Viruses were 
added to peritoneal macrophages at an M.O.I. of 10:1. 
 
Preparation and Stimulation of Peritoneal Macrophages 
Mice were injected with 4% thioglycollate and peritoneal exudate cells were 
routinely harvested 3–4 days later. To generate macrophages, peritoneal 
exudate cells were plated at 106 cells per well in 24-well plates in DMEM 
containing 10% FCS. Lipopolysaccharide (LPS) was obtained from Sigma and 
phenol extracted. Pam2CSK4 was obtained from EMC Microcollections 
(Tubingen, Germany). 
 
Statistical Analysis 
An unpaired, two-tailed Student’s t-test was used to determine statistical 
significance where indicated. Statistics were performed using GraphPad (Prism 
v5.0d) software. Values of P,0.05 were considered significant. 
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Appendix B: Forward genetic analysis of type I IFN responses to DNA ligands 
reveals a novel polymorphism in the MOLF/Ei STING gene.  
 
Preface to Appendix B 
 
The work of this chapter was done in collaboration with Jennie Chan and 
collaborators at the Tufts Sackler School of Biomedical Sciences, Alexander 
Poltorak, Guy Surpris, and Joe Sarhan. 
 
• Mikayla Thompson and Jennie Chan performed experiments in Figures 6.1. 
• Mikayla Thompson wrote all of Appendix B with edits from Jennie Chan.  
• Alexander Poltorak, Guy Surpris, and Joe Sarhan performed experiments in 
figures 6.2 and 6.3.  
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Introduction  
 
The innate immune response is the body’s first line of defense against 
infection. The ability of pattern recognition receptors to recognize various 
moieties from microbes is crucial for innate immune activation and clearance of 
pathogens. The role of Toll-like Receptors during host-defense is well known. 
Recently, intracellular receptors have been implicated in sensing nucleic acids 
that accumulate in the cytosol during viral and bacterial infections.  RNA and 
DNA are potent activators of pro-inflammatory cytokines, such as IL-1, IL-6 and 
type I interferons, all of which aid in the clearance of pathogens. A wide range of 
cytosolic RNA and DNA sensors have been defined, although how these 
receptors work together has yet to be determined. The ER-bound protein STING 
is central to these responses as many cytosolic sensors utilize the molecule as 
an adaptor to induce type I interferons in response to cytosolic DNA.  
In unstimulated cells, STING localizes to the ER and perhaps ER-
associated mitochondria (91). It contains 4 transmembrane helices and a 
cytosolic carboxyl terminal domain. Following stimulation with cytosolic DNA or 
HSV-1, STING translocates to perinuclear foci, via the Golgi, where it initiates 
downstream effects (89). Activation of STING leads to TANK binding kinase-1 
(TBK1) dependent phosphorylation of interferon regulatory factor 3 (IRF3) and 
transcription of type I IFN genes. Many cytosolic sensors, including IFI16, 
DDX41, and cGAS act upstream of STING. However, it is possible for cyclic-di-
nucleotides to bind STING directly to induce type I interferons. Although the role 
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of all sensors upstream of STING have yet to be clearly elucidated, it is evident 
that STING plays an important role in antiviral immunity to DNA viruses.  
Because the type I interferon response is so critical to antiviral immunity, it 
is likely that genes involved in this pathway would be favorable for evolutionary 
selection. This notion allows us to use evolutionarily distinct mouse strains to 
reveal novel signaling pathways. These experimental approaches use wild-
derived inbred strains of Mus musculus molossinus MOLF/Ei (MOLF), which are 
genetically divergent from the conventional laboratory Mus musculus musculus 
C57Bl/6 (B6) strains by several million years. When bred together, they produce 
fertile offspring with genetic differences that can be used to identify new alleles 
that contribute to activate or repress innate immune responses (263). Such 
approaches have been used to define an anti-inflammatory role for 
IRAK1BP1(264) and susceptibility to Salmonella typhimurium(265).  
In the present study, we observed that the wild derived MOLF mice lack 
the ability to produce type I interferons in response to DNA ligands. Using a 
forward genetic approach and quantitative trait locus analysis (QTL), we 
identified a mutation in STING that limits the production of type I interferons in 
response to DNA ligands.   
 
Results 
 
MOLF/Ei mice have a blunted IFN-β response to DNA ligands 
Since wild derived and B6 mice are genetically diverse, yet can be bred to 
produce fertile offspring, we used these two strains for forward genetic analysis. 
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We harvested peritoneal macrophages from B6 and MOLF mice and stimulated 
the cells with poly(dA:dT), HSV-1, MCMV, and Sendai Virus (SV) for 12 hours 
and then collected supernatant for analysis by ELISA. As compared to B6 mice, 
the wild derived MOLF mice have severely attenuated IFN-β production in 
response to all DNA ligands (Figure 6.1a). In contrast to these results, we did not 
see any difference in IFN-β production in response to Sendai Virus, suggesting 
that the phenotype is specific to DNA ligands. Furthermore, IL-1β production 
remained unchanged, suggesting the phenotype is specific to the type I 
interferon pathway (Figure 6.1b). F1 mice (B6XMOLF cross) yielded a phenotype 
similar to that of B6 mice, where IFN-β production was not attenuated in 
response to DNA ligands, suggesting that the gene responsible for the 
phenotype is dominant for B6 (Figure 6.1a and b). Thus we used a forward 
genetic screen of 35 N2 mice (F1XB6) in order to map the phenotype back to the 
genetic locus. Peritoneal macrophages were stimulated with poly(dA:dT) (Figure 
6.1c), HSV-1 (Figure 6.1e), Listeria, ci-di-AMP, and SV (data not shown) for 12 
hours and then supernatant was analyzed for IFN-β production by ELISA. N2 
mice varied in IFN-β production. The cells were also analyzed for IL-6 production 
(Figure 6.1d and f) as a control to confirm that the cells are functional and can 
produce other cytokines normally.  
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F 
 
Figure 6.1. MOLF/Ei mice display a blunted IFN-β response to DNA ligands. A. Peritoneal macrophages from B6, 
MOLF, and F1 mice were stimulated with poly(dA:dT), AT5, HSV, MCMV, and Sendai Virus for 12 hours supernatant 
was analyzed for IFN-β or B. IL-1β by ELISA. C. B6, MOLF, F1, and N2(1-35) mice were stimulated with poly(dA:dT) (C 
and D) or HSV-1 (E and F) for 12 hours. Supernatant was analyzed for IFNβ or IL-6 by ELISA.  
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Decreased IFN-β production in MOLF mice can be mapped to Chromosome 
18 and STING.  
 
To map the loci responsible for the observed phenotype, our collaborators 
at Tufts performed Quantitative trait loci analysis. In response to poly(dA:dT), 
they found a significant Logarithm of odds score (LOD) at both chromosomes 11 
and 18 (Figure 6.2a). A significant LOD score was also found for chromosome 18 
in response to ci-di-GMP (data not shown). Therefore, chromosome 18 was 
pursued further.   Fine mapping of the chromosome revealed that D18Mit202 
conferred the phenotype. After analysis of genes in the region that were 
polymorphic between the two mouse strains, we identified STING as a probable 
candidate in that region. The presence of both D18Mit202 and STING correlated 
with the parent strains and amount of IFN-β production, suggesting that STING is 
responsible for the observed phenotype (Figure 6.2b and c).  
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 Figure 6.2 Decreased IFN-β production in MOLF/Ei mice can be mapped to Chromosome 18 and STING. 
A. QTL Analysis of N2 panel in response to poly(dA:dT). Threshold indicates significant LOD scores. B. 
Effect of D18Mit202 and C. STING inheritance on IFN-β production for individual N2 mice.    
STING
A. 
B. C. 
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MOLF mice have multiple polymorphisms in STING 
In order to determine how MOLF STING is functionally different from B6 
STING, a sequence analysis was performed. Sequence analysis revealed 
several polymorphisms in the MOLF STING allele as compared to B6 (Figure 
6.3a). To test the functionality of MOLF STING, we cloned the gene and looked 
for its ability to activate the ISRE promoter by luciferase assay. B6 STING 
induced the IFN-β ISRE promoter more than 2 fold above MOLF STING (Figure 
6.3b). Furthermore, upon stimulation with DMXAA, cyclic-di-AMP, poly(dA:dT) 
and cyclic-di-GMP, MOLF STING induced less ISRE reporter activity. Lastly, we 
mutated B6 STING to mimic that of the MOLF STING polymorphisms. We found 
that in response to DMXAA, cyclic-di-AMP, poly(dA:dT) and cyclic-di-GMP, 
mutated B6 phenocopied the MOLF hypo-IFNβ responses, marked by less ISRE 
activation. These results provided further evidence that mutations in MOLF 
STING hinder the functionality of the gene. 
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Figure 6.3. MOLF/Ei mice have multiple polymorphisms in STING. A. Sequence analysis of B6 and MOLF STING. B. 
B6 and MOLF STING were transfected into cells and reporter assay was used to determine activation of ISRE 
luciferase. Cells are normalized to renilla. C. B6 and MOLF STING were transfected into HEK cells and stimulated 
with DMXAA, ci-di-AMP, ci-di-GMP, and poly(dA:dT). Cells were monitored for ISRE activation by reporter assay. D. 
Increasing concentrations of B6, MOLF, and mutant B6 STING were transfected into cells and reporter assay was 
used to determine activation of ISRE luciferase. Cells are normalized to renilla plasmid.  
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Discussion 
 
Here we used a forward genetic approach and QTL analysis to determine 
that a mutation in the wild derived MOLF STING is responsible for decreased 
functionality of the gene and an inability to produce type I interferons in response 
to DNA stimuli.  This finding highlights the importance of the evolution of STING 
as a central mediator for these responses in antiviral immunity. We found that 
MOLF mice are unable to produce type I interferons in response to HSV-1, 
MCMV, and Listeria monocytogenes. Further work is needed in order to 
determine whether MOLF mice are more susceptible to these pathogens in vivo. 
Mice deficient in STING are more susceptible to both HSV-1 and Listeria 
infections (89,266), suggesting that MOLF mice may be susceptible to these 
pathogens as well.  
DMXAA is a tumor-vascular disrupting agent that has been shown to 
induce type I interferons by activating STING (267,268). Surprisingly mouse 
STING, but not human STING had the ability to respond to DMXAA, providing 
explanation for why the drug failed as an anti-tumor medicine in clinical 
trials(269). The decreased functionality of mouse STING was mapped to the C-
terminal domain (CTD). When the C terminal domain of mouse STING was 
replaced with the C terminal domain of human STING, the ability to respond to 
DMXAA was restored(269). These studies highlight the importance of the C 
terminal domain of STING. Previous studies have shown that the CTD not only 
binds cyclic-di-nucleotides, but also interacts with TBK1 and IRF3 to activate 
downstream signaling effects. Furthermore, the CTD is important for keeping 
 151 
STING in its auto-inhibited state, which is then lifted upon binding on cyclic-di-
nucleotides.  
Interestingly, our studies unveiled a mutation in the N-terminus of MOLF 
STING. This discovery provides further insight into the functional domains of the 
gene. In our work we find that although IFN-β responses are blunted in MOLF 
mice, IL-1β and IL-6 responses are unaltered or increased, respectively. This 
finding is in contrast to previous results, which show that mutations in the C 
terminal domain of STING lead to abrogated NF-κB responses as well. Our 
results suggest that while the C terminus is responsible for the overall activation 
of STING, the N terminus may have more specific function related to the sensing 
of DNA ligands. Further work is needed to determine if MOLF STING forms a 
functional protein and is able to induce NF-κB responses.  
 
Materials and Methods 
 
 
Mice 
C57BL/6J and MOLF/Ei parental strains were obtained from The Jackson 
Laboratory. All mice were housed in a pathogen-free facility at the Tufts 
University School of Medicine. All mouse procedures were performed under a 
protocol approved by the Tufts University/Tufts Medical Center Institutional 
Animal Care and Use Committee as described in (264). 
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Genetic Analysis 
Genome-wide scanning was performed according to standard procedures, using 
two to three known polymorphic microsatellite markers per chromosome. Both 
genotypic and phenotypic data were analyzed using QTX software for genetic 
mapping of quantitative trait loci as described in (264). 
 
Reagents and Antibodies  
LPS and poly(dA:dT) were obtained from Sigma-Aldrich (St. Louis, MO). HSV 
60mer, and AT5 oligonucleotides were synthesized as described in (130), Cyclic-
di-GMP was from Biolog (Hayward, CA). L. monocytogenes (clinical isolate 
10403s) was from V. Boyartchuk (NTNY, Trondheim, Norway).  HSV-1 (7134) 
was a gift from D. Knipe (Harvard Medical School, MA).  Sendai virus (SeV, 
Cantrell strain) was purchased from Charles River Laboratories (Wilmington, 
MA). Lipofectamine 2000 was from Invitrogen (Carlsbad, CA).  Genejuice was 
from Novagen (Madison, WI).  
 
Cell Culture, Stimulation and ELISA 
Mice were injected with 4% thioglycollate and peritoneal exudate cells were 
routinely harvested 3–4 days later. For stimulations, poly(dA:dT) (1 µg/ml) or ci-
di-GMP (3 µM) were transfected into the cells with lipofectamine in accordance 
with the manufacturer's instructions. Cells were infected with mCMV or HSV-1 
viruses at multiplicities of infection (MOI) of 10.  Cells were infected with Sendai 
virus at 200 IU/ml. For bacterial infection, cells were challenged with L. 
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monocytogenes at an MOI of 5 for 1 hr.  Infected cells were then washed twice 
and medium containing gentamicin (100 µg/ml) was added to kill extracellular 
bacteria. Knockdown and control cells were challenged with stimulants or 
microbes for 12 hours (for protein analysis by ELISA). Cytokine and IFN levels in 
culture supernatants were assayed for IL-1β and IL-6 (BD Biosciences, Franklin 
Lakes, NJ) and IFN-β by sandwich ELISA. 
 
Luciferase promoter assays 
The indicated regions of the STING were amplified from C57BL/6J or MOLF/Ei 
genomic DNA and cloned into the pGL4.20 (Promega) firefly luciferase vector. 
HEK 293T cells were transfected with lipofectamine as per the manufacturer’s 
protocol, stimulated, and lysed using Passive Lysis buffer. Luciferase was read 
using Dual Luciferase reagent (Promega) in a single tube luminometer as 
described in (264). 
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